Here you are: IMGT Web resources > IMGT Repertoire (IG and TR) > Genes and clinical entities

Monoclonal antibodies with clinical indications

Definitions

Monoclonal antibodies and immunoadhesins approved for therapeutic or diagnostic use and are on the market (in 2012)

- 7 Mouse muromonab-CD3
(1992)
ORTHOCLONE OKT3® 		edrecolomab
(1995)
PANOREX® 		capromab
(1996)
PROSTASCINT® 		ibritumomab tiuxetan
(2002)
ZEVALIN® 		tositumomab
(2003)
BEXXAR® 		catumaxomab
(2009)
REMOVAB® 		besilesomab
(2010)
SCINTIMUN®
- 1 Rat catumaxomab
(2009)
REMOVAB®
- 6 Chimeric abciximab
(1993)
REOPRO® 		rituximab
(1997)
MABTHERA® /
RITUXAN® 		basiliximab
(1998)
SIMULECT® 		infliximab
(1998)
REMICADE® 		cetuximab
(2004)
ERBITUX® 		brentuximab vedotin
(2011)
ADCETRIS™
- 11 Humanized palivizumab
(1998)
SYNAGIS® 		trastuzumab
(1998)
HERCEPTIN® 		alemtuzumab
(2001)
CAMPATH® /
MABCAMPATH® 		omalizumab
(2003)
XOLAIR® 		bevacizumab
(2004)
AVASTIN® 		nimotuzumab
(2004)
THERACIM® 		natalizumab
(2004)
TYSABRI® /
ANTEGREN® (formerly) 		ranibizumab
(2006)
LUCENTIS® 		eculizumab
(2007)
SOLIRIS™ 		tocilizumab
(2008)
ACTEMRA™ /
RoACTEMRA® 		certolizumab pegol
(2008)
CIMZIA®
- 11 Human etanercept
(1998)
ENBREL® 		adalimumab
(2002)
HUMIRA® /
TRUDEXA® 		alefacept
(2003)
AMEVIVE® 		abatacept
(2005)
ORENCIA® 		panitumumab
(2006)
VECTIBIX™ 		rilonacept
(2008)
ARCALYST™ 		ustekinumab
(2009)
STELARA™ 		ofatumumab
(2009)
ARZERRA™ 		golimumab
(2009)
SIMPONI™ 		canakinumab
(2009)
ILARIS® 		belimumab
(2011)
BENLYSTA®

The INN is followed by the date of first FDA approval and the commercial mark(s).

Development status

These phases are defined by the FDA in the Code of Federal Regulations.

print To print these tables please use Internet Explorer and print in Landscape format and A3 paper size.

Mouse

Number of results: 65

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT receptor type Species IG class and subclass or IG format FPIA or RPI chain identification Conjugated/ Radiolabelled IMGT/2Dstructure-DB IMGT/3Dstructure-DB Specificity target name
[species]		 Origin clone species Origin clone name Company Application Clinical indication Development status Regulatory agency status and year Expression system Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
111 abagovomab 8659 95
(2006)		 57
(2007)		 ACA125,
MEN-2234		 IG Mus musculus IgG1 kappa

8659 MUC16 (mucin 16, MUC-16, cancer antigen 125, CA125) (idiotope) [Homo sapiens] Mus musculus 3D5 Menarini (Florence Italy) Therapeutic Ovarian cancers Phase III Oncology
315 afelimomab 7340 72
(1994)		 35
(1995)		 LU54107 IG Mus musculus IgG3 nd

Unknown Unknown Unknown ATC: L04AB03
312 altumomab 7046 68
(1992)		 33
(1993)		 ZCE025 IG Mus musculus IgG1 nd

CEA (anticarcinoembryonic antigen) [Homo sapiens] Unknown Unknown Unknown
287 anatumomab mafenatox 7655 79
(1998)		 41
(1999)		 ABR-214936,
pMB125		 IG Mus musculus IgG1 nd conjugated with Staphylococcus aureus enterotoxin A

 CA 72-4 (tumour associated glycoprotein 72, TAG-72, TAG, HMW mucin-like glycoprotein) [Homo sapiens] Unknown Renal cell carcinoma (RCC) Phase II Oncology
113 arcitumomab 7417 74
(1995)		 36
(1996)		 CEA-Scan,
IMMU-4		 CEA-SCAN™ IG Mus musculus Fab' - G1 nd

radiolabelled with Technetium-99m, Tc-99m		 CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e) [Homo sapiens] Mus musculus NP4, IMMU-4 Immunomedics Inc. (Morris Plains NJ USA) Diagnostic Colorectal cancers (radiodiagnostic imaging of tumors) Withdrawn EC withdrawal (on holders request) November 14, 2005, EC approval October 04, 1996, FDA approval June 28, 1996 Murine ascites, pepsin digestion Oncology FDA: (BLA) 103425

NCT

 [b] [n]
306 bectumomab 7514 75
(1996)		 37
(1997)		 99mTc-IMMU-LL2 Lymphoscan® IG Mus musculus Fab' - G2a kappa

CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) [Homo sapiens] LL2 Immunomedics Inc. (Morris Plains NJ USA) Diagnostic Non-Hodgkin's lymphoma (NHL) Oncology
258 besilesomab 8451 92
(2004)		 54
(2005)		 BW250/183 SCINTIMUN® (EU) IG Mus musculus IgG1 kappa

radiolabelled with Technetium-99m, Tc-99m		 CEACAM8 (carcinoembryonic antigen-related cell adhesion molecule 8 , NCA-95, nonspecific cross-reacting antigen 95 kDa, granulocyte cell antigen, CGM6, CD66b) [Homo sapiens] Iba Molecular Imaging (Louvain-la-Neuve Belgium) Diagnostic Bone marrow scintigraphy Phase M EMA approval January 11, 2010 Osteology EMA: H-C-001045
Diagnostic Peripheral bone infections Phase M EMA approval January 11, 2010 Osteology
Diagnostic Diagnosis of ostomyelitis Phase M EMA approval January 11, 2010 Osteology
131 biciromab 6867 66
(1991)		 32
(1992)		 Indium (111In) biciromab,
TT2G1		 FibriScint™ IG Mus musculus Fab' - G nd

radiolabelled with Indium-111, In-111		 fibrin II beta chain (NH2 terminus) [Homo sapiens] Mus musculus T2G1 Centocor Inc. (Horsham PA USA) Diagnostic Cardiovascular thrombosis (in vivo imaging agent) Withdrawn FDA withdrawal (PLA withdrawal, on holders request) June 01, 1993 Cardiology [b] (31)
101 blinatumomab 9028 100
(2008)		 62
(2009)		 BITE MT-103,
bscCD19xCD3,
MEDI-538/MT103		 IG Mus musculus scFv-scFv

9028 CD19 (B lymphocyte surface antigen B4, Leu-12) [Homo sapiens] ;
CD3E (CD3 epsilon) [Homo sapiens] ;
bispecific 		Homo sapiens MedImmune Inc. (Gaithersburg MD USA) (US) Therapeutic B cell lymphoma Discontinued FDA Orphan drug (for indolent B cell lymphoma) January 01, 2006 Oncology [p] (36)
115 capromab 7201 70
(1993)		 34
(1994)		 7E11-C5.3 radiolabelled,
capromab pendetide,
Indium In1111 ProstaScint®		 PROSTASCINT® IG Mus musculus IgG1 kappa conjugated with chelator pendetide (GYK-DPTA)

radiolabelled with Indium-111, In-111		 FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA) [Homo sapiens] Mus musculus 7E11-C5.3 EUSA Pharma (Doylestown PA USA) Diagnostic Prostate cancers Phase M FDA approval October 28, 1996 Oncology FDA: (BLA) 103608

NCT

 [b] [d] [n] (31)
218 catumaxomab 8406 93
(2005)		 55
(2006)		 Mus mus. anti-EPCAM (Ho-3/TP-A-01/TPBs01) G2a kappa / Rat sp. anti-CD3E (26/II/6-1.2/TPBs01) G2b lambda,
TPBs01		 REMOVAB® IG Mus musculus
Rattus sp.
Hybrid		 IgG2a kappa / G2b lambda

CD3E (CD3 epsilon) [Homo sapiens] ;
EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, epithelial cell adhesion molecule, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] ;
bispecific 		Fresenius Biotech GmbH (Bad Homburg Germany) / TRION Pharma (Munich Germany) Therapeutic Ovarian cancers Phase II/III Oncology ATC: L01XC09

 [o] (28) (36)
Therapeutic Gastric cancers Phase II/III EC Orphan drug November 03, 2006 Oncology
Therapeutic Malignant ascites Phase M EMA approval April 20, 2009 Oncology
313 detumomab 7156 70
(1993)		 34
(1994)		 SPECIFID IG Mus musculus

Unknown Cancers Oncology
207 dorlimomab aritox 6516 66
(1991)		 32
(1992)		 4197X-RA,
MDX-RA (Ricin A)		 IG Mus musculus conjugated with Ricinus communis ricin A

 Houston Biotechnology (The Woodlands TX USA) / Medarex (Princeton NJ USA) Therapeutic Secondary cataract, Secondary cataract
(Prevention)
Phase III Ophthalmology [b] [e] (29)
118 edobacomab 7056 69
(1993)		 34
(1994)		 E5,
XMMEN-0E5		 IG Mus musculus IgM nd

endotoxin (lipid A, domain of lipopolyaccharide, LPS) [Bacteria] Mus musculus Pfizer (New York NY USA) / Xoma (Berkeley CA USA) Therapeutic Septic shock Phase I Infectiology [e] (57)
Therapeutic Gram-negative sepsis Phase III Infectiology
119 edrecolomab 7471 74
(1995)		 36
(1996)		 17-1A PANOREX® IG Mus musculus IgG2a nd

EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, epithelial cell adhesion molecule, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) Therapeutic Colon cancers Phase M approval (Germany) January 01, 1995 Sp2/0 mouse myeloma cells Oncology ATC: L01XC01

NCI: C1554

 [a] [e]
268 elsilimomab 8371 89
(2003)		 51
(2004)		 B-E8 IG Mus musculus IgG1 nd

IL6 (interleukin 6, IL-6) [Homo sapiens] Unknown Cancers Oncology
120 enlimomab 6964 70
(1993)		 34
(1994)		 BIRR-1 IG Mus musculus IgG2a nd

ICAM1 (intercellular adhesion molecule 1, ICAM-1, CD54) [Homo sapiens] Mus musculus Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) Therapeutic Stroke Phase II/III Cardiology [a] [e]
Therapeutic Thermal injury Phase II Hematology
317 enlimomab pegol 7525 77
(1997)		 39
(1998)		 IG Mus musculus Fab' - G2a nd conjugated with pegol

 ICAM1 (intercellular adhesion molecule 1, ICAM-1, CD54) [Homo sapiens] Mus musculus BI-RR-1 Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) Therapeutic Renal transplant rejection Phase I Immunology [70]
303 epitumomab 7833 82
(1999)		 44
(2000)		 B1R1 IG Mus musculus IgG2a nd

MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Unknown Unknown Unknown
269 epitumomab cituxetan 8372 89
(2003)		 51
(2004)		 IG Mus musculus IgG1 kappa conjugated with chelator cituxetan

radiolabelled with Yttrium-90, Y-90		 MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227) [Homo sapiens] Mus musculus HMFG-1 Unknown Therapeutic Epithelial Ovarian cancers Phase III Oncology
219 ertumaxomab 8407 93
(2005)		 55
(2006)		 Murine G2a 250A/TP-A-02 (anti-ERBB2) / Rat sp. G2b lambda 26/II/6-1.2 (anti-CD3E),
TPBs03		 REXOMUN® IG Mus musculus
Rattus sp.
Hybrid		 IgG2a nd / G2b nd

CD3E (CD3 epsilon) [Homo sapiens] ;
ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340 [Homo sapiens] ;
bispecific 		Fresenius Biotech GmbH (Bad Homburg Germany) / TRION Pharma (Munich Germany) Therapeutic Breast cancers Phase II Oncology [o] (28) (36)
305 faralimomab 7496 76
(1996)		 38
(1997)		 64G12 IG Mus musculus IgG1 nd

IFNA1 (interferon alpha 1, IFN alpha, IFN alpha 1/13, IFN 13) [Homo sapiens] Medarex (Princeton NJ USA) Rheumatoid arthritis (RA) Immunology
Systemic lupus erythematosus (SLE) Immunology
112 gavilimomab 8060 84
(2000)		 46
(2001)		 ABX-CBL IG Mus musculus IgM nd

BSG (basigin, Ok blood group, CD147) [Homo sapiens] Mus musculus Abgenix (Fremont CA USA) Therapeutic Allograft rejection Phase II Immunology [a] [b] [52]
Therapeutic Graft-versus-host disease (GvHD) (steroid-refractory) Phase III Immunology
122 ibritumomab tiuxetan 7873 81
(1999)		 43
(2000)		 In-111 Zevalin,
Y-90 Zevalin		 ZEVALIN® IG Mus musculus IgG1 kappa conjugated with chelator tiuxetan

radiolabelled with Yttrium-90, Y-90 (Therapeutic) and Indium-111, In-111 (Diagnostic)		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus IDEC-Y2B8 Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Schering AG (Berlin Germany) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase M FDA approval February 19, 2002 CHO (Chinese Hamster Ovary) cells Oncology FDA: (BLA) 125019

NCT

 [j] [n] (31)
123 igovomab 7433 77
(1997)		 39
(1998)		 Indimacis 125,
OC125 chelator DTPA		 IG Mus musculus F(ab')2 - G1 nd conjugated with chelator pentetate (DPTA)

radiolabelled with Indium-111, In-111		 MUC16 (mucin 16, MUC-16, cancer antigen 125, CA125) (idiotope) [Homo sapiens] Mus musculus CIS Bio international (Bagnols/C France) Diagnostic Ovarian cancers Withdrawn EC withdrawal (on holders request) September 01, 1999, FDA approval September 01, 1996 Oncology [d] [n] (31)
124 imciromab 6605 66
(1991)		 32
(1992)		 R1D10 pentetate MYOSCINT® IG Mus musculus Fab - G2a kappa conjugated with chelator pentetate (DPTA)

radiolabelled with Indium-111, In-111		 myosin, cardiac [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / Eli Lilly (Indianapolis IN USA) Diagnostic Myocardial infection (imaging agent) Withdrawn FDA withdrawal (too expensive to manufacture) February 01, 1999, FDA approval July 03, 1996 Murine ascites, pepsin digestion Cardiology FDA: (BLA) 103634

 [b] [d] [n] (31)
126 inolimomab 7253 71
(1994)		 35
(1995)		 IG Mus musculus

IL2RA (interleukin-2 receptor, alpha subunit, IL-2RA, TAC, CD25) [Homo sapiens] Mus musculus OPI (Orphan Pharma International) (Dardilly France) Therapeutic Graft versus-host disease (GvHD), acute Phase II/III Immunology
281 lemalesomab 8046 84
(2000)		 46
(2001)		 78NCA-90, IMMU-MN3 IG Mus musculus IgG1 nd

NCA-90 (nonspecific cross-reacting antigens 90kDa glycoproteins, granulocyte cell antigen) [Homo sapiens] Unknown Diagnostic Inflammatory lesions Immunology
318 maslimomab 6614 66
(1991)		 32
(1992)		 IG Mus musculus IgG2b nd

T cell receptor (TR) TR alpha_beta [Homo sapiens] Unknown Unknown Unknown
309 minretumomab 7821 80
(1998)		 42
(1999)		 Mab CC-49 IG Mus musculus IgG1 nd

CA 72-4 (tumour associated glycoprotein 72, TAG-72, TAG, HMW mucin-like glycoprotein) [Homo sapiens] Unknown Unknown Unknown
130 mitumomab 7934 82
(1999)		 44
(2000)		 BEC2 IG Mus musculus IgG2b kappa

GD3 ganglioside [Homo sapiens] Mus musculus BEC2 ImClone Systems Inc. (Somerville NJ USA) / Memorial Sloan-Kettering Cancer Center (New York NY USA) / Merck KgaA (Darmstadt Germany) Therapeutic Melanoma Phase III Oncology [a] [e] (9)
Therapeutic Small cell lung cancers (SCLC) Phase III Oncology
198 moxetumomab pasudotox 9236 102
(2009)		 64
(2010)		 CAT-8015,
GCR-8015,
HA22		 IG Mus musculus Fv , disulfide stabilized conjugated with Pseudomonas aeruginosa exotoxin A

 9236 CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Therapeutic Chronic lymphocytic leukemia (CLL) Phase I Hematology, Oncology NCI: C68819

 (29)
Therapeutic Acute lymphocytic leukemia (ALL) Phase I Hematology, Oncology
Therapeutic Hairy cell leukemia (HCL) Phase I Hematology, Oncology
132 muromonab-CD3 6281 59
(1988)		 29
(1989)		 OKT3 ORTHOCLONE OKT3® IG Mus musculus IgG2a kappa

1sy6 CD3E (CD3 epsilon) [Homo sapiens] Mus musculus Centocor Ortho Biotech Products LP (Raritan NJ USA) Therapeutic Acute kidney transplant rejection (reversal) Phase M FDA approval September 14, 1992 Murine ascites, hybridoma Immunology FDA: (BLA) 103463

ATC: L04AA02

NCI: C1321

NCT

 [a] [b] [d] [j] [n]
Therapeutic Heart transplant rejection (reversal) Phase M FDA approval September 14, 1992 Murine ascites, hybridoma Immunology
Therapeutic Liver transplantation (reversal) Phase M FDA approval September 14, 1992 Murine ascites, hybridoma Immunology
316 nacolomab tafenatox 7227 71
(1994)		 35
(1995)		 r-c242Fab-SEA IG Mus musculus IgG1 nd conjugated with Staphylococcus aureus enterotoxin A

 MUC1 sialylated carbohydrate, tumour-associated (CA242, cancer antigen 242) [Homo sapiens] Mus musculus pK941 Unknown Unknown Unknown
65 naptumomab estafenatox 8598 96
(2006)		 58
(2007)		 ABR-217620,
ANYARA,
TTS CD3		 IG Mus musculus Fab - G1 kappa conjugated with Staphylococcus aureus enterotoxin E SEA/E120 superantigen (synthetic)

 8598 TPBG (trophoblast glycoprotein, 5T4) [Homo sapiens] Mus musculus 5T4 Active Biotech AB (Lund Sweden) Therapeutic Renal cell carcinoma (RCC) Oncology (29)
Therapeutic Non-small lung carcinomia Oncology
307 nerelimomab 7546 76
(1996)		 38
(1997)		 BAYX1351 IG Mus musculus IgG1 nd

TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Unknown Unknown Unknown
134 odulimomab 7364 73
(1995)		 36
(1996)		 afolimomab,
anti-LFA1		 ANTILFA® IG Mus musculus F(ab')2 - G1 nd

ITGAL (integrin alpha L subunit, lymphocyte function associated antigen 1, CD11a) [Homo sapiens] Mus musculus 25.3 Pasteur M (Lyon France) Therapeutic Allograft rejection Phase III not renewed April 01, 2000, ATU (Temporary Authorizations for Use) August 01, 1994 Immunology [a] [n]
136 oregovomab 8183 86
(2002)		 48
(2002)		 MAB-B43.13,
oregovamab		 OVAREX® IG Mus musculus IgG1 kappa

MUC16 (mucin 16, MUC-16, cancer antigen 125, CA125) (idiotope) [Homo sapiens] Mus musculus B43.13 AltaRex Corp. (Edmonton AB Canada) Therapeutic Ovarian cancers Phase II Oncology NCI: C1784

 [a]
225 racotumomab 8998 100
(2008)		 62
(2009)		 1E10 IG Mus musculus IgG1 kappa

8998 Anti-idiopatic, anti-N-glycolyl GM3 ganglioside (N-glycolylneuraminic acid (NeuGc, NGNA) GM3 gangliosides, NeuGcGM3) Mus musculus IgM-kappa P3 [Homo sapiens] ;
Anti-idiotype [Homo sapiens] 		Mus musculus CMI (Center of Molecular Immunology) (Playa Cuba) Therapeutic Breast cancers Preclinical Oncology
Therapeutic Melanoma Preclinical Oncology
138 satumomab 6977 68
(1992)		 33
(1993)		 Indium (111In) satumomab pendetide,
OncoScint CR/OV,
OncoScint CR103 		ONCOSCINT® IG Mus musculus IgG1 kappa conjugated with chelator pendetide (GYK-DPTA)

radiolabelled with Indium-111, In-111		 CA 72-4 (tumour associated glycoprotein 72, TAG-72, TAG, HMW mucin-like glycoprotein) [Homo sapiens] Mus musculus B72.3 Cytogen Corp. (Princeton NJ USA) / Lonza Biologics (Basel Switzerland) Diagnostic Ovarian cancers Withdrawn FDA approval December 01, 1992 Oncology [b] [n] (31) (38)
Diagnostic Colorectal cancers Withdrawn FDA approval December 01, 1992 Oncology
139 sulesomab 7519 75
(1996)		 37
(1997)		 IMMU-MN3,
Technetium (99mTc) sulesomab, LeukoScan		 LEUKOSCAN® IG Mus musculus Fab' - G1 nd

radiolabelled with Technetium-99m, Tc-99m		 NCA-90 (nonspecific cross-reacting antigens 90kDa glycoproteins, granulocyte cell antigen) [Homo sapiens] Mus musculus IMMU-MN3 Immunomedics Inc. (Morris Plains NJ USA) Diagnostic Osteomyelitis Immunology [b] [d] (10) (31)
Diagnostic Acute atypical appendicitis Immunology
282 taplitumomab paptox 8047 84
(2000)		 46
(2001)		 IG Mus musculus IgG1 kappa conjugated with Phytolacca americana (pokeweed) antiviral protein PAP

 CD19 (B lymphocyte surface antigen B4, Leu-12) [Homo sapiens] B43 Unknown Therapeutic Cancers Oncology
140 technetium (99mTc) fanolesomab 8150 86
(2002)		 48
(2002)		 NeutroSpec IG Mus musculus IgM nd

radiolabelled with Technetium-99m, Tc-99m		 CD15 (3-fucosyl-N-acetyl-lactosamine, Lewis x, stage-specific embryonic antigen 1, SSEA-1) [Homo sapiens] Mus musculus RB5 Palatin Technologies Inc. (Cranbury NJ USA) Diagnostic Appendicitis (Radionuclide imaging) Withdrawn FDA withdrawal (life-threatening adverse events) December 01, 2005, FDA approval July 02, 2004 Inflammation [j] (31)
133 technetium (99mTc) nofetumomab merpentan 7542 76
(1996)		 38
(1997)		 VERLUMA® IG Mus musculus Fab - G2b kappa conjugated with chelator merpentan

radiolabelled with Technetium-99m, Tc-99m		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus NR-LU-10 Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) / DuPont Merck Pharmaceutical (Billerica MA USA) / NeoRx Corp. (Seattle WA USA) Diagnostic Small cell lung cancers (SCLC) Withdrawn FDA approval August 20, 1996 Oncology [b] [d] [n] (31)
286 technetium (99mTc) pintumomab 7513 75
(1996)		 37
(1997)		 170 IG Mus musculus IgG1 kappa

radiolabelled with Technetium-99m, Tc-99m		 adenocarcinoma antigen [Homo sapiens] Mus musculus 170 Unknown Diagnostic Adenocarcinoma Oncology (31)
320 telimomab aritox 6345 66
(1991)		 32
(1992)		 T101-ricin A chain immunotoxin, T101-RTA IG Mus musculus Fab conjugated with Ricinus communis ricin A

 CD5 (T1, LEU-1) [Homo sapiens] Mus musculus T101 Unknown Therapeutic Chronic lymphocytic leukemia (CLL) Phase I Discontinued Hematology, Oncology
226 tenatumomab 8832 98
(2007)		 60
(2008)		 ST2146 IG Mus musculus IgG2b nd

8832 TNC (tenascin C, hexabrachion, HXB) [Homo sapiens] Mus musculus SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (Pomezia Italy) Therapeutic Cancers Oncology
142 tositumomab 7827 80
(1998)		 42
(1999)		 BEXXAR® IG Mus musculus IgG2a nd

radiolabelled with Iodine-131, I-131		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus Corixa Corp. (Seattle WA USA) / GlaxoSmithKline (Brentford UK) Therapeutic Non-Hodgkin's lymphoma (NHL) (follicular, CD20 positive, following chemotherapy relapse) Phase M FDA approval June 27, 2003 Hybridoma Oncology FDA: (BLA) 125011

NCI: C2543

Drugnum: 834

NCT

 [j] [n] (31)
310 vepalimomab 7757 80
(1998)		 42
(1999)		 1B2 IG Mus musculus IgM nd

VAP-1 (vascular adhesion protein) [Homo sapiens] Unknown Unknown Unknown
314 zolimomab aritox 7055 69
(1993)		 34
(1994)		 H65-ricin A chain immunotoxin, H65-RTA IG Mus musculus conjugated with Ricinus communis ricin A

 CD5 (T1, LEU-1) [Homo sapiens] Mus musculus H65 Unknown Therapeutic Graft-versus-host disease (GvHD) Phase I Discontinued Immunology
Therapeutic Cutaneous T cell lymphoma (CTCL) Phase I Discontinued Oncology
Therapeutic Systemic lupus erythematosus (SLE) Phase I Discontinued Immunology
125 131I-IMMU-LL2,
ImmuRAIT-LL2		 IG Mus musculus IgG2a kappa

radiolabelled with Iodine-131, I-131		 CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) [Homo sapiens] Mus musculus LL2 Immunomedics Inc. (Morris Plains NJ USA) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase I/II Oncology [e] (31) (54)
108 14F7 IG Mus musculus IgG1 kappa

1rih N-glycolyl GM3 ganglioside (N-glycolylneuraminic acid (NeuGc, NGNA) GM3 ganglioside, NeuGcGM3) [Homo sapiens] Mus musculus 14F7 Centre of Molecular Immunology (Havana Cuba) Diagnostic Cancers Oncology [p]
109 14G2a IG Mus musculus IgG2a nd

GD2 ganglioside [Homo sapiens] Mus musculus National Cancer Institute (Bethesda MD USA) Melanoma Phase I Oncology [e]
Solid tumors Phase I Oncology
110 177 Lu-J591,
HuJ591-GS		 Mus musculus

radiolabelled with Lutetium-177, Lu-177		 FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA) [Homo sapiens] Mus musculus Weill Cornell Medical (New York NY USA) Therapeutic Prostate cancers, metastatic (androgen-Independent) Phase I/II Oncology (23) (31) (37)
141 225.28S,
Tecnemab-K-1		 IG Mus musculus F(ab')2, Fab/Fab2 mix

radiolabelled with Technetium-99m, Tc-99m		 CSPG4 (chondroitin sulfate proteoglycan 4, high molecular weight-melanoma-associated antigen, HMW-MAA) [Homo sapiens] Mus musculus Sorin Radiofarmaci S.R.L. (Milan Italy) Cutaneous melanoma lesions Withdrawn EC withdrawal (on holders request) February 01, 2000, EC approval April 01, 1997, FDA approval September 01, 1996 Oncology [d] [n] (31)
99 4D5 and UCHT1,
trastuzumab coupled with UCHT1 F(ab')2		 IG Homo sapiens
Mus musculus
Hybrid		 IgG1 kappa / F(ab')2

CD3E (CD3 epsilon) [Homo sapiens] ;
ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340 [Homo sapiens] ;
bispecific 		Mus musculus Charing Cross Sunley Research Centre (UK) / Genentech Inc. (S. San Francisco CA USA) / ICRF (UK) Cancers (overexpressing ERBB2) Oncology [c] (36) [42]
116 COL-1 Mus musculus

CEACAM3 (carcinoembryonic antigen-related cell adhesion molecule 3 , CGM1, CD66d) [Homo sapiens] Mus musculus National Cancer Institute (Bethesda MD USA) Colorectal cancers Phase I Oncology [e]
Gastric cancers Phase I Oncology
117 CYT-356-Y-90 ONCOLTAD® Mus musculus

Mus musculus Cytogen Corp. (Princeton NJ USA) Prostate cancers (targeted radiotherapy) Phase II Oncology [e]
121 HNK20 IG Mus musculus IgA nd

RSV (human respiratory syncytial virus, glycoprotein F) [Respiratory syncytial virus] Mus musculus OraVax Inc. (Cambridge MA USA) Respiratory Syncytial Virus (RSV) disease Phase III Infectiology, Pulmonary, Respiratory diseases [a] [n]
159 Iodine 131-ILym-1,
Lym-1,
Oncolym		 ONCOLYM® IG Mus musculus IgG2a nd

radiolabelled with Iodine-131, I-131		 HLA-DR10 (DRB1*1001) [Homo sapiens] Mus musculus Peregrine Pharmaceuticals Inc. (Tustin CA USA) Therapeutic Non-Hodgkin's lymphoma (NHL) Discontinued FDA Orphan drug (for NHL) November 27, 1998 Oncology [e] [p] (19) (31) (55)
128 MAK-195F IG Mus musculus F(ab')2

TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Mus musculus Abbott Laboratories (Abbott Park IL USA) / Knoll Pharmaceutical (Mount Olive NJ USA) Sepsis toxic shock Phase III Infectiology [a] [b] [e]
129 MEDI-500,
T10B9,
T10B9.1A-31		 IG Mus musculus IgM kappa

T cell receptor (TR) TR alpha_beta [Homo sapiens] Mus musculus MedImmune Inc. (Gaithersburg MD USA) Graft-versus-host disease (GvHD) Phase III Immunology [a]
137 RING SCAN Mus musculus

radiolabelled with Indium-111, In-111		 CA 72-4 (tumour associated glycoprotein 72, TAG-72, TAG, HMW mucin-like glycoprotein) [Homo sapiens] Mus musculus Neoprobe Corp. (Dublin OH USA) Breast cancers Oncology [j] (31)
Rectal cancers Oncology
Colon cancers Oncology
7 muMAb VEGF A.4.6.1,
muMAb VEGF A4.6.1,
muMAb-VEGF		 IG Mus musculus IgG1 nd

VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) Cancers Oncology [c] [6]
114 AVICIDIN® IG Mus musculus

radiolabelled with Yttrium-90, Y-90		 EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, epithelial cell adhesion molecule, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] Mus musculus NeoRx Corp. (Seattle WA USA) Colon cancers Phase II Oncology [e] (31) (35)
Ovarian cancers Phase II Oncology
Prostate cancers Phase II Oncology
Non-Hodgkin's lymphoma (NHL) Phase I Oncology

up

Rat

Number of results: 2

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT receptor type Species IG class and subclass or IG format FPIA or RPI chain identification Conjugated/ Radiolabelled IMGT/2Dstructure-DB IMGT/3Dstructure-DB Specificity target name
[species]		 Origin clone species Origin clone name Company Application Clinical indication Development status Regulatory agency status and year Expression system Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
218 catumaxomab 8406 93
(2005)		 55
(2006)		 Mus mus. anti-EPCAM (Ho-3/TP-A-01/TPBs01) G2a kappa / Rat sp. anti-CD3E (26/II/6-1.2/TPBs01) G2b lambda,
TPBs01		 REMOVAB® IG Mus musculus
Rattus sp.
Hybrid		 IgG2a kappa / G2b lambda

CD3E (CD3 epsilon) [Homo sapiens] ;
EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, epithelial cell adhesion molecule, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] ;
bispecific 		Fresenius Biotech GmbH (Bad Homburg Germany) / TRION Pharma (Munich Germany) Therapeutic Ovarian cancers Phase II/III Oncology ATC: L01XC09

 [o] (28) (36)
Therapeutic Gastric cancers Phase II/III EC Orphan drug November 03, 2006 Oncology
Therapeutic Malignant ascites Phase M EMA approval April 20, 2009 Oncology
219 ertumaxomab 8407 93
(2005)		 55
(2006)		 Murine G2a 250A/TP-A-02 (anti-ERBB2) / Rat sp. G2b lambda 26/II/6-1.2 (anti-CD3E),
TPBs03		 REXOMUN® IG Mus musculus
Rattus sp.
Hybrid		 IgG2a nd / G2b nd

CD3E (CD3 epsilon) [Homo sapiens] ;
ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340 [Homo sapiens] ;
bispecific 		Fresenius Biotech GmbH (Bad Homburg Germany) / TRION Pharma (Munich Germany) Therapeutic Breast cancers Phase II Oncology [o] (28) (36)

up

Chimeric

Number of results: 33

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT receptor type Species IG class and subclass or IG format FPIA or RPI chain identification Conjugated/ Radiolabelled IMGT/2Dstructure-DB IMGT/3Dstructure-DB Specificity target name
[species]		 Origin clone species Origin clone name Company Application Clinical indication Development status Regulatory agency status and year Expression system Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
146 abciximab 7200 70
(1993)		 34
(1994)		 c7E3 REOPRO® IG Chimeric Fab - G1 kappa

ITGA2B_ITGB3 (integrin alpha2b_beta3, integrin αIIbβ3, GPIIbIIIa, fibrinogen receptor, CD41_CD61) platelet [Homo sapiens] Mus musculus 7E3 Centocor Inc. (Horsham PA USA) / Eli Lilly (Indianapolis IN USA) Therapeutic Anti-platelet prevention of blood clots in the setting of high risk percutaneous transluminal coronary angioplasty Phase M FDA approval December 16, 1993 Sp2/0 mouse myeloma cells Cardiology FDA: (BLA) 103575

Drugnum: 332

NCT

 [a] [b] [e] [f] [j]
Therapeutic Refractory unstable angina when percutaneous coronary intervention is planned Phase M FDA approval November 05, 1997 Sp2/0 mouse myeloma cells Cardiology
64 amatuximab 9343 104
(2010)		 66
(2011)		 MORAb-009 IG Chimeric IgG1 kappa

9343 MSLN (mesothelin, pre-pro-megakaryocyte-potentiating factor, megakaryocyte potentiating factor, MPF, CAK1) [Homo sapiens] Homo sapiens Morphotek Inc. (Exton PA USA) Therapeutic Pancreatic cancers Phase II EC Orphan drug April 01, 2008 Oncology
Therapeutic Malignant pleural mesothelioma Phase II Parental A431 cells and A431-K5 cells (expressing mesothelin) Oncology
148 basiliximab 7578 76
(1996)		 38
(1997)		 CHI621 SIMULECT® IG Chimeric IgG1 kappa

3iu3
1mim		 IL2RA (interleukin-2 receptor, alpha subunit, IL-2RA, TAC, CD25) [Homo sapiens] Mus musculus CHI621 Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Kidney transplant rejection, acute
(Prevention)
Phase M FDA approval January 02, 2003 Immunology FDA: (BLA) 103764

ATC: L04AC02

Drugnum: 440

NCT

 [a] [b] [d] [f] [j] (53) [56]
Therapeutic Organ transplant rejection, acute
(Prevention)
Phase M FDA approval May 12, 1998 Immunology
149 bavituximab 8734 95
(2006)		 57
(2007)		 Tarvacin ch3G4 IG Chimeric IgG1 kappa

8734 phosphatidylserine [Homo sapiens] Mus musculus Peregrine Pharmaceuticals Inc. (Tustin CA USA) Therapeutic Influenza Preclinical Infectiology [p]
Therapeutic Breast cancers Phase II Oncology
Therapeutic Hepatitis C Phase I Infectiology
Therapeutic Non-small cell lung cancers (NSCLC) Phase II Oncology
324 brentuximab vedotin 9144 103
(2010)		 65
(2011)		 cAC10-Val-Cit-MMAE,
SGN-35		 ADCETRIS™ IG Chimeric IgG1 kappa conjugated with monomethyl auristatin E (MMAE)

 9144 TNFRSF8 (tumor necrosis factor receptor (TNFR) superfamily member 8, CD30) [Homo sapiens] Seattle genetics, Inc. (Bothell WA USA) Therapeutic Anaplastic large cell lymphoma (ALCL) Phase M FDA approval August 19, 2011 Oncology FDA: (BLA) 125388


FDA: (BLA) 125399
Therapeutic Hodgkin lymphoma Phase M FDA approval August 19, 2011 Oncology
151 cetuximab 7906 82
(1999)		 44
(2000)		 Fab C225,
IMC-225		 ERBITUX® IG Chimeric IgG1 kappa

7906 1yy8
1yy9		 EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) (epitope on external domain) [Homo sapiens] Mus musculus C225 ImClone Systems Inc. (Somerville NJ USA) (US) / Merck & Co., Inc. (Whitehouse Station NJ USA) (EU) Therapeutic Colorectal cancers, metastatic (EGFR positive) Phase M FDA approval February 12, 2004 Sp2/0 mouse myeloma cells Oncology FDA: (BLA) 125084

ATC: L01XC06

NCI: C1723

Drugnum: 850

NCT

 [a] [b] [e] [j]
152 clenoliximab 7615 77
(1997)		 39
(1998)		 CE9γ4PE,
IDEC-151		 PRIMATIZED® IG Chimeric IgG4 lambda

CD4 (p55) [Homo sapiens] Macaca fascicularis Biogen IDEC Pharmaceuticals (Cambridge MA USA) / GlaxoSmithKline (Brentford UK) Therapeutic Asthma Phase II Immunology [a] [b] (21)
Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
274 ecromeximab 8239 87
(2002)		 49
(2003)		 KM871 IG Chimeric IgG1 nd

GD3 ganglioside [Homo sapiens] Unknown Unknown Unknown
349 ensituximab 9300 103
(2010)		 65
(2011)		 NPC-1C IG Chimeric IgG1 kappa

9300 MUC5AC (mucin 5AC, mucin 5 subtypes A and C tracheobronchial/gastric) [Homo sapiens] Neogenix Oncology, Inc.'s (Rockville, MD 20850 Maryland USA) Therapeutic Colorectal cancers Phase I Oncology
Therapeutic Pancreatic cancers Phase I Oncology
154 galiximab 8339 89
(2003)		 51
(2004)		 IDEC-114 IG Chimeric IgG1 lambda

CD80 (B7-1, CD28LG1) [Homo sapiens] Macaca fascicularis Biogen IDEC Pharmaceuticals (Cambridge MA USA) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase II Oncology NCI: C26447

 [a] [g]
Therapeutic Rheumatoid arthritis (RA) Immunology
Therapeutic Psoriasis Phase II Immunology
328 girentuximab 9116 101
(2009)		 63
(2010)		 cG250,
WX-G250		 RENCAREX® IG Chimeric IgG1 kappa

9116 CA9 (carbonic anhydrase IX, CAIX, MN, G250) [Homo sapiens] Wilex AG (Munich Germany) Therapeutic Renal cell carcinoma (RCC)
(Treatment)
Phase III Oncology
389 indatuximab ravtansine 9486 105
(2011)		 67
(2012)		 BT062,
nBT062-DM4		 IG Chimeric IgG4 kappa conjugated with maytansinoid DM4

 9486 SDC1 (syndecan-1, CD138) [Homo sapiens] Biotest AG (Dreieich Germany) Multiple myeloma Phase I Hematology, Immunology, Oncology [u]
156 infliximab 7602 77
(1997)		 39
(1998)		 cA2 REMICADE® IG Chimeric IgG1 nd

7602 TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Mus musculus A2 Centocor Inc. (Horsham PA USA) Therapeutic Ankylosing spondylitis (AS) Phase M FDA approval December 17, 2004 Sp2/0 mouse myeloma cells Immunology FDA: (BLA) 103772

REMS

ATC: L04AB02

NCI: C1789

Drugnum: 703

Drugnum: 759

NCT

 [a] [b] [d] [f] [j] [53] [54]
Therapeutic Psoriasis, severe chronic plaque Phase M FDA approval September 26, 2006 Immunology
Therapeutic Crohn's disease (CD)
(Treatment)
Phase M FDA approval August 24, 1998 Sp2/0 mouse myeloma cells Immunology
Therapeutic Ulcerative colitis (UC) Phase M FDA approval September 15, 2005 Sp2/0 mouse myeloma cells Immunology
Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval May 18, 2005 Sp2/0 mouse myeloma cells Immunology
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval November 10, 1999 Sp2/0 mouse myeloma cells Immunology
329 iodine (124I) girentuximab 9117 101
(2009)		 63
(2010)		 124I_cG250,
124I_WX-G250		 REDECTANE® IG Chimeric IgG1 kappa

radiolabelled with Iodine-124, I-124		 9117 CA9 (carbonic anhydrase IX, CAIX, MN, G250) [Homo sapiens] Wilex AG (Munich Germany) Diagnostic Kidney tumours
(Treatment)
Phase III Oncology (31)
Diagnostic Renal mass Urology
157 keliximab 7560 76
(1996)		 38
(1997)		 IDEC CE9.1/SB-210396 IG Chimeric IgG1 lambda

CD4 (p55) [Homo sapiens] Macaca fascicularis Biogen IDEC Pharmaceuticals (Cambridge MA USA) Therapeutic Rheumatoid arthritis (RA)
(Treatment)
(chronic)		 Immunology (21)
158 lumiliximab 8443 90
(2004)		 52
(2004)		 IDEC-152,
P5E8		 IG Chimeric IgG1 kappa

FCER2 (immunoglobulin E Fc receptor low affinity II, Fc epsilon RII, CD23) [Homo sapiens] Macaca fascicularis Biogen IDEC Pharmaceuticals (Cambridge MA USA) Therapeutic Allergic asthma Phase I Immunology NCI: C26448

 [a] [h] [i]
Therapeutic Chronic lymphocytic leukemia (CLL) Phase I Hematology, Oncology
235 otelixizumab 8864 98
(2007)		 60
(2008)		 ChAglyCD,
TRX4		 IG Hybrid
Chimeric
Humanized		 IgG1 lambda

8864 CD3E (CD3 epsilon) [Homo sapiens] Rattus sp. YTH12.5 GlaxoSmithKline (Brentford UK) Therapeutic Psoriasis Phase I Immunology
TolerRx (Cambridge CA USA) Therapeutic Type 1 diabetes Phase III Immunology
253 pagibaximab 8643 93
(2005)		 55
(2006)		 IG Chimeric IgG1 kappa

Staphylococcus epidermidis lipoteichoic acid [Staphylococcus epidermidis] Mus musculus Unknown Unknown Unknown
160 priliximab 7263 72
(1994)		 35
(1995)		 cm-MT412 IG Chimeric IgG1 kappa

CD4 (p55) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) Therapeutic Crohn's disease (CD) Phase II Immunology
161 rituximab 7609 77
(1997)		 39
(1998)		 IDEC-C2B8 MABTHERA®
RITUXAN® (US, Canada and Japan) 		IG Chimeric IgG1 kappa

7609 1l6x
2osl		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus IDEC-C2B8 CureTech (Yavne Israel) / IDEC Pharmaceuticals, Inc. (San Diego USA CA) Therapeutic Chronic lymphocytic leukemia (CLL) (CD20-positive, in combination with fludaraline and cyclophosphamide (FC) ) Phase M FDA approval (orphan drug) February 18, 2010 Hematology, Oncology FDA: (BLA) 103705


FDA: (BLA) 103737

ATC: L01XC02

NCI: C1702

Drugnum: 349

NCT

 [a] [b] [d] [f] [j] [q] (18) (49) [55]
Genentech Inc. (S. San Francisco CA USA) / IDEC Pharmaceuticals, Inc. (San Diego USA CA) Therapeutic Non-Hodgkin's lymphoma (NHL)
(Treatment)
(follicular, CD20 positive, relapsed or refractory low grade)		 Phase M FDA approval November 01, 1997 Oncology
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval February 28, 2006 Immunology
Therapeutic Wegener's Granulomatosis (WG) and Microscopic Polygamiitis (MPA), in combination with glucocorticoides Phase M FDA approval April 19, 2011 Hematology
297 siltuximab 9051 100
(2008)		 62
(2009)		 CLLB8,
CNTO 328		 IG Chimeric IgG1 kappa

9051 IL6 (interleukin 6, IL-6) [Homo sapiens] Centocor Inc. (Horsham PA USA) Therapeutic Multiple myeloma Phase II Hematology, Immunology, Oncology
Therapeutic Neoplasms Phase I Oncology
Therapeutic Renal cell carcinoma (RCC) Phase II Oncology
276 teneliximab 8211 87
(2002)		 49
(2003)		 chi220 IG Chimeric IgG1 nd

CD40 (tumor necrosis factor receptor superfamily member 5, TNFRSF5, p50) [Homo sapiens] Unknown Unknown Unknown
372 ublituximab 9334 104
(2010)		 66
(2011)		 LFB-R603 IG Chimeric IgG1 kappa

9334 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Laboratoire Français du fractionnement et des Biotechnologies (LFB) (Courtabœuf France) Therapeutic Chronic lymphocytic leukemia (CLL) Phase I Hematology, Oncology [67]
277 vapaliximab 8207 87
(2002)		 49
(2003)		 2D10 IG Chimeric IgG2 nd

VAP-1 (vascular adhesion protein) [Homo sapiens] Unknown Unknown Unknown
256 volociximab 8600 93
(2005)		 55
(2006)		 IG Chimeric IgG4 nd

ITGA5 (integrin alpha 5 subunit, CD49e) [Homo sapiens] Mus musculus p200-M Unknown Unknown Unknown NCI: C48426
153 12D10 Fab,
12D10-Fab		 CORSEVIN™ M IG Chimeric Fab

Factor VII [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / Corvas International Inc. (San Diego CA USA) Antithrombotic abandonned Hematology [a] [e] (56)
143 131I-chTNT (Tumor Necrosis Therapy) -1/B COTARA® Chimeric

radiolabelled with Iodine-131, I-131		 Mus musculus Peregrine Pharmaceuticals Inc. (Tustin CA USA) Glioblastoma multiforme (GBM) Phase III Oncology [b] (31)
Solid tumors Phase II Oncology
Malignant glioma (brain cancers) Phase II Oncology
144 14,18 Chimeric

Mus musculus National Cancer Institute (Bethesda MD USA) Leukemia Phase II NCI trial Hematology, Oncology [b] [e]
Melanoma Phase II NCI trial Oncology
Neuroblastoma Phase II NCI trial Oncology
Solid tumors Phase II NCI trial Oncology
145 90Y-cT84.66 Chimeric

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e) [Homo sapiens] Mus musculus T84.66 Beckman Research Institute (Duarte CA USA) Cancers Phase I Oncology [p] [59]
147 ALG-991 Chimeric

Mus musculus Allergene (San Mateo CA USA) Poison ivy Phase III Immunology [e]
Poison oak Phase III Immunology
150 BMS-182248,
BR96		 IG Chimeric conjugated with doxorubicin

1cly
1clz		 Mus musculus Bristol-Myers Squibb (Princeton NJ USA) Ovarian cancers Phase II Oncology
Breast cancers Phase II Oncology
155 IC14 Chimeric

CD14 [Homo sapiens] Mus musculus 28C5 ICOS Corporation (Bothell WA USA) Sepsis toxic shock (severe) Phase I CHO (Chinese Hamster Ovary) cells Infectiology [a] [b]
179 IMC-1C11 Chimeric

VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] ImClone Systems Inc. (Somerville NJ USA) Angiogenesis
(Prevention)
Oncology NCI: C2037

up

Humanized

Number of results: 160

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT receptor type Species IG class and subclass or IG format FPIA or RPI chain identification Conjugated/ Radiolabelled IMGT/2Dstructure-DB IMGT/3Dstructure-DB Specificity target name
[species]		 Origin clone species Origin clone name Company Application Clinical indication Development status Regulatory agency status and year Expression system Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
233 alacizumab pegol 8976 98
(2007)		 60
(2008)		 CDP791,
g165 DFM-PEG		 IG Humanized Fab' conjugated with pegol

 8976 KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Therapeutic Cancers Oncology
11 alemtuzumab 8005 83
(2000)		 45
(2001)		 Campath-1H,
LDP-03		 CAMPATH® (US)
MABCAMPATH® (EU) 		IG Humanized IgG1 kappa

8005 1bey
1ce1		 CD52 [Homo sapiens] Rattus norvegicus YTH34.5HL Berlex Inc. (Wayne NJ USA) (US) / Genzyme Corp. (Cambridge MA USA) (EU) / Millennium Pharmaceuticals Inc. (Cambridge MA USA) (EU/US) Therapeutic Kidney transplant rejection Phase I/II CHO (Chinese Hamster Ovary) cells Immunology FDA: (BLA) 103948

ATC: L01XC04

NCI: C1681

Drugnum: 702

NCT

 [a] [b] [c] [19] [75] [76] [77] [78] [79] [80] [81] [82] [83]
Therapeutic Chronic lymphocytic leukemia (CLL) Phase M FDA approval May 07, 2001 CHO (Chinese Hamster Ovary) cells Hematology, Oncology
Therapeutic Multiple sclerosis (MS) Phase I/II CHO (Chinese Hamster Ovary) cells Immunology
231 anrukinzumab 8942 98
(2007)		 60
(2008)		 IMA-638 IG Humanized IgG1 nd

8942 IL13 (interleukin 13, IL-13) [Homo sapiens] Mus musculus IMA-638 Wyeth Pharmaceuticals (Madison NJ USA) Therapeutic Asthma Phase II Immunology
18 apolizumab 8210 87
(2002)		 49
(2003)		 Hu1D10 REMITOGEN™
SMART™ 		IG Humanized IgG1 nd

HLA-DRB (HLA-DR beta) [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) Therapeutic Chronic lymphocytic leukemia (CLL) (refractory) Phase II Hematology, Oncology NCI: C2228

 [b]
Therapeutic Non-Hodgkin's lymphoma (NHL) Phase II Oncology
272 aselizumab 8291 88
(2003)		 50
(2003)		 HuDreg-55 IG Humanized IgG4 nd

SELL (L-selectin, CD62) [Homo sapiens] Unknown Unknown Unknown
252 bapineuzumab 8624 93
(2005)		 55
(2006)		 AAB-001 IG Humanized IgG1 nd

amyloid beta (Abeta) [Homo sapiens] Mus musculus Johnson & Johnson (Langhorne PA USA) / Pfizer (New York NY USA) Therapeutic Alzheimer's disease Phase III Neurology (32) (33)
334 benralizumab 9233 102
(2009)		 64
(2010)		 BIW-8405,
MEDI-563		 IG Humanized IgG1 kappa

9233 IL5RA (interleukin 5 receptor alpha subunit, CD125) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Therapeutic Asthma Phase II Immunology
24 bevacizumab 8017 83
(2000)		 45
(2001)		 12-IgG1,
F(ab)-12 IgG1,
Fab-12 IgG1,
rhuMAb-VEGF		 AVASTIN® IG Humanized IgG1 nd

8017 1bj1 VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Mus musculus muMAb-VEGF, muMAb VEGF A.4.6.1, muMAb VEGF A4.6.1 Genentech Inc. (S. San Francisco CA USA) (EU) Therapeutic Renal cell carcinoma (RCC) Phase M FDA approval July 31, 2009 Oncology FDA: (BLA) 125085

ATC: L01XC07

Drugnum: 851

NCT

 [a] [b] (20)
Therapeutic Breast cancers (metastatic ERB2 negative) Phase M FDA approval February 22, 2008 CHO (Chinese Hamster Ovary) cells Oncology
Therapeutic Colorectal cancers, metastatic Phase M FDA approval February 26, 2004 CHO (Chinese Hamster Ovary) cells Oncology
Therapeutic Glioblastoma Phase M FDA approval February 08, 2011 Oncology
Therapeutic Non-small cell lung cancers, metastatic Phase M FDA approval October 11, 2006 CHO (Chinese Hamster Ovary) cells Oncology
283 bivatuzumab 7965 83
(2000)		 45
(2001)		 BIWA4 IG Humanized IgG1 nd

CD44 (homing function and Indian blood group system, chondroitin sulfate proteoglycan 8, CSPG8) [Homo sapiens] Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) Therapeutic Squamous cancers Phase I Market discontinued (skin toxicity) February 01, 2005 Oncology
375 blosozumab 9440 105
(2011)		 67
(2012)		 LY2541546 IG Humanized IgG4 kappa

9440 SOST (sclerostin) [Homo sapiens] Eli Lilly (Indianapolis IN USA) Therapeutic Postmenopausal women osteoporosis Phase II Osteology
52 cantuzumab mertansine 8223 89
(2003)		 51
(2004)		 huC242-DM1,
SB408075		 IG Humanized IgG1 kappa conjugated with maytansinoid DM1

 MUC1 sialylated carbohydrate, tumour-associated (CA242, cancer antigen 242) [Homo sapiens] Mus musculus C242 GlaxoSmithKline (Brentford UK) / ImmunoGen Inc. (Cambridge MA USA) Therapeutic Colorectal cancers Phase I/II Oncology [b]
Therapeutic Pancreatic cancers Phase I/II Oncology
Therapeutic Non-small cell lung cancers (NSCLC) Phase I/II Oncology
387 cantuzumab ravtansine 9441 105
(2011)		 67
(2012)		 huC242-DM4,
IMGN242		 IG Humanized IgG1 kappa conjugated with maytansinoid DM4

 9441 MUC1 sialylated carbohydrate, tumour-associated (CA242, cancer antigen 242) [Homo sapiens] ImmunoGen Inc. (Cambridge MA USA) Gastric cancers (metastatic or locally advanced) Phase II Oncology
GE Junction Cancer (metastatic or locally advanced) Phase II Oncology
Neoplasms (Stomach) Phase II Oncology
78 cedelizumab 7567 77
(1997)		 39
(1998)		 ORTHOCLONE OKT4 A IG Humanized IgG nd

CD4 (p55) [Homo sapiens] Mus musculus Centocor Ortho Biotech Products LP (Raritan NJ USA) Therapeutic Allograft rejection
(Prevention)
Phase II Immunology [a] [b]
Therapeutic Autoimmune diseases, CD4 mediated
(Treatment)
Phase II Immunology
242 certolizumab pegol 8448 90
(2004)		 52
(2004)		 CDP870,
PHA-738144		 CIMZIA® IG Humanized Fab' conjugated with pegol

 TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Therapeutic Crohn's disease (CD) Phase M FDA approval April 22, 2008 Immunology FDA: (BLA) 125160

REMS

ATC: L04AB05

NCT
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval May 13, 2009 Immunology
236 citatuzumab bogatox 9046 99
(2008)		 61
(2009)		 VB6-845 IG Humanized Fab - G1 kappa conjugated with Bougainvillea spectabilis Willd bouganin

 9046 EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, epithelial cell adhesion molecule, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] Mus musculus Viventia Biotechnologies Inc. (Mississauga ON Canada) Therapeutic Solid tumors Phase I Oncology (29)
378 crenezumab 9482 105
(2011)		 67
(2012)		 MABT5102A IG Humanized IgG4 kappa

9482 amyloid beta (Abeta) peptides Aβ42 and Aβ40 [Homo sapiens] Genentech Inc. (S. San Francisco CA USA) Alzheimer's disease Phase II Neurology
232 dacetuzumab 8959 98
(2007)		 60
(2008)		 huS2C,
SGN-40		 IG Humanized IgG1 nd

8959 CD40 (tumor necrosis factor receptor superfamily member 5, TNFRSF5, p50) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) / Seattle genetics, Inc. (Bothell WA USA) Therapeutic Multiple myeloma Phase I Hematology, Immunology, Oncology [p]
Therapeutic Non-Hodgkin's lymphoma (NHL) Phase I Oncology
Therapeutic Diffuse large B cell lymphoma (DLBCL) Phase II Oncology
36 daclizumab 7164 78
(1997)		 40
(1998)		 ZENAPAX® (EC withdrawal 2009) IG Humanized IgG1 nd

7164 3nfp
3nfs		 IL2RA (interleukin-2 receptor, alpha subunit, IL-2RA, TAC, CD25) [Homo sapiens] Mus musculus 1H4 F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) Therapeutic Kidney transplant rejection, acute
(Prevention)
Withdrawn EC withdrawal (on holders request whith effect from Jan 1, 2009) June 01, 2008, FDA approval December 10, 1997 Immunology FDA: (BLA) 103749

ATC: L04AC01

NCI: C1569

Drugnum: 359

NCT

 [b] [c] [j] (53) [46] [50]
PDL (Protein Design Labs) BioPharma (Fremont CA USA) Therapeutic Liver transplantation Phase II Immunology
Therapeutic Psoriasis Phase II Immunology
Therapeutic Ulcerative colitis (UC) Phase II Immunology
Therapeutic Asthma Phase II Immunology
Therapeutic Graft-versus-host disease (GvHD) Phase II Immunology
Therapeutic Pediatric kidney transplantation Phase I/II Immunology
Therapeutic Tropical spastic paraparesis (TSP model for multiple sclerosis) Phase I/II Immunology, Infectiology, Myelopathy
Therapeutic Uveitis Phase I/II Ophthalmology
Therapeutic Blood cancers Phase II Immunology, Oncology
333 dalotuzumab 9200 102
(2009)		 64
(2010)		 MK-0646 IG Humanized IgG1 kappa

9200 IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Merck & Co., Inc. (Whitehouse Station NJ USA) Therapeutic Solid tumors Phase I Oncology NCI: C70411
37 eculizumab 8231 87
(2002)		 49
(2003)		 5G1.1 SOLIRIS™ IG Humanized IgG nd

C5 (complement 5) [Homo sapiens] Mus musculus Alexion Pharmaceuticals Inc. (New Haven CT USA) Therapeutic Psoriasis Phase I/II Immunology FDA: (BLA) 125166

REMS

ATC: L04AA25

NCI: C48386

Drugnum: 945

NCT

 [a] [b]
Therapeutic Dermatomyositis Phase I/II Immunology
Therapeutic Paroxysmal nocturnal hemoglobinuria (PNH) Phase M FDA approval March 16, 2007 Hematology
Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
Therapeutic Nephritis Phase II Urology
38 efalizumab 8122 85
(2001)		 47
(2002)		 hu1124 RAPTIVA® IG Humanized IgG1 kappa

8122 3eo9
3eoa
3eob		 ITGAL (integrin alpha L subunit, lymphocyte function associated antigen 1, CD11a) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) (EU/US) / Merck Serono International S.A. (Geneva Switzerland) (EU) / Xoma (Berkeley CA USA) (US) Therapeutic Psoriasis (infection in chronic moderate to severe plaque) Withdrawn FDA withdrawal (risk of developing progressive multifocal leukoencephalopathy) March 13, 2009, FDA approval October 27, 2003 CHO (Chinese Hamster Ovary) cells Immunology FDA: (BLA) 125075

ATC: L04AA21

NCI: C68831

 [a] [b] [j]
291 elotuzumab 9074 100
(2008)		 62
(2009)		 HuLuc63,
PDL-063,
PDL063		 IG Humanized IgG1 kappa

9074 SLAMF7 (SLAM family member 7, CD2 subset 1, CS1, CD2-like receptor-activating cytotoxic cells, CRACC,19A24, CD319) [Homo sapiens] Homo sapiens PDL (Protein Design Labs) BioPharma (Fremont CA USA) Therapeutic Multiple myeloma Phase I Hematology, Immunology, Oncology
360 enavatuzumab 9354 104
(2010)		 66
(2011)		 PDL 192 IG Humanized IgG1 kappa

9354 TNFRSF12A (tumor necrosis factor receptor (TNFR) superfamily member 12A, fibroblast growth factor (FGF)-inducible 14 kDa protein, Fn14, TNF-like weak inducer of apoptosis (Tweak) receptor, Tweak receptor, TweakR, CD266) [Homo sapiens] Facet Biotech (Redwood City CA USA) Therapeutic Solid tumors Phase I Oncology NCI: C80045

 [r]
361 enokizumab 9262 104
(2010)		 66
(2011)		 7F3com-2H2,
MEDI-528		 IG Humanized IgG1 kappa

9262 IL9 (interleukin 9, IL-9, T cell growth factor p40) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Therapeutic Asthma Phase II Immunology [72]
40 epratuzumab 7920 82
(1999)		 44
(2000)		 90Y-DOTA-hLL2,
90Y-epratuzumab tetraxetan,
90Y-hLL2,
AMG-412,
hLL2,
IMMU-hLL2		 LYMPHOCIDE™ IG Humanized IgG1 nd conjugated with chelator tetraxetan (DOTA)

radiolabelled with Yttrium-90, Y-90		 CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) [Homo sapiens] Mus musculus LL2 Immunomedics Inc. (Morris Plains NJ USA) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase I/II Oncology [a] [b] [e] (31)
Therapeutic Systemic lupus erythematosus (SLE) Immunology
280 erlizumab 8076 84
(2000)		 46
(2001)		 rhuMAb IG Humanized IgG1 nd

ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] Unknown Unknown Unknown
240 etaracizumab 8862 99
(2008)		 61
(2009)		 hLM60,
MEDI-522		 VITAXIN®
ABEGRIN™ 		IG Humanized IgG1 nd

8862 ITGAV_ITGB3 (integrin alphaV_beta3, integrin αVβ3, CD51_GPIIIa, vitronectin receptor, VNR, CD51_CD61) [Homo sapiens] Mus musculus LM609 MedImmune Inc. (Gaithersburg MD USA) Therapeutic Sarcoma Phase II Oncology [a]
Therapeutic Melanoma, metastatic Phase II Oncology
362 etrolizumab 9290 104
(2010)		 66
(2011)		 Anti-Beta7,
PRO145223,
RG7413,
rhuMAb Beta7		 IG Humanized IgG1 kappa

9290 ITGA4_ITGB7 (integrin alpha4_beta7, integrin α4β7, lymphocyte Peyer's patch adhesion molecule 1, LPAM-1) [Homo sapiens] ;
ITGAE_ITGB7 (integrin alphaE_beta7, integrin αEβ7, human mucosal lymphocyte antigen 1, HML-1) [Homo sapiens] 		F. Hoffmann-La Roche Ltd. (Basel Switzerland) Therapeutic Ulcerative colitis (UC) Phase I Immunology
292 farletuzumab 9067 100
(2008)		 62
(2009)		 M3,
MORAb-003		 IG Humanized IgG1 kappa

9067 FOLR1 (folate receptor 1, folate receptor FR alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18) [Homo sapiens] Morphotek Inc. (Exton PA USA) Therapeutic Ovarian cancers Phase II EC Orphan drug April 01, 2008 Oncology
86 felvizumab 7623 77
(1997)		 39
(1998)		 SB 209763 IG Humanized IgG1 nd

RSV (human respiratory syncytial virus, glycoprotein F) [Respiratory syncytial virus] Mus musculus Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) Therapeutic Respiratory Syncytial Virus (RSV) disease
(Treatment)
(Prophylaxis)		 Phase III Infectiology, Pulmonary, Respiratory diseases [e]
379 ficlatuzumab 9465 105
(2011)		 67
(2012)		 AV-299 ,
SCH 900105		 IG Humanized IgG1 kappa

9465 HGF (hepatocyte growth factor, scatter factor, SF, hepatopoeitin A) [Homo sapiens] Mus musculus AVEO Pharmaceuticals (Cambridge MA US) Neoplasms Phase I Oncology
Lung cancers Phase I Oncology
Solid tumors Phase I Oncology
Non-small cell lung cancers (NSCLC) Phase II Oncology
43 fontolizumab 8264 87
(2002)		 49
(2003)		 IG Humanized IgG1 nd

IFNG (interferon gamma, IFN gamma) [Homo sapiens] Mus musculus Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) Therapeutic Crohn's disease (CD) Phase I/II Immunology
44 gemtuzumab 8024 83
(2000)		 45
(2001)		 CMA-676,
gemtuzumab ozogamicin		 MYLOTARG® IG Humanized IgG4 kappa conjugated with calicheamicin

 CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) [Homo sapiens] Mus musculus P67.6 Pfizer (New York NY USA) Therapeutic Acute myeloid leukemia (AML) (CD33 positive) Withdrawn FDA withdrawal (by Pfizer, on concerns about the product's safety and absence of clinical benefit in trials) June 01, 2010, FDA approval May 17, 2000 Hematology, Oncology ATC: L01XC05

 [f] [j] (17) (33)
102 gevokizumab 9310 104
(2010)		 66
(2011)		 XOMA 052 IG Humanized IgG2 kappa

9310 IL1B (interleukin 1 beta, IL-1B) [Homo sapiens] Mus musculus Xoma (Berkeley CA USA) Therapeutic Cardiovascular disease Phase II Cardiology [p] [71]
Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
Therapeutic Type 2 diabetes Phase II Immunology
Therapeutic Type 1 diabetes Phase II Immunology
332 glembatumumab 9199 102
(2009)		 64
(2010)		 CDX-011,
CR011-vcMMAE,
glembatumumab vedotin		 IG Humanized IgG2 kappa conjugated with monomethyl auristatin E (MMAE)

 9199 GPNMB (glycoprotein transmembrane NMB, hematopoeitic growth factor inducible neurokinin-1 type, HGFIN) extracellular domain [Homo sapiens] Celldex Therapeutics, Inc. (Needham USA) Therapeutic Breast cancers Phase II Oncology (29)
Therapeutic Melanoma, metastatic Phase II Oncology
241 ibalizumab 8818 97
(2007)		 59
(2008)		 Hu5A8,
TNX-355		 IG Humanized IgG4 nd

8818 3o2d CD4 (p55) [Homo sapiens] Mus musculus Tanox Inc. (Houston TX USA) Therapeutic HIV infection, AIDS Phase II Infectiology [l]
259 inotuzumab ozogamicin 8574 92
(2004)		 54
(2005)		 CMC-544 IG Humanized IgG4 kappa conjugated with calicheamicin

 CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) [Homo sapiens] Mus musculus G544 Wyeth Pharmaceuticals (Madison NJ USA) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase II Oncology
Therapeutic Diffuse large B cell lymphoma (DLBCL) Phase II Oncology
351 itolizumab 9321 103
(2010)		 65
(2011)		 T1h IG Humanized IgG1 kappa

9321 CD6 (Tp120) [Homo sapiens] Biocon (Bangalore India) Therapeutic Psoriasis Phase II Immunology
Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
380 ixekizumab 9467 105
(2011)		 67
(2012)		 LY2439821 IG Humanized IgG4 kappa

9467 IL17A (interleukin 17A, IL-17A) [Homo sapiens] Eli Lilly (Indianapolis IN USA) Psoriasis Phase II Immunology
Rheumatoid arthritis (RA) Phase II Immunology
62 labetuzumab 8127 85
(2001)		 47
(2002)		 hMN14 CEACIDE™ IG Humanized IgG nd

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e) [Homo sapiens] Mus musculus Immunomedics Inc. (Morris Plains NJ USA) Therapeutic Colorectal cancers Phase I/II Oncology NCI: C2043

 [b]
325 lebrikizumab 9165 101
(2009)		 63
(2010)		 MILR1444A,
PRO301444		 IG Humanized IgG4 kappa

9165 IL13 (interleukin 13, IL-13) [Homo sapiens] Genentech Inc. (S. San Francisco CA USA) Therapeutic Allergic asthma Immunology
53 lintuzumab 7580 76
(1996)		 38
(1997)		 HuM195,
SGN-33		 ZAMYL™
Smart™ M195 		IG Humanized IgG nd

CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) / Seattle genetics, Inc. (Bothell WA USA) Therapeutic Acute myeloid leukemia (AML) Discontinued Sp2/0 mouse myeloma cells (ATCC CRL 1581) Hematology, Oncology [b] (58) [32]
58 lorvotuzumab mertansine 9299 103
(2010)		 65
(2011)		 BB-10901,
huN901-DM1,
IMGN901		 IG Humanized IgG1 kappa conjugated with maytansinoid DM1

 9299 NCAM1 (neural cell adhesion molecule 1, NCAM-1, NCAM, CD56) [Homo sapiens] Mus musculus ImmunoGen Inc. (Cambridge MA USA) Therapeutic Small cell lung cancers (SCLC) CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Oncology [c] [36]
39 matuzumab 8103 88
(2003)		 50
(2003)		 EMD-72000,
EMD72000		 IG Humanized IgG1 nd

3c09 EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) (epitope on external domain) [Homo sapiens] Mus musculus 425 Merck Serono International S.A. (Geneva Switzerland) / Takeda Pharmaceutical Co. Ltd. (Osaka Japan) Therapeutic Gastric cancers Phase II Oncology [c] [k] [4]
Therapeutic Lung cancers Phase II Oncology
335 mavrilimumab 9234 102
(2009)		 64
(2010)		 CAM-3001 IG Humanized IgG1 lambda

9234 CSF2RA (colony-stimulating factor 2(granulocyte-macrophage) receptor alpha subunit, GM-CSF-R-alpha, CD116) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
87 mepolizumab 7876 81
(1999)		 43
(2000)		 SB-240563 Bosatria® IG Humanized

IL5 (interleukin 5, IL-5) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) Therapeutic Asthma Phase II Immunology ATC: L04AC06

 [a]
Therapeutic Atopic dermatitis Phase II Immunology
Therapeutic Hypereosinophilic syndrome (HES) Phase III Hematology
135 milatuzumab 8922 98
(2007)		 60
(2008)		 hLL1,
MEDI-115		 IG Humanized IgG1 nd

8922 CD74 (major histocompatibility class II invariant chain, MH2) [Homo sapiens] Mus musculus Immunomedics Inc. (Morris Plains NJ USA) Therapeutic Multiple myeloma Hematology, Immunology, Oncology
366 mogamulizumab 9374 104
(2010)		 66
(2011)		 AMG-761,
KM8761,
KW-0761		 IG Humanized IgG1 kappa

9374 CCR4 (chemokine (C-C motif) receptor 4, chemokine CC receptor 4, CCR-4, CKR4, k5-5, CD194) [Homo sapiens] Amgen (Thousand Oaks CA USA) Therapeutic Asthma Phase I Immunology NCI: C62510

 (51) [73]
Kyowa Hakko Kirin (Tokyo Japan) Therapeutic Peripheral T cell lymphoma and cutaneous T cell lymphoma Phase I/II Oncology
Therapeutic Peripheral T/NK cell lymphoma Phase II Hematology, Oncology
Therapeutic Adult T cell leukemia / lymphoma Phase II Hematology, Oncology
73 motavizumab 8693 95
(2006)		 57
(2007)		 MEDI-524 NUMAX® IG Humanized IgG1 kappa

8693 3ixt
3qwo		 RSV (human respiratory syncytial virus, glycoprotein F) [Respiratory syncytial virus] Mus musculus MedImmune Inc. (Gaithersburg MD USA) Therapeutic Respiratory Syncytial Virus (RSV) disease
(Unknow)
Phase II Infectiology, Pulmonary, Respiratory diseases [p]
75 natalizumab 7716 79
(1998)		 41
(1999)		 AN100226 TYSABRI®
ANTEGREN® (formerly) 		IG Humanized IgG4 nd

ITGA4 (integrin apha 4 subunit, CD49d) [Homo sapiens] Mus musculus AN100226m Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Elan Pharmaceuticals International Ltd. (Dublin Ireland) Therapeutic Inflammatory conditions, acute and chronic COS cells transient expression Immunology FDA: (BLA) 125104

ATC: L04AA23

Drugnum: 869

NCT

 [a] [b] [c] [e] [j] [k] (3) (4) [7]
Therapeutic Colitis Phase II Immunology
Therapeutic Crohn's disease (CD) Phase M FDA approval January 14, 2008 NSO mouse myeloma cells Immunology
Therapeutic Multiple sclerosis (MS) Phase M FDA SBLA reintroduced June 05, 2006, Market suspension (three patients developed progressive multifocal leukoencephalopathy (PML)) February 28, 2005, FDA approval November 23, 2004 NSO mouse myeloma cells Immunology
76 nimotuzumab 8545 94
(2005)		 56
(2006)		 hR3,
Theraloc		 THERACIM® (India, China, Cuba, Argentina, Columbia) IG Humanized IgG1 kappa

3gkw EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) (epitope on external domain) [Homo sapiens] Mus musculus YM BioSciences Inc. (Mississauga Canada) Therapeutic Pancreatic cancers Phase M EMA Orphan drug June 03, 2008 NSO mouse myeloma cells Oncology NCI: C2733

 [n]
Therapeutic Lung cancers Phase II Oncology
Therapeutic Head cancers Phase M NSO mouse myeloma cells Oncology
Therapeutic Gastric cancers Phase II Oncology
Therapeutic Glioma cancers Phase M EMA withdrawal December 04, 2008, EMA Orphan drug September 02, 2004 NSO mouse myeloma cells Oncology
Therapeutic Pancreatic cancers, metastatic Phase II Oncology
Therapeutic Neck cancers Phase M NSO mouse myeloma cells Oncology
238 obinutuzumab 9043 99
(2008)		 GA101 IG Humanized IgG1 kappa

9043 3pp3
3pp4		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus B-ly1 Biogen IDEC Pharmaceuticals (Cambridge MA USA) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) / Genentech Inc. (S. San Francisco CA USA) Therapeutic Non-Hodgkin's lymphoma (NHL) Oncology [p] (40)
227 ocrelizumab 8636 94
(2005)		 56
(2006)		 2H7 IG Humanized IgG1 nd

MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus Biogen IDEC Pharmaceuticals (Cambridge MA USA) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) / Genentech Inc. (S. San Francisco CA USA) Therapeutic Systemic lupus erythematosus (SLE) Phase III Immunology NCI: C66250
Therapeutic Rheumatoid arthritis (RA) Phase III Immunology
Therapeutic Lupus nephritis Phase III Immunology
Therapeutic Multiple sclerosis (MS) (relapsing remitting) Phase II Immunology
353 olokizumab 9333 103
(2010)		 65
(2011)		 CDP 6038 IG Humanized IgG4 kappa

9333 IL6 (interleukin 6, IL-6) [Homo sapiens] UCB (Brussels Belgium) Therapeutic Autoimmune diseases Phase I Immunology
77 omalizumab 8039 84
(2000)		 46
(2001)		 IGE25,
olizumab,
pSVIE26,
rhuMab-E25		 XOLAIR® IG Humanized IgG1 kappa

8039 IgE Fc [Homo sapiens] Mus musculus MaE11 Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Tanox Inc. (Houston TX USA) Therapeutic Asthma, severe persistent (allergic asthma) Phase M FDA approval (for subcutaneous use) June 20, 2003 CHO (Chinese Hamster Ovary) cells Immunology FDA: (BLA) 103976

REMS

NCI: C29299

NCT

 [a] [b] [l]
368 onartuzumab 9368 104
(2010)		 66
(2011)		 MetMAb,
OA-5D5,
PRO 143966		 IG Humanized Fab/Fc - IgG1 kappa

9368 MET (met proto-oncogene, hepatocyte growth factor HGF receptor, HGFR, scatter factor SF receptor, HGF/SF receptor, tyrosine protein kinase c-met, papillary renal cell carcinoma 2, RCCP2) [Homo sapiens] Genentech Inc. (S. San Francisco CA USA) Therapeutic Solid tumors Phase I Oncology
237 oportuzumab monatox 9045 100
(2008)		 62
(2009)		 VB4-845 PROXINIUM™
VICINIUM™ 		IG Humanized scFv conjugated with Pseudomonas aeruginosa exotoxin A

 9045 EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, epithelial cell adhesion molecule, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] Homo sapiens Viventia Biotechnologies Inc. (Mississauga ON Canada) Therapeutic Head cancers Phase II/III FDA Orphan drug (US) February 01, 2005 Oncology (29)
Therapeutic Bladder cancers Phase II FDA Orphan drug (US) February 01, 2005 Oncology
Therapeutic Neck cancers Phase II/III FDA Orphan drug (US) February 01, 2005 Oncology
235 otelixizumab 8864 98
(2007)		 60
(2008)		 ChAglyCD,
TRX4		 IG Hybrid
Chimeric
Humanized		 IgG1 lambda

8864 CD3E (CD3 epsilon) [Homo sapiens] Rattus sp. YTH12.5 GlaxoSmithKline (Brentford UK) Therapeutic Psoriasis Phase I Immunology
TolerRx (Cambridge CA USA) Therapeutic Type 1 diabetes Phase III Immunology
382 ozoralizumab 9369 105
(2011)		 67
(2012)		 ATN-103 IG Humanized VH-VH'-VH

TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] ;
ALB (albumin, human serum albumin, HSA) [Homo sapiens] ;
bispecific 		Lama glama Pfizer (New York NY USA) (USA/Japan) Rheumatoid arthritis (RA) Phase II Immunology
79 palivizumab 7753 79
(1998)		 41
(1999)		 MEDI-493 SYNAGIS® IG Humanized IgG1 kappa

RSV (human respiratory syncytial virus, glycoprotein F) [Respiratory syncytial virus] Mus musculus Abbott Laboratories (Abbott Park IL USA) (EU) / MedImmune Inc. (Gaithersburg MD USA) (US) Therapeutic Respiratory Syncytial Virus (RSV) disease (prophylaxis of lower respiratory tract disease in pediatric patients) Phase M AMM Market authorization (Abbott) August 01, 1999, FDA approval June 19, 1998 NSO mouse myeloma cells Infectiology, Pulmonary, Respiratory diseases FDA: (BLA) 103770

NCI: C2625

Drugnum: 447

NCT

 [a] [b] [d] [j] [49]
88 pascolizumab 8227 87
(2002)		 49
(2003)		 SB-240683 IG Humanized

IL4 (interleukin 4, IL-4) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) Therapeutic Allergy Phase II Immunology [a]
Therapeutic Asthma Phase II Immunology
383 pateclizumab 9428 105
(2011)		 67
(2012)		 MLTA3698A,
PRO283698,
RG7416		 IG Humanized IgG1 kappa

9428 LTA (lymphotoxin alpha, TNF superfamily member 1, TNFSF1, LT) [Homo sapiens] F. Hoffmann-La Roche Ltd. (Basel Switzerland) Rheumatoid arthritis (RA) Phase II Immunology [t]
Disease-Modifying Anti-Rheumatic Drug (DMARD) Phase II Immunology
80 pertuzumab 8380 89
(2003)		 51
(2004)		 rhuMAB 2C4 OMNITARG™ IG Humanized IgG1 kappa

8380 1l7i
1s78		 ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340 [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) Therapeutic Breast cancers Phase III Oncology NCI: C38692
Therapeutic Prostate cancers Phase II Oncology
81 pexelizumab 8153 85
(2001)		 47
(2002)		 5G1.1-SC IG Humanized scFv

C5 (complement 5) [Homo sapiens] Mus musculus Alexion Pharmaceuticals Inc. (New Haven CT USA) Therapeutic Cardiopulmonary bypass Phase III Cardiology [a]
Therapeutic Myocardial infection Phase II Cardiology
369 ponezumab 9322 104
(2010)		 66
(2011)		 clone 9TL,
PF-04360365,
RN-1219		 IG Humanized IgG2 kappa

9322 amyloid beta (Abeta) peptide Aβ40 [Homo sapiens] Homo sapiens 9TL Pfizer (New York NY USA) Therapeutic Alzheimer's disease Phase II Neurology
84 ranibizumab 8313 90
(2004)		 52
(2004)		 Fab-12 variant Y0317,
RhuFab		 LUCENTIS® IG Humanized Fab

8313 1cz8 VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Mus musculus muMAb-VEGF, muMAb VEGF A.4.6.1, muMAb VEGF A4.6.1 Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Age related macular degeneration (AMD), neovascular (wet) Phase M FDA approval June 30, 2006 E.coli (Escherichia coli) Ophthalmology FDA: (BLA) 125156

Drugnum: 904

NCT
279 reslizumab 8106 85
(2001)		 47
(2002)		 JES139D10,
SCH55700		 IG Humanized IgG4 nd

IL5 (interleukin 5, IL-5) [Homo sapiens] Cephalon (Frazer PA USA) Therapeutic Adult eosinophilic asthma Phase III Immunology
327 rontalizumab 9114 101
(2009)		 63
(2010)		 RhuMAB IFNalpha IG Humanized IgG1 kappa

9114 IFNA1 (interferon alpha 1, IFN alpha, IFN alpha 1/13, IFN 13) [Homo sapiens] Genentech Inc. (S. San Francisco CA USA) Therapeutic Systemic lupus erythematosus (SLE)
(Treatment)
Phase II Immunology
304 rovelizumab 7869 81
(1999)		 43
(2000)		 Hu23F2G LEUKARREST™ IG Humanized IgG4 nd

ITGAL (integrin alpha L subunit, lymphocyte function associated antigen 1, CD11a) [Homo sapiens] ;
ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] ;
bispecific 		Eli Lilly (Indianapolis IN USA) Therapeutic Ischemic stroke Phase III Hematology [b]
Therapeutic Multiple sclerosis (MS) Phase II Immunology
Therapeutic Myocardial infection Phase II Cardiology
17 ruplizumab 8014 83
(2000)		 45
(2001)		 BG-9588,
hu5c8		 Antova™ IG Humanized IgG1 kappa

CD40LG (CD40 ligand, CD40L, tumor necrosis factor ligand superfamily member 5, TNFSF5, tumor necrosis factor related activation protein, TRAP, CD154) [Homo sapiens] Mus musculus Biogen IDEC Pharmaceuticals (Cambridge MA USA) Therapeutic Allograft rejection Phase I/II Immunology [a]
Therapeutic Systemic lupus erythematosus (SLE) Phase II Immunology
356 samalizumab 9307 103
(2010)		 65
(2011)		 ALXN6000,
Anti-CD200,
hB7V3V2 G2G4		 IG Humanized IgG2/G4 kappa

9307 CD200 (OX-2) [Homo sapiens] Alexion Pharmaceuticals Inc. (New Haven CT USA) Therapeutic Blood cancers Preclinical Immunology, Oncology [68]
Therapeutic Multiple myeloma Preclinical Hematology, Immunology, Oncology
285 sibrotuzumab 7866 81
(1999)		 43
(2000)		 BIBH1 IG Humanized

FAP ( fibroblast activation protein, alpha) [Homo sapiens] Unknown Unknown Unknown
71 siplizumab 8251 87
(2002)		 49
(2003)		 MEDI-507 IG Humanized IgG1 nd

CD2 (lymphocyte function-antigen 2, LFA-2) [Homo sapiens] Rattus sp. BT1-322 BioTransplant (Charlestown MA USA) / MedImmune Inc. (Gaithersburg MD USA) Therapeutic Acute kidney transplant rejection Phase I/II Immunology [a] [b]
Therapeutic Graft-versus-host disease (GvHD) Phase II Immunology
Therapeutic Psoriasis Phase II Immunology
298 solanezumab 9097 100
(2008)		 62
(2009)		 LY2062430 IG Humanized IgG1 kappa

9097 amyloid beta (Abeta) peptide soluble monomer [Homo sapiens] Homo sapiens Eli Lilly (Indianapolis IN USA) Therapeutic Alzheimer's disease Phase II Neurology
251 sontuzumab 8438 94
(2005)		 56
(2006)		 AS1402,
huHMFG-1		 IG Humanized IgG1 nd

MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227) [Homo sapiens] Mus musculus Antisoma (London UK) Therapeutic Breast cancers Phase I Oncology
330 suvizumab 9185 102
(2009)		 64
(2010)		 KD-247 IG Humanized IgG1 nd

9185 HIV-1 (human immunodeficiency virus) IIIB gp120 V3 loop [Human immunodeficiency virus 1] Mus musculus C25 The Chemo-Sero-Therapeutic Research Institute (Kumamoto Japan ) Unknown HIV infection, AIDS
(Treatment)
Phase I Infectiology [63]
103 tadocizumab 8651 94
(2005)		 56
(2006)		 C4G1,
YM-337		 IG Humanized Fab - G1 kappa

8651 ITGA2B_ITGB3 (integrin alpha2b_beta3, integrin αIIbβ3, GPIIbIIIa, fibrinogen receptor, CD41_CD61) platelet [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) / Yamanouchi USA (White Plains NY USA) Therapeutic Platelet aggregation Phase II Hematology [b]
271 talizumab 8370 89
(2003)		 51
(2004)		 Hu901 IG Humanized IgG1 nd

IgE Fc [Homo sapiens] Unknown Unknown Unknown
230 tanezumab 8941 99
(2008)		 61
(2009)		 RN624 IG Humanized IgG2 nd

8941 NGF (nerve growth factor, nerve growth factor beta polypeptide, NGFB, beta-NGF) [Homo sapiens] Mus musculus Pfizer (New York NY USA) Therapeutic Pain, severe acute Phase II Neurology
Therapeutic Pain chronic Phase II Neurology
261 tefibazumab 8500 92
(2004)		 54
(2005)		 Aurexis IG Humanized IgG1 nd

ClfA (Clumping factor A) [Staphylococcus aureus] Unknown Unknown Unknown
92 teplizumab 8869 97
(2007)		 59
(2008)		 hOKT3-gamma-1 (Ala-Ala),
humanized OKT3,
MGA031		 IG Humanized IgG1 kappa

8869 CD3E (CD3 epsilon) [Homo sapiens] Mus musculus OKT3 MacroGenics Inc. (Rockville MD USA) Therapeutic Type 1 diabetes Phase I/II CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells, COS-1 cells transient expression and larger scale preparation in roller bottles Immunology [c] [37]
234 tigatuzumab 8979 98
(2007)		 60
(2008)		 CS-1008,
TRA-8		 IG Humanized IgG1 nd

8979 TNFRSF10B (tumor necrosis factor receptor (TNFR) superfamily member 10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAILR2, TRAIL-R2, TR-2, CD262) [Homo sapiens] Mus musculus Daiichi Sankyo Inc. (Parsippany NJ USA) Unknown Unknown
96 tocilizumab 8394 90
(2004)		 52
(2004)		 atlizumab,
MRA,
rhPM-1		 ACTEMRA™
RoACTEMRA® (EU) 		IG Humanized IgG1 kappa

8394 IL6R (interleukin 6 receptor, IL-6R, CD126) [Homo sapiens] Mus musculus Chugai pharmaceuticals Co. Ltd. (Tokyo Japan) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) Therapeutic Lymphoproliferative disorder giant lymph node hyperplasia (Castleman's disease) Phase III Approval (by Japan) June 01, 2005, NDA approval April 01, 2005 CHO (Chinese Hamster Ovary) DHFR cells Oncology FDA: (BLA) 125276

REMS

EMA: H-C-955

ATC: L04AC07

NCT

 [c] (5) [38] [84] [85]
Therapeutic Multiple myeloma CHO (Chinese Hamster Ovary) DHFR cells Hematology, Immunology, Oncology
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval January 08, 2010, EMA approval January 16, 2009, Approval (by Japan) April 17, 2008 CHO (Chinese Hamster Ovary) DHFR cells Immunology
Diagnostic, Therapeutic Systemic juvenile idiopathic athritis (SJIA) Phase M FDA approval (sBLA) April 15, 2011 Immunology
60 toralizumab 8232 87
(2002)		 49
(2003)		 E6040,
IDEC-131		 IG Humanized

CD40LG (CD40 ligand, CD40L, tumor necrosis factor ligand superfamily member 5, TNFSF5, tumor necrosis factor related activation protein, TRAP, CD154) [Homo sapiens] Mus musculus Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Eisai Co. Ltd. (Tokyo Japan) Therapeutic Systemic lupus erythematosus (SLE) Phase I Immunology [a] [b]
Therapeutic Multiple sclerosis (MS) Phase II Immunology
97 trastuzumab 7637 78
(1997)		 40
(1998)		 4D5V8,
Herceptin		 HERCEPTIN® IG Humanized IgG1 kappa

7637 1n8z ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340 [Homo sapiens] Mus musculus 4D5 F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) / Genentech Inc. (S. San Francisco CA USA) (US) Therapeutic Breast cancers overexpressing ERBB2, metastatic Phase M AMM Market authorization (Roche) August 01, 2000, FDA approval September 01, 1998 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Oncology FDA: (BLA) 103792

ATC: L01XC03

NCI: C1647

Drugnum: 485

NCT

 [a] [b] [d] [e] [j] [48]
Genentech Inc. (S. San Francisco CA USA) Therapeutic Gastric cancers Phase M FDA approval October 20, 2010 Oncology
357 trastuzumab emtansine 9295 103
(2010)		 65
(2011)		 PRO132365,
T-DM1,
trastuzumab-MCC-DM1		 IG Humanized IgG1 kappa conjugated with maytansinoid DM1

 9295 ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340 [Homo sapiens] F. Hoffmann-La Roche Ltd. (Basel Switzerland) Therapeutic Breast cancers overexpressing ERBB2, metastatic Phase III FDA denies accelerated approval August 01, 2010 Oncology
371 tregalizumab 9413 104
(2010)		 66
(2011)		 BT-061,
hB-F5,
hBF5(H37L_L4M)		 IG Humanized IgG1 kappa

9413 CD4 (p55) [Homo sapiens] Biotest AG (Dreieich Germany) Therapeutic Psoriasis Phase II Immunology [s]
Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
254 tucotuzumab celmoleukin 8652 94
(2005)		 56
(2006)		 EMD 273066,
huKS-IL2,
KSA-Interleukin-2		 IG Humanized IgG1 nd conjugated with interleukin 2

 EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, epithelial cell adhesion molecule, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] Merck Serono International S.A. (Geneva Switzerland) Therapeutic Ovarian cancers Phase II Oncology
Therapeutic Small cell lung cancers (SCLC) Phase II Oncology
265 urtoxazumab 8276 90
(2004)		 52
(2004)		 HuVTm1.1 IG Humanized

Shiga-like toxin II B subunit [Escherichia coli] Unknown Unknown Unknown
386 vatelizumab 9439 105
(2011)		 67
(2012)		 GBR500 IG Humanized IgG4 kappa

9439 ITGA2 (integrin alpha 2, GPIa, subunit of the alpha2beta1 integrin (VLA-2, collagen receptor), CD49b) [Homo sapiens] Glenmark Pharmaceuticals SA (Neuchâtel Switzerland) / Sanofi-Aventis (Paris France) Multiple sclerosis (MS) Phase I Immunology
Chronic Obstructive Pulmonary Disease (COPD) Phase I Pulmonary, Respiratory diseases
Inflammatory bowel disease (IBD) Phase I Immunology
300 vedolizumab 9093 100
(2008)		 62
(2009)		 LDP-02,
LDP02,
MLN-02,
MLN0002,
MLN02		 IG Humanized IgG1 kappa

9093 ITGA4_ITGB7 (integrin alpha4_beta7, integrin α4β7, lymphocyte Peyer's patch adhesion molecule 1, LPAM-1) [Homo sapiens] Homo sapiens Genentech Inc. (S. San Francisco CA USA) / Millennium Pharmaceuticals Inc. (Cambridge MA USA) / MRC Technology (London UK) Therapeutic Ulcerative colitis (UC) Phase II Immunology [a] [b] [k]
21 veltuzumab 8932 98
(2007)		 60
(2008)		 hA20,
IMMU-106		 IG Humanized IgG1 nd

8932 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus Immunomedics Inc. (Morris Plains NJ USA) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase I Oncology
100 visilizumab 8054 84
(2000)		 46
(2001)		 HuM291 NUVION®
SMART™ anti-CD3 		IG Humanized IgG2 nd

CD3E (CD3 epsilon) [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) Therapeutic Kidney transplantation Phase II Immunology NCI: C2687

 [a] [b]
Therapeutic Allograft rejection Phase I/II Immunology
Therapeutic Intravenous steroid-refractory ulcerative colitis (IVSR-UC) Phase I/II Immunology
Therapeutic Psoriasis Phase I/II Immunology
Therapeutic Autoimmune diseases Phase I Immunology
229 yttrium (90 Y) clivatuzumab tetraxetan 9226 102
(2009)		 64
(2010)		 IG Humanized IgG1 kappa conjugated with chelator tetraxetan (DOTA)

radiolabelled with Yttrium-90, Y-90		 9226 MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227) [Homo sapiens] Immunomedics Inc. (Morris Plains NJ USA) Therapeutic Pancreatic cancers (metastatic) Phase II Oncology (31)
255 yttrium (90Y) tacatuzumab tetraxetan 8484 91
(2004)		 55
(2006)		 hAFP-31 AFP-Cide™ IG Humanized IgG1 kappa conjugated with chelator tetraxetan (DOTA)

radiolabelled with Yttrium-90, Y-90		 AFP (alpha-fetoprotein) [Homo sapiens] Mus musculus Immunomedics Inc. (Morris Plains NJ USA) Therapeutic Cancers Oncology (31)
1 0.5B,
0.5beta		 IG Humanized IgG1 nd

1qnz HIV-1 (human immunodeficiency virus) IIIB gp120 V3 loop [Human immunodeficiency virus 1] Mus musculus Kaketsuken (Kumamoto Japan) / MRC Technology (London UK) HIV infection, AIDS
(Prevention and treatment)
Preclinical COS cells transient expression Infectiology [c] [k] (1) [1]
2 15,
4F2		 IG Humanized IgG1 nd

SFRP1 (selected frizzled-related protein 1, fusion regulatory protein 1, FRP-1) [Homo sapiens] ;
SLC3A2 (solute carrier family 3 (activators of dibasic and neutral amino acid transport) member 2, 4F2 antigen heavy chain, 4F2HC, CD98 heavy chain, CD98hc, CD98) [Homo sapiens] 		Mus musculus Merck KgaA (Darmstadt Germany) / MRC Technology (London UK) Therapeutic Cancers Oncology
3 1B4 IG Humanized IgG4 nd

ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] Mus musculus Merck & Co., Inc. (Whitehouse Station NJ USA) / NIH (Bethesda MD USA) Acute inflammatory disease CV1P cells Immunology [c] [2]
4 3α4D10 IG Humanized IgG1 nd

toxin (epitope ARGFAK) [Clostridium perfringens] Mus musculus Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) Gas gangrene YB2/0 rat myeloma cells Infectiology [c] [3]
220 520C9XH22,
MDX-H210,
Murine 520C9 (anti-ERBB2)/ Humanized H22 (anti-FcγRI)		 IG Humanized F(ab') 2 - G1 nd

FCGR1 (immunoglobulin G Fc receptor high affinity I, Fc gamma RI, CD64, encoded by human FCGR1A, FCGR1B, FCGR1C) [Homo sapiens] ;
ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340 [Homo sapiens] ;
bispecific 		Mus musculus 22 (anti-FcγRI), 520C9 (anti-ERBB2) Medarex (Princeton NJ USA) Therapeutic Prostate cancers Phase II Oncology [e] (36) (45) (46) (47) (48) [33]
Therapeutic All ERBB2-positive malignancies Phase I/II Oncology
5 5c8 IG Humanized

15c8
1i9r
25c8
35c8		 CD40LG (CD40 ligand, CD40L, tumor necrosis factor ligand superfamily member 5, TNFSF5, tumor necrosis factor related activation protein, TRAP, CD154) [Homo sapiens] Mus musculus Biogen IDEC Pharmaceuticals (Cambridge MA USA) / MRC Technology (London UK) Unknown Inflammation Immunology [k]
Unknown Autoimmune diseases Immunology
6 60,3 IG Humanized IgG1 nd

ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] Mus musculus Bristol-Myers Squibb (Princeton NJ USA) Myocardial infection Ag8.653 mouse myeloma cells Cardiology [c] (2) [5]
33 7F11C7,
CTM01		 IG Humanized IgG4 nd

1ad9 MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Ovarian cancers NSO mouse myeloma cells, Transient in CHO (Chinese Hamster Ovary) L761h cells Oncology [c] (6) (7) [18]
Breast cancers Oncology
34 ABC-48,
CY-174		 Humanized

SELP (P-selectin, CD62) [Homo sapiens] Mus musculus Cytel Corporation (San Diego CA USA) / MRC Technology (London UK) Inflammation Preclinical Immunology [k]
35 ABC-88,
CY-178		 Humanized

SELE (E-selectin, CD62E) [Homo sapiens] Mus musculus Cytel Corporation (San Diego CA USA) / MRC Technology (London UK) Inflammation Immunology [k]
9 AD-159 Humanized

HIV-1 (human immunodeficiency virus) IIIB gp120 V3 loop [Human immunodeficiency virus 1] Mus musculus Tanox Inc. (Houston TX USA) HIV infection, AIDS Phase I/II Infectiology [a]
10 AD-439 Humanized

HIV-1 (human immunodeficiency virus) IIIB gp120 V3 loop [Human immunodeficiency virus 1] Mus musculus Tanox Inc. (Houston TX USA) HIV infection, AIDS Phase II Infectiology [a] [e]
257 AS1409,
BC1-IL12,
huBC1-huIL12		 IG Humanized conjugated with interleukin 12

 ED-B (fibronectin extra domain B) [Homo sapiens] Antisoma (London UK) Renal cancers Phase I Oncology
Melanoma Phase I Oncology
19 AT13/5 IG Humanized IgG1 nd

CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10) [Homo sapiens] Mus musculus Tenovus Research (Cardiff UK) / Wellcome (London UK) Therapeutic Multiple myeloma CHO (Chinese Hamster Ovary) cells, NSO mouse myeloma cells Hematology, Immunology, Oncology [c] [8]
20 AUK12-20 IG Humanized IgG1 nd

IL6R (interleukin 6 receptor, IL-6R, CD126) [Homo sapiens] Mus musculus Chugai pharmaceuticals Co. Ltd. (Tokyo Japan) / MRC Technology (London UK) / Osaka University Medical School (Osaka Japan) IL6 dependent tumors COS cells transient expression Immunology [c] [k] (5) [9]
16 Anti-TAC 90 Υ-HAT IG Humanized

Mus musculus National Cancer Institute (Bethesda MD USA) Lymphoma Phase II NCI trial Oncology
30 BAY 103356,
BAY W 3356,
CDP571		 Humicade™ IG Humanized IgG4 nd

TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Crohn's disease (CD) Phase II Immunology [a]
Rheumatoid arthritis (RA) Phase II Immunology
23 BC-1 Humanized

ED-B (fibronectin extra domain B) [Homo sapiens] Mus musculus Antisoma (London UK) / MRC Technology (London UK) Angiogenesis Preclinical Oncology [k] [51]
25 BMA 031 IG Humanized IgG1 nd

T cell receptor (TR) TR alpha_beta [Homo sapiens] Mus musculus Behringwerke Aktiengesellschaft (Marburg Germany) / Genzyme Corp. (Cambridge MA USA) Autoimmunity Sp2/0 mouse myeloma cells Immunology [c] [13]
Graft-versus-host disease (GvHD) Sp2/0 mouse myeloma cells Immunology
Transplantation Sp2/0 mouse myeloma cells Immunology
27 BW431/26 IG Humanized IgG3 nd

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e) [Homo sapiens] Mus musculus Behringwerke Aktiengesellschaft (Marburg Germany) / MRC Laboratory of Molecular Biology (Cambridge UK) Breast cancers BHK cells (ATCC CCL 10) Oncology [c] [15]
Colorectal cancers BHK cells (ATCC CCL 10) Oncology
Lung cancers BHK cells (ATCC CCL 10) Oncology
26 BrE-3 IG Humanized IgG1 nd

MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227) [Homo sapiens] Mus musculus Cancer Research Fund of Contra Costa (Walnut Creek CA USA) / NIH (Bethesda MD USA) Breast cancers Sp2/0-Ag14 mouse myeloma cells Oncology [c] [16]
95 C21/AL-90,
HU-901,
TNX-901		 Humanized

IgE Fc [Homo sapiens] Mus musculus MRC Technology (London UK) / Novartis (Basel Switzerland) / Tanox Inc. (Houston TX USA) Peanut allergy (severe) Phase II Immunology [b] [k] [l]
28 CAMPATH-9 Humanized

CD4 (p55) [Homo sapiens] Rattus sp. Pathology Dept., University of Cambridge (Cambridge UK) Establishment of immunological tolerance state CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Immunology [c] [20]
239 CAR RN 894777-94-7 IG Humanized scFv-Fc

MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus Unknown Unknown Unknown
29 CC49 IG Humanized IgG1 nd

1za6 CA 72-4 (tumour associated glycoprotein 72, TAG-72, TAG, HMW mucin-like glycoprotein) [Homo sapiens] Mus musculus NIH (Bethesda MD USA) Diagnostic Cancers Oncology [c] [e] [17]
31 CDP850 Humanized

SELE (E-selectin, CD62E) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Psoriasis Phase I Immunology [a]
32 CE25/B7 Humanized

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e) [Homo sapiens] Mus musculus MRC Technology (London UK) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Cancers Oncology [k]
41 Fd138-80 IG Humanized IgG1 nd

HSV (herpes simplex virus) gD glycoprotein [Human herpesvirus 1] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) / University of Alabama (Tuscaloosa AL USA) Neutralisation activity of HSV-1 Sp2/0 mouse myeloma cells Immunology [c] [24]
42 Fd79 IG Humanized IgG1 nd

HSV (herpes simplex virus) gD glycoprotein [Human herpesvirus 1] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) / University of Alabama (Tuscaloosa AL USA) Neutralisation activity of HSV-1 Sp2/0 mouse myeloma cells Immunology [c] [24]
45 H17E2 IG Humanized IgG1 nd

ALPP (alkaline phosphatase, placental, EC 3.1.3.1) [Homo sapiens] Mus musculus Unilever (London UK) Ovarian cancers NSO mouse myeloma cells Oncology [c] [25]
Testicular cancers NSO mouse myeloma cells Oncology
46 H52,
Huh52		 IG Humanized IgG1 nd

1fgv
2fgw		 ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) Potential to ameliorate deleterious immunological and inflammatory processes E.coli (Escherichia coli) Immunology [c] [26]
49 HMFG1 IG Humanized IgG1 nd

MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227) [Homo sapiens] Mus musculus The Netherlands CRC Labs (Nottingham UK) / Unilever (London UK) Neoplasms of epithelial origin, particularly carcinomas of breast, ovary, cervix, bronchus, and gastrointestinal tract NSO mouse myeloma cells Oncology [c] (7) [29]
59 ICM3 Humanized

ICAM3 (intercellular adhesion molecule 3, ICAM-3, CD50) [Homo sapiens] Mus musculus ICOS Corporation (Bothell WA USA) Psoriasis Phase I/II Immunology [a]
61 JES1-39D10 IG Humanized IgG4 nd

IL5 (interleukin 5, IL-5) [Homo sapiens] Rattus sp. Schering-Plough (Kenilworth NJ USA) / University of Alabama (Tuscaloosa AL USA) IL5 induced eosinophils diseases (eg asthma) COS cells transient expression Immunology [c] [30]
106 KB001 IG Humanized Fab'

Pseudomonas aeruginosa PcrV (located at the tip of the syringe-like TTSS (Type Three Secretion System)) [Pseudomonas aeruginosa] Mus musculus KaloBios Pharmaceuticals Inc. (Palo Alto CA USA) Pseudomonas aeruginosa infections Phase I/II Infectiology [p] (43)
63 LDP-01,
MLNM2201		 IG Humanized IgG nd

ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] Mus musculus Millennium Pharmaceuticals Inc. (Cambridge MA USA) Allograft rejection (in kidney transplantation) Immunology [a] [b]
Stroke Phase I/II Cardiology
67 M4 IG Humanized IgG1 nd

CA 72-4 (tumour associated glycoprotein 72, TAG-72, TAG, HMW mucin-like glycoprotein) [Homo sapiens] Mus musculus University of Saskatchewan (Saskatchewan Canada) Ovarian cancers Sp2/0-Ag14 mouse myeloma cells Oncology [c] [12]
Gastric cancers Sp2/0-Ag14 mouse myeloma cells Oncology
Colorectal cancers Sp2/0-Ag14 mouse myeloma cells Oncology
221 MDX-220 Humanized

CA 72-4 (tumour associated glycoprotein 72, TAG-72, TAG, HMW mucin-like glycoprotein) [Homo sapiens] ;
bispecific 		Genmab A/S (Copenhagen Denmark) / Medarex (Princeton NJ USA) Acute myeloid leukemia (AML) Phase I Hematology, Oncology (36) (45)
222 MDX-447 Humanized

FCGR1 (immunoglobulin G Fc receptor high affinity I, Fc gamma RI, CD64, encoded by human FCGR1A, FCGR1B, FCGR1C) [Homo sapiens] ;
EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) (epitope on external domain) [Homo sapiens] ;
bispecific 		Genmab A/S (Copenhagen Denmark) / Medarex (Princeton NJ USA) Cancers Phase II Oncology (36) (45)
69 MDX-CD4 IG Humanized IgG nd

CD4 (p55) [Homo sapiens] Mus musculus Eisai Co. Ltd. (Tokyo Japan) / Genmab A/S (Copenhagen Denmark) / Medarex (Princeton NJ USA) Rheumatoid arthritis (RA) Phase I Immunology [a]
70 ME361 Humanized

GD2 ganglioside [Homo sapiens] Mus musculus Merck KgaA (Darmstadt Germany) / MRC Technology (London UK) Cancers Oncology
68 MaE11 IG Humanized IgG1 nd

IgE Fc [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) IgE mediated allergies Adenovirus transformed human embryonic 293 kidney cells Immunology [c] [34]
72 MikB1 IG Humanized IgG1 nd

IL2RB (interleukin-2 receptor beta subunit, IL-2RB, p70, CD122) [Homo sapiens] Mus musculus F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) / Kyoto-Katsura Hospital (Kyoto Japan) / National Cancer Institute (Bethesda MD USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) Allograft rejection
(Prevention)
(in conjunction with humanized anti-Tac)		 Sp2/0 mouse myeloma cells Immunology [c] [35]
Autoimmune diseases Sp2/0 mouse myeloma cells Immunology
Graft-versus-host disease (GvHD) Sp2/0 mouse myeloma cells Immunology
82 PRO542 Humanized

HIV-1 (human immunodeficiency virus) IIIB gp120 V3 loop [Human immunodeficiency virus 1] Mus musculus Genzyme Corp. (Cambridge MA USA) / Progenics Pharmaceuticals Inc. (Tarrytown NY USA) HIV infection, AIDS Phase I/II Infectiology [a]
85 RSV19 IG Humanized IgG1 nd

RSV (human respiratory syncytial virus, glycoprotein F) [Respiratory syncytial virus] Mus musculus AFRC Inst. Animal Health (UK) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) Respiratory Syncytial Virus (RSV) disease (acute respiratory illness in young children) YB2/0 rat myeloma cells (from ATCC) Infectiology, Pulmonary, Respiratory diseases [c] [39]
390 SGN-70 IG Humanized IgG1 nd

CD70 (tumor necrosis factor superfamily member 7, TNFSF7, CD27LG, CD27L) [Homo sapiens] Seattle genetics, Inc. (Bothell WA USA) Autoimmune diseases Phase I Immunology
Psoriasis Phase I Immunology
343 SGN-75 IG Humanized conjugated with monomethyl auristatin F (MMAF)

 CD70 (tumor necrosis factor superfamily member 7, TNFSF7, CD27LG, CD27L) [Homo sapiens] Seattle genetics, Inc. (Bothell WA USA) Non-Hodgkin's lymphoma (NHL) Phase I Oncology
CD70-positive hematologic malignancies Phase I Hematology, Immunology
Renal cell carcinoma (RCC) Phase I Oncology
91 SK2 IG Humanized IgG1 nd

IL6 (interleukin 6, IL-6) [Homo sapiens] Mus musculus Chugai pharmaceuticals Co. Ltd. (Tokyo Japan) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) HIV infection, AIDS CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression Infectiology [c] [40]
Cardiac myxoma CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression Cardiology
Increased levels of IL6 in sepsis CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression Immunology
Rheumatoid arthritis (RA) CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression Immunology
93 TES-C21 IG Humanized IgG1 nd

IgE Fc [Homo sapiens] Mus musculus Ciba-Geigy AG (Basel Switzerland) / MRC Laboratory of Molecular Biology (Cambridge UK) Immediate-type hypersensitivities COS cells transient expression, NSO mouse myeloma cells Immunology [c] [41]
104 YFC51.1 IG Humanized IgG1 nd
IgG4 nd

ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] Rattus sp. Cambridge University (Cambridge UK) / Wellcome (London UK) Influx of leukocytes in Sepsis or reperfusion injury, adult respiratory distress syndrome and graft rejection
(Prevention)
COS cells transient expression, NSO mouse myeloma cells Immunology [c] (2) [43]
105 YTH12.5 IG Humanized IgG1 nd

CD3E (CD3 epsilon) [Homo sapiens] Rattus sp. Cambridge University (Cambridge UK) Autoimmunity CHO (Chinese Hamster Ovary) DHFR cells Immunology [c] [44]
T cell lymphoma CHO (Chinese Hamster Ovary) DHFR cells Immunology
Organ rejection CHO (Chinese Hamster Ovary) DHFR cells Immunology
13 anti-B4 IG Humanized IgG1 nd

CD19 (B lymphocyte surface antigen B4, Leu-12) [Homo sapiens] Mus musculus ImmunoGen Inc. (Cambridge MA USA) / University Bath (Bath UK) B cell malignancies COS cells transient expression Hematology, Oncology [c] [45]
14 anti-CD18 IG Humanized F(ab')2

ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) Acute myocardial infarction Phase II Cardiology [a] [b]
15 anti-IL4 Humanized

IL4 (interleukin 4, IL-4) [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) Asthma Phase I Immunology [b]
50 hT84.66,
T84.66 M5A		 Humanized

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e) [Homo sapiens] Mus musculus T84.66 Beckman Research Institute (Duarte CA USA) Colorectal cancers, metastatic Oncology [p] [58]
54 humanized B1-8 IG Humanized IgE nd

hapten NP-cap (4-hydroxy-3-nitrophenacetyl caproic acid) [Homo sapiens] ;
NIP-cap (3-iodo-4-hydroxy-5-nitrophenyl-acetyl caproic acid) [Homo sapiens] 		Mus musculus B1-8 MRC Laboratory of Molecular Biology (Cambridge UK) Unknown Proof of concept Stably transformed J558L cells Unknown [c] [10]
55 humanized D1.3 IG Humanized IgG1 nd
IgG2 nd

lysozyme [Homo sapiens] Mus musculus D1.3 MRC Laboratory of Molecular Biology (Cambridge UK) Unknown Proof of concept J558L mouse myeloma cells, NSO mouse myeloma cells Unknown [c] [21] [22]
56 humanized DX48 IG Humanized IgG1 nd

digoxin [Homo sapiens] Rattus sp. DX48 Wellcome (London UK) Unknown Proof of concept Unknown [c] [23]
57 humanized K20 IG Humanized IgG1 nd

ITGB1 (integrin beta1 subunit, GPIIa, CD29) [Homo sapiens] Mus musculus MuK20 INSERM (Montpellier France) / LIGM (Montpellier France) Unknown Immunosuppression Proof of concept Insect cells, NSO mouse myeloma cells Immunology [c] [31]
47 humanized-HCMV16 IG Humanized IgG1 kappa

HCMV (human cytomegalovirus) gB glycoprotein gH envelope glycoprotein [Human herpesvirus 5] Mus musculus HCMV16 (51C1) Royal Free Hospital School of Medicine (London UK) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) Human cytomegalovirus (HCMV)
(Prevention and treatment)
(infections in immunocompromised patients (Passive immunisation either alone or in combination with antiviral agents))		 NSO mouse myeloma cells, YB2/0 rat myeloma cells Immunology [c] [27]
48 humanized-HCMV37 IG Humanized IgG1 kappa

HCMV (human cytomegalovirus) gB glycoprotein gH envelope glycoprotein [Human herpesvirus 5] Mus musculus HCMV37 Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) Human cytomegalovirus (HCMV) (Herpes infections in immunocompromised individuals) YB2/0 rat myeloma cells Immunology [c] [86]
74 mu-39.1 Humanized

HIV-1 (human immunodeficiency virus) IIIB gp120 V3 loop [Human immunodeficiency virus 1] Mus musculus Kaketsuken (Kumamoto Japan) / MRC Technology (London UK) HIV infection, AIDS Infectiology [k]
98 IG Humanized IgG1 kappa conjugated with calicheamicin

radiolabelled with Indium-111, In-111		 ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340 [Homo sapiens] Mus musculus 4D5 Genentech Inc. (S. San Francisco CA USA) Ovarian cancers (overexpressing ERBB2) Adenovirus transformed human embryonic 293 kidney cells Oncology [c] (31) [47]
Breast cancers (overexpressing ERBB2) Adenovirus transformed human embryonic 293 kidney cells Oncology
89 Humanized

IL5 (interleukin 5, IL-5) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) / Schering AG (Berlin Germany) Allergy Phase I Immunology [a]
Asthma Phase I Immunology
12 ALLOMUNE™ Humanized

CD2 (lymphocyte function-antigen 2, LFA-2) [Homo sapiens] Mus musculus BioTransplant (Charlestown MA USA) Hodgkin's disease (HD) Phase I Hematology, Oncology [b]
Non-Hodgkin's lymphoma (NHL) (refractory) Phase I Oncology

up

Human

Number of results: 104

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT receptor type Species IG class and subclass or IG format FPIA or RPI chain identification Conjugated/ Radiolabelled IMGT/2Dstructure-DB IMGT/3Dstructure-DB Specificity target name
[species]		 Origin clone species Origin clone name Company Application Clinical indication Development status Regulatory agency status and year Expression system Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
212 abatacept 8495 91
(2004)		 53
(2005)		 BMS-188667,
CTLA4-Ig		 ORENCIA® FPIA Homo sapiens CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)-IGHG1 Fc

CD80 (B7-1, CD28LG1) [Homo sapiens] ;
CD86 (B7-2, CD28LG2) [Homo sapiens] 		Homo sapiens Bristol-Myers Squibb (Princeton NJ USA) Therapeutic Juvenile Idiopathic Arthitis Phase M sBLA August 01, 2008 Immunology FDA: (BLA) 125118

ATC: L04AA24

Drugnum: 888

NCT

 [j] [n] (16) (30)
Therapeutic Graft-versus-host disease (GvHD) (solid organ transplant) Phase I CHO (Chinese Hamster Ovary) cells Immunology
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval December 23, 2005 CHO (Chinese Hamster Ovary) cells Immunology
Therapeutic Psoriasis Phase I CHO (Chinese Hamster Ovary) cells Immunology
165 adalimumab 7860 82
(1999)		 44
(2000)		 D2E7 HUMIRA® (EU/US)
TRUDEXA® (EU) 		IG Homo sapiens IgG1 kappa

7860 TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Homo sapiens Abbott Laboratories (Abbott Park IL USA) (EU/US) Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval October 03, 2005 CHO (Chinese Hamster Ovary) cells Immunology FDA: (BLA) 125057

REMS

EMA: H-C-481

ATC: L04AB04

Drugnum: 814

NCT

 [a] [j] (12)
Abbott Laboratories (Abbott Park IL USA) Therapeutic Juvenile Idiopathic Arthitis Phase M FDA approval February 21, 2008 Immunology
Therapeutic Crohn's disease (CD) (if inadequate response to conventional therapy) Phase M FDA approval February 27, 2010 Immunology
Therapeutic Ankylosing spondylitis (AS) Phase M FDA approval August 28, 2006 Immunology
Therapeutic Psoriasis, severe chronic plaque Phase M FDA approval January 18, 2008 Immunology
Abbott Laboratories (Abbott Park IL USA) (EU/US) Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval December 31, 2002 CHO (Chinese Hamster Ovary) cells Immunology
164 adecatumumab 8449 90
(2004)		 52
(2004)		 MT201 IG Homo sapiens IgG1 nd

EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, epithelial cell adhesion molecule, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] Homo sapiens Micromet AG (Munich Germany) Therapeutic Breast cancers Phase II Oncology [p]
Therapeutic Prostate cancers Phase II Oncology
214 aflibercept 8739 95
(2006)		 57
(2007)		 VEGF Trap,
VEGF Trap R1/R2,
VEGF-trapR1,
VEGF-TRAPR1R2		 FPIA Homo sapiens FLT1 (fms-related tyrosine kinase 1, vascular endothelaal growth factor receptor 1, VEGFR-1 VEGFR, FLT, RFT, vascular permeability factor receptor) - VEGFR2 KDR (kinase insert domain receptor, FLK1, CD309) - IGHG1 Fc

8739 VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Homo sapiens Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) / Sanofi-Aventis (Paris France) Therapeutic Ovarian cancers Phase II Oncology [p] (30)
215 alefacept 8059 84
(2000)		 46
(2001)		 CD58-Fc,
LFA3-Fc		 AMEVIVE® FPIA Homo sapiens CD58 (LFA3, lymphocyte function associated antigen 3)-IGHG1 Fc

CD2 (lymphocyte function-antigen 2, LFA-2) [Homo sapiens] Homo sapiens Biogen Canada Inc. (Mississauga ON Canada) Therapeutic Psoriasis, severe chronic plaque Phase M FDA approval January 31, 2003 CHO (Chinese Hamster Ovary) cells Immunology FDA: (BLA) 125036

ATC: L04AA15

Drugnum: 820

NCT

 [j] [n] (30)
289 alvircept sudotox 7105 69
(1993)		 34
(1994)		 sCD4-PE40 RPI Homo sapiens CD4- Pseudomonas aeruginosa exotoxin A conjugated with Pseudomonas aeruginosa exotoxin A

 HIV-1 (human immunodeficiency virus) IIIB gp120 V3 loop [Human immunodeficiency virus 1] pT4B National Institute of Allergy and Infectious Diseases (NIAID) (Bethesda USA) Therapeutic HIV infection, AIDS Discontinued Infectiology
213 atacicept 8669 95
(2006)		 57
(2007)		 TACI-Fc,
TACI-Ig		 FPIA Homo sapiens TNFRSF13B (tumor necrosis factor receptor (TNFR) superfamily member 13B, TACI, transmembrane activator and CAML Interactor, CD267)-IGHG1 Fc

8669 TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, a proliferation-including ligand, APRIL, CD256) [Homo sapiens] ;
TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, B cell activating factor, BAFF, TALL1, BLyS, B lymphocyte activator, CD257) [Homo sapiens] 		Homo sapiens Merck Serono International S.A. (Geneva Switzerland) / ZymoGenetics Inc. (Seattle WA USA) Therapeutic Multiple myeloma Phase I Hematology, Immunology, Oncology [p] (30)
Therapeutic Non-Hodgkin's lymphoma (NHL) Phase I Oncology
Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
Therapeutic Systemic lupus erythematosus (SLE) Phase II Immunology
358 atinumab 9336 104
(2010)		 66
(2011)		 6A3-IgG4,
ATI355		 IG Homo sapiens IgG4 kappa

9336 RTN4 (reticulon 4, neurite outgrowth inhibitor, NOGO) [Homo sapiens] Novartis (Basel Switzerland) Therapeutic Spinal cord injury, acute Phase I Myelopathy
308 atorolimumab 7647 80
(1998)		 42
(1999)		 P3x22914G4 IG Homo sapiens IgG3 nd

RHD (Rhesus blood group D antigen, RhD, CD240D) [Homo sapiens] Unknown Unknown Unknown
245 baminercept 8944 98
(2007)		 60
(2008)		 BG9924,
TT-47		 FPIA Homo sapiens LTBR ( lymphotoxin beta receptor, TNFRSF3, tumor necrosis factor receptor superfamily member 3, TNFCR)-IGHG1 Fc

8944 LTA (lymphotoxin alpha, TNF superfamily member 1, TNFSF1, LT) [Homo sapiens] ;
LTB (lymphotoxin beta, TNF superfamily member 3, TNFSF3, p33) [Homo sapiens] ;
TNFSF14 (tumor necrosis factor (TNF) superfamily member 14, LIGHT, HVEM-L, CD258) [Homo sapiens] 		Homo sapiens Biogen IDEC Pharmaceuticals (Cambridge MA USA) Therapeutic Rheumatoid arthritis (RA) Immunology (30)
247 belatacept 8627 93
(2005)		 59
(2008)		 BMS-224818,
LEA29Y		 FPIA Homo sapiens CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)-IGHG1 Fc

CD80 (B7-1, CD28LG1) [Homo sapiens] ;
CD86 (B7-2, CD28LG2) [Homo sapiens] ;
bispecific 		Bristol-Myers Squibb (Princeton NJ USA) Therapeutic Rheumatoid arthritis (RA) Immunology ATC: L04AA28

 (30)
266 belimumab 8381 89
(2003)		 51
(2004)		 BENLYSTA® IG Homo sapiens IgG1 nd

TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, B cell activating factor, BAFF, TALL1, BLyS, B lymphocyte activator, CD257) [Homo sapiens] HGSI (Human Genome Sciences Inc.) (Rockville MD USA) Therapeutic Systemic lupus erythematosus (SLE) Phase M FDA approval March 10, 2011 Immunology FDA: (BLA) 125370

ATC: L04AA26

NCT
170 bertilimumab 8332 88
(2003)		 50
(2003)		 CAT-213,
iCo-008		 IG Homo sapiens IgG4 kappa

CCL11 (chemokine (C-C motif) ligand 11, chemokine CC 11, eotaxin1) [Homo sapiens] Homo sapiens iCo Therapeutics Inc. (Vancouver BC Canada) Therapeutic Allergies, severe ocular Phase I Immunology (42)
278 bifarcept 8109 86
(2002)		 48
(2002)		 RPI Homo sapiens IFNAR2 (interferon alpha/beta receptor 2, IFNABR)

IFNA1 (interferon alpha 1, IFN alpha, IFN alpha 1/13, IFN 13) [Homo sapiens] ;
IFNB1 (interferon beta 1, IFNB) [Homo sapiens] ;
bispecific 		Unknown Unknown Unknown
162 briakinumab 9153 101
(2009)		 63
(2010)		 ABT-874 IG Homo sapiens IgG1 lambda

9153 IL12B (interleukin 12 beta, IL-12B, IL12 p40, CMLF2, NKSF2) [Homo sapiens] Homo sapiens Abbott Laboratories (Abbott Park IL USA) Therapeutic Crohn's disease (CD) Phase I Immunology ATC: L04AC09

 [p]
Therapeutic Multiple sclerosis (MS) Phase I Immunology
Therapeutic Psoriasis Phase II Immunology
246 briobacept 8963 98
(2007)		 60
(2008)		 BR3-Fc,
SS-79		 FPIA Homo sapiens TNFRSF13C (tumor necrosis factor receptor (TNFR) superfamily member 13C, BAFFR, BR3, B cell activating factor receptor, CD268)-IGHG1 Fc

8963 TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, B cell activating factor, BAFF, TALL1, BLyS, B lymphocyte activator, CD257) [Homo sapiens] Homo sapiens Genentech Inc. (S. San Francisco CA USA) Therapeutic Rheumatoid arthritis (RA) Phase I Immunology (30)
376 brodalumab 9475 105
(2011)		 67
(2012)		 AMG827 IG Homo sapiens IgG2 kappa

9475 IL17RA (interleukin 17 receptor A, CD217) [Homo sapiens] Amgen (Thousand Oaks CA USA) Therapeutic Asthma Phase II Immunology
Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
Therapeutic Psoriasis Phase II Immunology
244 canakinumab 8836 97
(2007)		 59
(2008)		 ACZ885 ILARIS® IG Homo sapiens IgG1 kappa

8836 IL1B (interleukin 1 beta, IL-1B) [Homo sapiens] Homo sapiens Novartis (Basel Switzerland) Therapeutic Rheumatoid arthritis (RA) Immunology FDA: (BLA) 125319

ATC: L04AC08

NCT
Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Cryopyrin-Associated Periodic Syndromes (CAPS) (including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 4 and older) Phase M FDA approval June 17, 2009 Hereditary inflammatory diseases, Immunology
359 carlumab 9372 104
(2010)		 66
(2011)		 CNTO 888 IG Homo sapiens IgG1 kappa

9372 CCL2 (chemokine (C-C motif) 2, chemokine CC 2, monocyte chemoattractant protein-1, MCP-1, monocyte chemotactic and activating factor, MCAF, small inducible cytokine A2, SCYA2, HC11) [Homo sapiens] Centocor Inc. (Horsham PA USA) Therapeutic Pulmonary Fibrosis Phase I Pulmonary, Respiratory diseases NCI: C71010
290 cixutumumab 9099 100
(2008)		 62
(2009)		 IMC-A12 IG Homo sapiens IgG1 lambda

9099 IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Homo sapiens ImClone Systems Inc. (Somerville NJ USA) Therapeutic Solid tumors Phase I Oncology
224 conatumumab 9029 99
(2008)		 61
(2009)		 AMG 655,
TRAIL-R2mAb,
XG1-048 v w		 IG Homo sapiens IgG1 kappa

9029 TNFRSF10B (tumor necrosis factor receptor (TNFR) superfamily member 10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAILR2, TRAIL-R2, TR-2, CD262) [Homo sapiens] Homo sapiens Amgen (Thousand Oaks CA USA) Therapeutic Non-small cell lung cancers (NSCLC) Oncology
377 conbercept 9487 105
(2011)		 67
(2012)		 FP3 protein,
KH902,
KH903		 FPIA Homo sapiens FLT1 (fms-related tyrosine kinase 1, vascular endothelaal growth factor receptor 1, VEGFR-1 VEGFR, FLT, RFT, vascular permeability factor receptor) - VEGFR2 KDR (kinase insert domain receptor, FLK1, CD309) - IGHG1 Fc

9487 VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Chengdu Kanghong Biotech Co.,Ltd. (China) Age related macular degeneration (AMD), neovascular (wet) Phase II Ophthalmology
Therapeutic Diabetic Macular Edema Phase I/II Immunology
Solid tumors Phase I Oncology
388 dalantercept 9427 105
(2011)		 67
(2012)		 ACE-041 FPIA Homo sapiens ACVRL1 (activin A receptor type II-like 1, activin receptorlike kinase 1, ALK1, ALK-1, serine/threonine-protein kinase receptor R3, SKR3, transforming growth factor-beta superfamily receptor type I, TGF-B superfamily receptor type I, TSR-I, HHT2, ORW2) - IGHG1 Fc

9427 Activin A [Homo sapiens] Acceleron Pharma, Inc (Cambridge UK) Multiple myeloma Phase I Hematology, Immunology, Oncology
Solid tumors Phase I Oncology
301 daratumumab 9128 101
(2009)		 63
(2010)		 HuMax-CD38 IG Homo sapiens IgG1 kappa

9128 CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10) [Homo sapiens] Genmab A/S (Copenhagen Denmark) Therapeutic Multiple myeloma Phase I/II Hematology, Immunology, Oncology NCI: C74007
249 denosumab 8653 94
(2005)		 56
(2006)		 AMG162 XGEVA™
PROLIA® 		IG Homo sapiens IgG2 nd

TNFSF11 (tumor necrosis factor (TNF) superfamily member 11, osteoclast differentiation factor, ODF, OPGL, RANKL, TRANCE, CD254) [Homo sapiens] Homo sapiens Amgen (Thousand Oaks CA USA) Therapeutic Postmenopausal women osteoporosis Phase III FDA approval June 01, 2010 Osteology FDA: (BLA) 125320

REMS

ATC: M05BX04

NCI: C61313

NCT

 (52)
Therapeutic skeletal-related events in patients with bone metastases from solid tumors
(Prevention)
Phase III FDA approval June 01, 2010 Osteology
348 drozitumab 9255 103
(2010)		 65
(2011)		 anti-DR5,
PRO95780,
rhuMAb DR5		 IG Homo sapiens IgG1 lambda

9255 TNFRSF10B (tumor necrosis factor receptor (TNFR) superfamily member 10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAILR2, TRAIL-R2, TR-2, CD262) [Homo sapiens] Genentech Inc. (S. San Francisco CA USA) Therapeutic Colorectal cancers Phase I Oncology
173 efungumab 8658 95
(2006)		 57
(2007)		 HSP90mab Mycograb® IG Homo sapiens scFv

8658 heat shock protein 90 homolog [Candida albicans] Homo sapiens NeuTec Pharma plc (Manchester UK) / Supplier: Onicon Chemical Co. Ltd. (HangZhou China) Candidiasis (yeast infection) EMA refusal of marketing March 20, 2007 Immunology
216 etanercept 7783 81
(1999)		 43
(2000)		 TNFR-immunoadhesin,
TNFRSF1B-Fc		 ENBREL® FPIA Homo sapiens TNFRSF1B (tumor necrosis factor receptor (TNFR) superfamily member 1B, TNFBR, p75, CD120b) - IGHG1 Fc

7783 TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Homo sapiens Immunex Corporation Amgen (Thousand Oaks CA USA) Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval November 02, 1998 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Immunology FDA: (BLA) 103795

REMS

ATC: L04AB01

Drugnum: 737

NCT

 [f] [j] [n] (15) (30)
Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval February 15, 2002 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Immunology
262 exbivirumab 8536 91
(2004)		 53
(2005)		 19.79.5 IG Homo sapiens IgG1 nd

HBV (hepatitis B virus) [Homo sapiens] F. Hoffmann-La Roche Ltd. (Basel Switzerland) / Genentech Inc. (S. San Francisco CA USA) Therapeutic Stroke Phase II Cardiology
323 fezakinumab 9137 101
(2009)		 63
(2010)		 ILV-094 IG Homo sapiens IgG1 lambda

9137 IL22 (interleukin 22, IL-22) [Homo sapiens] Wyeth Pharmaceuticals (Madison NJ USA) Therapeutic Inflammatory conditions, acute and chronic
(Treatment)
Immunology
293 figitumumab 9085 100
(2008)		 62
(2009)		 CP-751871 IG Homo sapiens IgG2 kappa

9085 IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Homo sapiens 2.13.2 Pfizer (New York NY USA) Therapeutic Non-small cell lung cancers (NSCLC) Phase I Oncology NCI: C52187
Therapeutic Solid tumors Phase I Oncology
350 foralumab 9309 103
(2010)		 65
(2011)		 NI-0401 IG Homo sapiens IgG1 kappa

9309 CD3E (CD3 epsilon) [Homo sapiens] NovImmmune (Geneva Switzerland) Therapeutic Type 1 diabetes Phase I Immunology [65]
Therapeutic Multiple sclerosis (MS) Phase I Immunology
Therapeutic Crohn's disease (CD) Phase I Immunology
Therapeutic Transplantation Phase I Immunology
Therapeutic Ulcerative colitis (UC) Phase I Immunology
Therapeutic Atherosclerosis Phase I Immunology
Therapeutic Psoriasis Phase I Immunology
90 foravirumab 9053 99
(2008)		 61
(2009)		 CR4098 IG Homo sapiens IgG1 kappa

9053 rabies virus glycoprotein [Homo sapiens] Homo sapiens Crucell (CN Leiden Netherlands) Therapeutic Rabies prophylaxis
(Prevention)
Phase II Immunology, Infectiology (27)
174 fresolimumab 9158 101
(2009)		 63
(2010)		 GC-1008 IG Homo sapiens IgG4 kappa

9158 TGFB1 (transforming growth factor beta1, TGF beta) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (Cambridge UK) / Genzyme Corp. (Cambridge MA USA) Therapeutic Idiopathic pulmonary fibrosis Phase I Pulmonary, Respiratory diseases
363 fulranumab 9373 104
(2010)		 66
(2011)		 4D4,
AMG-403,
JNJ-42160443		 IG Homo sapiens IgG2 kappa

9373 NGF (nerve growth factor, nerve growth factor beta polypeptide, NGFB, beta-NGF) [Homo sapiens] Amgen (Thousand Oaks CA USA) / Johnson & Johnson (Langhorne PA USA) Therapeutic Pain chronic Phase II Neurology
168 ganitumab 9323 103
(2010)		 65
(2011)		 AMG 479 IG Homo sapiens IgG1 kappa

9323 IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Homo sapiens Amgen (Thousand Oaks CA USA) Cancers Phase I Oncology [p]
223 gantenerumab 8894 97
(2007)		 59
(2008)		 R1450 IG Homo sapiens IgG1 nd

8894 amyloid beta (Abeta) peptides Aβ42 and Aβ40 [Homo sapiens] Homo sapiens F. Hoffmann-La Roche Ltd. (Basel Switzerland) Therapeutic Alzheimer's disease Neurology
175 golimumab 8497 91
(2004)		 53
(2005)		 CNTO 148 SIMPONI™ IG Homo sapiens IgG1 kappa

TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Homo sapiens Centocor Ortho Biotech Inc. (Horsham PA USA) Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval April 24, 2009 Immunology FDA: (BLA) 125289

REMS

ATC: L04AB06

NCT
Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval April 24, 2009 Immunology
Therapeutic Ankylosing spondylitis (AS) Phase M FDA approval April 24, 2009 Immunology
365 icrucumab 9370 104
(2010)		 66
(2011)		 18F1,
IMC-18F1		 IG Homo sapiens IgG1 kappa

9370 FLT1 (fms-related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor receptor) [Homo sapiens] ImClone Systems Inc. (Somerville NJ USA) Therapeutic Colon cancers Phase II Oncology
Therapeutic Rectal cancers Phase II Oncology
321 intetumumab 9134 101
(2009)		 63
(2010)		 CNTO 095,
CNTO-95		 IG Homo sapiens IgG1 kappa

9134 ITGAV_ITGB3 (integrin alphaV_beta3, integrin αVβ3, CD51_GPIIIa, vitronectin receptor, VNR, CD51_CD61) [Homo sapiens] Johnson & Johnson (Langhorne PA USA) Therapeutic Solid tumors Oncology
180 ipilimumab 8568 94
(2005)		 56
(2006)		 MDX-010 YERVOY™ IG Homo sapiens IgG1 kappa

CTLA4 (cytotoxic T lymphocyte-associated antigen 4, CD152) [Homo sapiens] Homo sapiens Bristol-Myers Squibb (Princeton NJ USA) / Medarex (Princeton NJ USA) Therapeutic Melanoma, metastatic Phase II/III FDA approval March 25, 2011 Oncology FDA: (BLA) 125377

REMS

NCI: C2654
250 iratumumab 8713 94
(2005)		 56
(2006)		 MDX-060 IG Homo sapiens IgG1 kappa

TNFRSF8 (tumor necrosis factor receptor (TNFR) superfamily member 8, CD30) [Homo sapiens] Homo sapiens Medarex (Princeton NJ USA) Therapeutic Hodgkin's disease (HD) Phase II FDA Orphan drug October 01, 2004 Hematology, Oncology
Therapeutic Anaplastic large cell lymphoma (ALCL) Phase II Oncology
288 lenercept 7310 72
(1994)		 35
(1995)		 TNFR55-Ig1,
TNFRSF1A-Fc		 FPIA Homo sapiens TNFRSF1A (tumor necrosis factor receptor (TNFR) superfamilly member 1A, TNFAR, TNF-alpha, p55, CD120a) - IGHG1 Fc

TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] pTJ5 Cγ 1 Genentech Inc. (S. San Francisco CA USA) Therapeutic Severse sepsis and early septic shock Phase III Immunology [69]
182 lerdelimumab 7882 83
(2000)		 45
(2001)		 CAT-152,
Trabio		 IG Homo sapiens IgG4 nd

TGFB2 (transforming growth factor beta 2) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (Cambridge UK) Therapeutic Glaucoma surgery Phase III Ophthalmology [a] (42) [12]
183 lexatumumab 8753 95
(2006)		 57
(2007)		 HGS-ETR2 IG Homo sapiens IgG1 lambda

8753 TNFRSF10B (tumor necrosis factor receptor (TNFR) superfamily member 10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAILR2, TRAIL-R2, TR-2, CD262) [Homo sapiens] Homo sapiens HGSI (Human Genome Sciences Inc.) (Rockville MD USA) Therapeutic Cancers Phase I Oncology NCI: C64621

 [p]
263 libivirumab 8481 91
(2004)		 53
(2005)		 17.1.41 IG Homo sapiens IgG1 nd

HBV (hepatitis B virus) [Homo sapiens] Unknown Unknown Unknown
176 lucatumumab 8887 98
(2007)		 60
(2008)		 CHIR-12,12,
HCD122		 IG Homo sapiens IgG1 nd

8887 CD40 (tumor necrosis factor receptor superfamily member 5, TNFRSF5, p50) [Homo sapiens] Homo sapiens Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Xoma (Berkeley CA USA) Therapeutic Chronic lymphocytic leukemia (CLL) Phase I Hematology, Oncology [p]
Therapeutic Multiple myeloma Phase I Hematology, Immunology, Oncology
184 mapatumumab 8635 93
(2005)		 55
(2006)		 HGS-ETR1,
TRM-1		 IG Homo sapiens IgG1 nd

TNFRSF10A (tumor necrosis factor receptor (TNFR) superfamily member 10A, death receptor 4, DR4, TNF-related apoptosis-inducing ligand receptor 1, TRAILR1, TRAIL-R1, TR-1, CD261) agonistic antibody [Homo sapiens] Homo sapiens Cambridge Antibody Technology (Cambridge UK) / HGSI (Human Genome Sciences Inc.) (Rockville MD USA) Therapeutic Colorectal cancers Phase II Oncology NCI: C61502
Therapeutic Lung cancers, Lung cancers (non small-cell) Phase II Oncology
Therapeutic Non-Hodgkin's lymphoma (NHL) Phase II Oncology
186 metelimumab 8087 86
(2002)		 48
(2002)		 CAT-192 IG Homo sapiens IgG4 kappa

TGFB1 (transforming growth factor beta1, TGF beta) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (Cambridge UK) / Genzyme Corp. (Cambridge MA USA) Therapeutic Scarring Phase I/II Dermatology (42) [12]
Therapeutic Diffuse scleroderma Phase I/II Dermatology
Therapeutic Fibrotic diseases Phase I/II Dermatology
264 mirococept 8412 91
(2004)		 53
(2005)		 Mirococept Mirococept® RPI Homo sapiens CR1 (complement receptor type 1, C3b/C4b receptor, C3BR, Knops blood group, KN, CD35)

complement C3b, C4b [Homo sapiens] pET04-01 Inflazymme Pharmaceuticals Therapeutic Acute myocardial infarction Phase II Cardiology (44)
Therapeutic Transplantation Phase II Immunology
311 morolimumab 7646 79
(1998)		 41
(1999)		 IG Homo sapiens IgG1 nd

RHD (Rhesus blood group D antigen, RhD, CD240D) [Homo sapiens] Unknown Unknown Unknown
367 namilumab 9382 104
(2010)		 66
(2011)		 MT203 IG Homo sapiens IgG1 kappa

9382 CSF2 (colony stimulating factor 2 (granulocyte-macrophage), granulocyte-macrophage colony stimulating factor, GM-CSF) [Homo sapiens] Micromet Inc. (Munich Germany) / Nycomed (Zurich Switzerland) Therapeutic Rheumatoid arthritis (RA) Phase I Immunology [74]
Therapeutic Multiple sclerosis (MS) Phase I Immunology
381 narnatumab 9447 105
(2011)		 67
(2012)		 IMC RON-8,
IMC-RON8,
RON8		 IG Homo sapiens IgG1 kappa

9447 MST1R (macrophage stimulating 1 receptor, macrophage stimulating protein receptor, MSP receptor, c-met-related tyrosine kinase, protein- tyrosine kinase 8, PTK8, RON, p185-Ron, CD136) [Homo sapiens] ImClone Systems Inc. (Somerville NJ USA) Solid tumors Phase I Oncology
193 nebacumab 6658 66
(1991)		 32
(1992)		 centoxin,
HA-1A,
septomonab		 IG Homo sapiens IgM kappa

endotoxin (lipid A, domain of lipopolyaccharide, LPS) [Bacteria] Homo sapiens CSL Behring (King of Prussia PA USA) Therapeutic Gram-negative sepsis Infectiology (57)
Therapeutic Septic shock Phase I Infectiology
294 necitumumab 9083 100
(2008)		 62
(2009)		 11F8,
IMC-11F8		 IG Homo sapiens IgG1 kappa

9083 EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) (epitope on external domain) [Homo sapiens] Homo sapiens ImClone Systems Inc. (Somerville NJ USA) Therapeutic Colorectal cancers, metastatic Phase II Oncology
Therapeutic Solid tumors Phase I Oncology
194 ofatumumab 8606 93
(2005)		 55
(2006)		 HuMax-CD20® ARZERRA™ IG Homo sapiens IgG1 kappa

MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) / GlaxoSmithKline (Brentford UK) Therapeutic Chronic lymphocytic leukemia (CLL) (Refractory) Phase M FDA approval October 26, 2009, sBLA April 01, 2009 Hematology, Oncology FDA: (BLA) 125326

ATC: L01XC10

NCI: C66952

NCT
Therapeutic Non-Hodgkin's lymphoma (NHL) (combination study) Phase III Oncology
Therapeutic Rheumatoid arthritis (RA) Phase III Immunology
352 olaratumab 9308 103
(2010)		 65
(2011)		 3G3,
IMC-3G3,
IMC3G3		 IG Homo sapiens IgG1 kappa

9308 PDGFRA (platelet-derived growth factor receptor alpha subunit, PDGFR2, CD140a) [Homo sapiens] ImClone Systems Inc. (Somerville NJ USA) Therapeutic Solid tumors Phase I Oncology [66]
284 onercept 7042 82
(1999)		 44
(2000)		 RPI Homo sapiens TNFRSF1A (tumor necrosis factor receptor (TNFR) superfamilly 1A, TNF-RI, p55, CD120a) soluble form (TNF- binding protein 1)

TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Unknown Unknown Unknown
354 oxelumab 9320 103
(2010)		 65
(2011)		 huMAb OX40L,
R4930,
RO4989991		 IG Homo sapiens IgG1 kappa

9320 TNFSF4 (tumor necrosis factor (TNF) superfamily member 4, OX40 ligand, OX-40L, TAX transcriptionally-activated glycoprotein 1, TXGP1, gp34, CD252) [Homo sapiens] Mus musculus F. Hoffmann-La Roche Ltd. (Basel Switzerland) Therapeutic Asthma Phase I Immunology
Therapeutic Allergic rhinitis Phase I Immunology
196 panitumumab 8499 91
(2004)		 53
(2005)		 ABX-EGF,
E7.6.3		 VECTIBIX™ IG Homo sapiens IgG2 kappa

EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) (epitope on external domain) [Homo sapiens] Homo sapiens Amgen (Thousand Oaks CA USA) Therapeutic Colorectal cancers, metastatic Phase M FDA approval September 27, 2006 CHO (Chinese Hamster Ovary) cells Oncology FDA: (BLA) 125147

ATC: L01XC08

NCI: C1857

Drugnum: 933

NCT

 [b] [n] (11) (13) (41)
Therapeutic Colorectal cancers Phase III CHO (Chinese Hamster Ovary) cells Oncology
Therapeutic Neck cancers Phase III CHO (Chinese Hamster Ovary) cells Oncology
Therapeutic Head cancers Phase III CHO (Chinese Hamster Ovary) cells Oncology
243 panobacumab 8888 100
(2008)		 62
(2009)		 Aerumab 11 IG Homo sapiens IgM kappa

8888 Pseudomonas aeruginosa serotype IATS O11 [Pseudomonas aeruginosa] Homo sapiens Kenta Biotech Ltd (Berne Switzerland) Therapeutic Pseudomonas aeruginosa, hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa
(Treatment)
Phase I Infectiology
275 pegsunercept 8241 87
(2002)		 49
(2003)		 PEG sTNF-RI RPI Homo sapiens TNFRSF1A (tumor necrosis factor receptor (TNFR) superfamilly 1A, TNF-RI, p55, CD120a) soluble form (TNF- binding protein 1)

TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Amgen (Thousand Oaks CA USA) Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
270 pritumumab 8132 89
(2003)		 51
(2004)		 CLN G11 IG Homo sapiens IgG1 nd

VIM (vimentin) [Homo sapiens] Unknown Cancers Oncology
370 radretumab 9340 104
(2010)		 66
(2011)		 L19-131 I ,
L19-SIP		 IG Homo sapiens scFv - CH dimer

9340 ED-B (fibronectin extra domain B) [Homo sapiens] Phylogen (Sovicille Italy) Therapeutic Solid tumors Phase II Oncology
Therapeutic Lymphoproliferative disease Phase II Oncology
94 rafivirumab 9052 99
(2008)		 61
(2009)		 CR57 IG Homo sapiens IgG1 lambda

9052 rabies virus glycoprotein [Homo sapiens] Homo sapiens Crucell (CN Leiden Netherlands) Therapeutic Rabies prophylaxis
(Prevention)
Phase II Immunology, Infectiology (27)
295 ramucirumab 9098 100
(2008)		 62
(2009)		 1121B,
IMC-1121B		 IG Homo sapiens IgG1 kappa

9098 KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309) [Homo sapiens] Homo sapiens ImClone Systems Inc. (Somerville NJ USA) Therapeutic Tumor vasculature Phase I Oncology [p]
260 raxibacumab 8580 92
(2004)		 54
(2005)		 PA IG Homo sapiens IgG1 nd

anthrax antigen [Homo sapiens] Unknown Unknown Unknown
197 regavirumab 7250 71
(1994)		 35
(1995)		 TI-23 IG Homo sapiens IgG1 kappa

HCMV (human cytomegalovirus) gB glycoprotein gH envelope glycoprotein [Homo sapiens] Homo sapiens Teijin America Inc. (New York NY USA) / Teijin Ltd. (Tokyo Japan) Therapeutic Cytomegalovirus (CMV) diseases, acute Phase I Infectiology [e]
217 rilonacept 8750 95
(2006)		 57
(2007)		 ARCALYST™ FPIA Homo sapiens Interleukin-1 receptor accessory protein (IL1RAP)-type 1 interleukin-1 receptor-IGHG1 Fc

8750 IL1A (interleukin 1 alpha, IL-1A) [Homo sapiens] Homo sapiens Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) Therapeutic Osteoarthritis Immunology FDA: (BLA) 125249

ATC: L04AC04

NCT

 [p] (30)
Therapeutic Rheumatoid arthritis (RA) Immunology
Therapeutic Autoinflammatory diseases Immunology
Therapeutic Cryopyrin-Associated Periodic Syndromes (CAPS)
(Treatment)
(including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS))		 Phase M FDA approval February 27, 2008 Hereditary inflammatory diseases, Immunology
302 rilotumumab 9123 101
(2009)		 63
(2010)		 IG Homo sapiens IgG2 nd

9123 HGF (hepatocyte growth factor, scatter factor, SF, hepatopoeitin A) [Homo sapiens] Amgen (Thousand Oaks CA USA) Therapeutic Cancers Phase II Oncology
296 robatumumab 9092 100
(2008)		 62
(2009)		 19D12,
SCH 717454,
SCH717454		 IG Homo sapiens IgG1 kappa

9092 IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Homo sapiens Medarex (Princeton NJ USA) Therapeutic Blood cancers Preclinical Immunology, Oncology
Therapeutic Colon sarcoma Phase II Oncology
355 roledumab 9335 103
(2010)		 65
(2011)		 LFB-R593 DMATRIA™ IG Homo sapiens IgG1 kappa

9335 RHD (Rhesus blood group D antigen, RhD, CD240D) [Homo sapiens] Laboratoire Français du fractionnement et des Biotechnologies (LFB) (Courtabœuf France) Therapeutic prevention of feto-maternal allo-immunization in RhD- women Phase II Immunology [67]
326 secukinumab 9182 102
(2009)		 64
(2010)		 AIN457 IG Homo sapiens IgG1 kappa

9182 IL17A (interleukin 17A, IL-17A) [Homo sapiens] Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Psoriasis Phase III Immunology
83 sevirumab 6560 66
(1991)		 32
(1992)		 PROTOVIR™ IG Homo sapiens IgG1 kappa

HCMV (human cytomegalovirus) gB glycoprotein gH envelope glycoprotein [Human herpesvirus 5] Mus musculus Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) Therapeutic Human cytomegalovirus (HCMV) Phase III Immunology [a]
322 sifalimumab 9135 101
(2009)		 63
(2010)		 MDX-1103,
MEDI-545		 IG Homo sapiens IgG1 kappa

9135 IFNA1 (interferon alpha 1, IFN alpha, IFN alpha 1/13, IFN 13) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Therapeutic Dermatomyositis
(Treatment)
Phase I Immunology
Therapeutic Polymyositis
(Treatment)
Phase I Immunology
Therapeutic Systemic lupus erythematosus (SLE)
(Treatment)
Phase II Immunology
384 sirukumab 9431 105
(2011)		 67
(2012)		 CNTO 136 IG Homo sapiens IgG1 kappa

9431 IL6 (interleukin 6, IL-6) [Homo sapiens] Centocor Inc. (Horsham PA USA) Rheumatoid arthritis (RA) (Despite Methotrexate Therapy) Phase II Immunology
Lupus nephritis Phase II Immunology
331 sotatercept 9188 102
(2009)		 64
(2010)		 ACE-011 FPIA Homo sapiens ACVR2A (activin receptor type 2a, activin receptor type IIA ) - IGHG1 Fc

9188 activin A, activin B and inhibin B [Homo sapiens] Acceleron Pharma, Inc (Cambridge UK) / Celgene corporation (Summit USA) Therapeutic Breast cancers Phase II Oncology NCI: C80038
192 stamulumab 8683 94
(2005)		 56
(2006)		 MYO-029 IG Homo sapiens IgG1 nd

MSTN (myostatin, growth differentiation factor 8, GDF8) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (Cambridge UK) / Wyeth Pharmaceuticals (Madison NJ USA) Therapeutic Muscular dystrophy Phase I/II Myology
385 tabalumab 9430 105
(2011)		 67
(2012)		 LY2127399 IG Homo sapiens IgG4 kappa

9430 TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, B cell activating factor, BAFF, TALL1, BLyS, B lymphocyte activator, CD257) [Homo sapiens] Eli Lilly (Indianapolis IN USA) Connective tissue disease Phase III Immunology
Autoimmune diseases Phase III Immunology
Systemic lupus erythematosus (SLE) Phase III Immunology
Multiple myeloma Phase I Hematology, Immunology, Oncology
336 teprotumumab 9107 101
(2009)		 63
(2010)		 IG Homo sapiens IgG1 nd

9107 IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Unknown Unknown Unknown
171 tralokinumab 9235 102
(2009)		 64
(2010)		 CAT-354 IG Homo sapiens IgG1 lambda

9235 IL13 (interleukin 13, IL-13) [Homo sapiens] Homo sapiens MedImmune Inc. (Gaithersburg MD USA) Therapeutic Asthma, severe
(Treatment)
Phase II Immunology (42)
248 tremelimumab 8716 94
(2005)		 59
(2008)		 CP-675206 IG Homo sapiens IgG2 nd

CTLA4 (cytotoxic T lymphocyte-associated antigen 4, CD152) [Homo sapiens] Homo sapiens 11.2.1 Abgenix (Fremont CA USA) / Pfizer (New York NY USA) Therapeutic Melanoma Oncology NCI: C49085
169 tuvirumab 6559 66
(1991)		 32
(1992)		 anti-hepatitis B IG Homo sapiens

HBV (hepatitis B virus) [Hepatitis B virus] Homo sapiens PDL (Protein Design Labs) BioPharma (Fremont CA USA) Therapeutic Hepatitis B (Chronic active) Phase II Infectiology [e]
Therapeutic Hepatitis B, chronic infection causing end-stage renal disease in liver transplant patients Phase I/II Infectiology
373 urelumab 9365 104
(2010)		 66
(2011)		 IG Homo sapiens IgG4 kappa

9365 TNFRSF9 (tumor necrosis factor receptor (TNFR) superfamily member 9, 4-1BB, T cell antigen ILA, CD137) [Homo sapiens] Bristol-Myers Squibb (Princeton NJ USA) Therapeutic Tumors Phase II Oncology NCI: C62449
172 ustekinumab 8954 99
(2008)		 61
(2009)		 CNTO 1275,
TT-20		 STELARA™ IG Homo sapiens IgG1 nd

8954 IL12B (interleukin 12 beta, IL-12B, IL12 p40, CMLF2, NKSF2) [Homo sapiens] Homo sapiens Centocor Ortho Biotech Inc. (Horsham PA USA) / Medarex (Princeton NJ USA) Therapeutic Inflammation Phase III Immunology FDA: (BLA) 125261

REMS

EMA: H-C-958

ATC: L04AC05

NCT
Therapeutic Psoriasis Phase M FDA approval September 25, 2009, EMA approval January 16, 2009 Immunology
Therapeutic Multiple sclerosis (MS) Phase II Immunology
Therapeutic Crohn's disease (CD) Phase III Immunology
374 vesencumab 9380 104
(2010)		 66
(2011)		 MNRP1685A IG Homo sapiens IgG1 kappa

9380 NRP1 (neuropilin 1, NRP, vascular endothelial cell growth factor 165 receptor, VEGF165 receptor, VEGF165R, CD304) extracellular domain [Homo sapiens] Genentech Inc. (S. San Francisco CA USA) Therapeutic Solid tumors Phase I Oncology
199 votumumab 7165 70
(1993)		 34
(1994)		 Technetium (99mTc) votumumab HumaSPECT® IG Homo sapiens IgG3 kappa

radiolabelled with Technetium-99m, Tc-99m		 carcinoma associated antigen CTAA16.88 (complex of cytokeratin polypeptides (35-40kDa)) [Homo sapiens] Homo sapiens 88-BV59 KS Biomedix Ltd (Guildford UK) / Organon Teknika Corp. (Durham NC USA) Therapeutic Colon cancers Withdrawn EC withdrawal (Not renewed by KS Biomedix) September 24, 2003, EC approval September 25, 1998 Oncology [d] (31) (39)
Therapeutic Rectum cancers Withdrawn EC withdrawal (Not renewed by KS Biomedix) September 24, 2003, EC approval September 25, 1998 Oncology
200 zalutumumab 8605 93
(2005)		 55
(2006)		 HuMax-EGFr HuMaX-EGFR™ IG Homo sapiens IgG1 kappa

EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) (epitope on external domain) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) Therapeutic Head cancers Phase III Oncology NCI: C64620
Therapeutic Neck cancers Phase III Oncology
201 zanolimumab 8298 90
(2004)		 52
(2004)		 HuMax-CD4 HuMax-CD4® IG Homo sapiens IgG1 kappa

CD4 (p55) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) / Medarex (Princeton NJ USA) Therapeutic Cutaneous T cell lymphoma (CTCL) Phase III Oncology
Therapeutic Non-cutaneous T cell lymphoma (NCTCL) Phase II Oncology
8 ziralimumab 8061 84
(2000)		 46
(2001)		 ABX-RB2 IG Homo sapiens IgM nd

BSG (basigin, Ok blood group, CD147) [Homo sapiens] Homo sapiens Abgenix (Fremont CA USA) Therapeutic Autoimmune diseases Preclinical Immunology (41)
Therapeutic Solid organ transplantation Preclinical Immunology
Therapeutic Graft-versus-host disease (GvHD) Preclinical Immunology
99 4D5 and UCHT1,
trastuzumab coupled with UCHT1 F(ab')2		 IG Homo sapiens
Mus musculus
Hybrid		 IgG1 kappa / F(ab')2

CD3E (CD3 epsilon) [Homo sapiens] ;
ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340 [Homo sapiens] ;
bispecific 		Mus musculus Charing Cross Sunley Research Centre (UK) / Genentech Inc. (S. San Francisco CA USA) / ICRF (UK) Cancers (overexpressing ERBB2) Oncology [c] (36) [42]
163 ABX-IL8 IG Homo sapiens IgG2 nd

IL8 (interleukin 8, IL-8) [Homo sapiens] Homo sapiens Abgenix (Fremont CA USA) Melanoma Preclinical Oncology [a] [b] (11)
Angiogenesis Preclinical Oncology
Rheumatoid arthritis (RA) Phase II Immunology
Psoriasis Phase II Immunology
166 AGS-PSCA,
MK-4721		 IG Homo sapiens IgG1 kappa

PSCA (prostate stem cell antigen) [Homo sapiens] Homo sapiens Agensys (Santa Monica CA USA) / Merck & Co., Inc. (Whitehouse Station NJ USA) Prostate cancers Phase I Oncology [p] (59)
Bladder cancers Phase I Oncology
Pancreatic cancers Phase I Oncology
167 AL-901 Homo sapiens

IgE Fc [Homo sapiens] Homo sapiens Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Tanox Inc. (Houston TX USA) Allergic rhinitis Phase II Immunology [e]
Allergic asthma Phase II Immunology
177 HuMax-IL15 Homo sapiens

IL15 (interleukin 15, IL-15) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) / Immunex Corporation Amgen (Thousand Oaks CA USA) Psoriasis Phase I/II Immunology
Inflammatory arthritis diseases Phase I/II Immunology
Celiac disease Phase I/II Immunology
228 HuMax-TAC™ Homo sapiens

IL2RA (interleukin-2 receptor, alpha subunit, IL-2RA, TAC, CD25) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) Autoimmune disorders Preclinical Immunology
Transplant rejection Preclinical Immunology
181 J695 Homo sapiens

IL12A (interleukin 12 alpha, IL-12A, IL12 p35, CMLF1, NKSF1) [Homo sapiens] Homo sapiens BASF (Ludwigshafen Germany) / Cambridge Antibody Technology (Cambridge UK) (US) Rheumatoid arthritis (RA) Immunology [12]
Multiple sclerosis (MS) Immunology
Crohn's disease (CD) Immunology
185 MDX-33 Homo sapiens

FCGR1 (immunoglobulin G Fc receptor high affinity I, Fc gamma RI, CD64, encoded by human FCGR1A, FCGR1B, FCGR1C) [Homo sapiens] Homo sapiens CSL Behring (King of Prussia PA USA) / Medarex (Princeton NJ USA) Idiopathic thrombocytopenic purpura Phase I Hematology [a] [b]
Autoimmune diseases Phase I Immunology
187 MOR101 IG Homo sapiens Fab

ICAM1 (intercellular adhesion molecule 1, ICAM-1, CD54) [Homo sapiens] Homo sapiens MorphoSys (Martinsried/Pla Germany) Deep dermal burn Preclinical Dermatology [n] (22)
188 MOR102 IG Homo sapiens Fab - G4 nd

ICAM1 (intercellular adhesion molecule 1, ICAM-1, CD54) [Homo sapiens] Homo sapiens MorphoSys (Martinsried/Pla Germany) Psoriasis Preclinical Immunology [n] (22)
189 MOR103 Homo sapiens

Homo sapiens MorphoSys (Martinsried/Pla Germany) Rheumatoid arthritis (RA) Phase I Immunology [n] (22)
190 MOR202 IG Homo sapiens IgG1 nd

CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10) [Homo sapiens] Homo sapiens MorphoSys (Martinsried/Pla Germany) Therapeutic Multiple myeloma Preclinical Hematology, Immunology, Oncology [n] (22)
191 MORAb-028 IG Homo sapiens IgM nd

GD2 ganglioside [Homo sapiens] CMC Biopharmaceuticals (Copenhagen Denmark) / Morphotek Inc. (Exton PA USA) Melanoma Oncology [p]
195 OST 577 OSTAVIR™ Homo sapiens

HBV (hepatitis B virus) [Hepatitis B virus] Homo sapiens Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) Hepatitis B Phase II Infectiology [a]

up

Antibodies and immunoadhesins approved for therapeutic or diagnostic use and on the market (in 2012)

Number of results: 35

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT receptor type Species IG class and subclass or IG format FPIA or RPI chain identification Conjugated/ Radiolabelled IMGT/2Dstructure-DB IMGT/3Dstructure-DB Specificity target name
[species]		 Origin clone species Origin clone name Company Application Clinical indication Development status Regulatory agency status and year Expression system Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
212 abatacept 8495 91
(2004)		 53
(2005)		 BMS-188667,
CTLA4-Ig		 ORENCIA® FPIA Homo sapiens CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)-IGHG1 Fc

CD80 (B7-1, CD28LG1) [Homo sapiens] ;
CD86 (B7-2, CD28LG2) [Homo sapiens] 		Homo sapiens Bristol-Myers Squibb (Princeton NJ USA) Therapeutic Juvenile Idiopathic Arthitis Phase M sBLA August 01, 2008 Immunology FDA: (BLA) 125118

ATC: L04AA24

Drugnum: 888

NCT

 [j] [n] (16) (30)
Therapeutic Graft-versus-host disease (GvHD) (solid organ transplant) Phase I CHO (Chinese Hamster Ovary) cells Immunology
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval December 23, 2005 CHO (Chinese Hamster Ovary) cells Immunology
Therapeutic Psoriasis Phase I CHO (Chinese Hamster Ovary) cells Immunology
146 abciximab 7200 70
(1993)		 34
(1994)		 c7E3 REOPRO® IG Chimeric Fab - G1 kappa

ITGA2B_ITGB3 (integrin alpha2b_beta3, integrin αIIbβ3, GPIIbIIIa, fibrinogen receptor, CD41_CD61) platelet [Homo sapiens] Mus musculus 7E3 Centocor Inc. (Horsham PA USA) / Eli Lilly (Indianapolis IN USA) Therapeutic Anti-platelet prevention of blood clots in the setting of high risk percutaneous transluminal coronary angioplasty Phase M FDA approval December 16, 1993 Sp2/0 mouse myeloma cells Cardiology FDA: (BLA) 103575

Drugnum: 332

NCT

 [a] [b] [e] [f] [j]
Therapeutic Refractory unstable angina when percutaneous coronary intervention is planned Phase M FDA approval November 05, 1997 Sp2/0 mouse myeloma cells Cardiology
165 adalimumab 7860 82
(1999)		 44
(2000)		 D2E7 HUMIRA® (EU/US)
TRUDEXA® (EU) 		IG Homo sapiens IgG1 kappa

7860 TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Homo sapiens Abbott Laboratories (Abbott Park IL USA) (EU/US) Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval October 03, 2005 CHO (Chinese Hamster Ovary) cells Immunology FDA: (BLA) 125057

REMS

EMA: H-C-481

ATC: L04AB04

Drugnum: 814

NCT

 [a] [j] (12)
Abbott Laboratories (Abbott Park IL USA) Therapeutic Juvenile Idiopathic Arthitis Phase M FDA approval February 21, 2008 Immunology
Therapeutic Crohn's disease (CD) (if inadequate response to conventional therapy) Phase M FDA approval February 27, 2010 Immunology
Therapeutic Ankylosing spondylitis (AS) Phase M FDA approval August 28, 2006 Immunology
Therapeutic Psoriasis, severe chronic plaque Phase M FDA approval January 18, 2008 Immunology
Abbott Laboratories (Abbott Park IL USA) (EU/US) Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval December 31, 2002 CHO (Chinese Hamster Ovary) cells Immunology
215 alefacept 8059 84
(2000)		 46
(2001)		 CD58-Fc,
LFA3-Fc		 AMEVIVE® FPIA Homo sapiens CD58 (LFA3, lymphocyte function associated antigen 3)-IGHG1 Fc

CD2 (lymphocyte function-antigen 2, LFA-2) [Homo sapiens] Homo sapiens Biogen Canada Inc. (Mississauga ON Canada) Therapeutic Psoriasis, severe chronic plaque Phase M FDA approval January 31, 2003 CHO (Chinese Hamster Ovary) cells Immunology FDA: (BLA) 125036

ATC: L04AA15

Drugnum: 820

NCT

 [j] [n] (30)
11 alemtuzumab 8005 83
(2000)		 45
(2001)		 Campath-1H,
LDP-03		 CAMPATH® (US)
MABCAMPATH® (EU) 		IG Humanized IgG1 kappa

8005 1bey
1ce1		 CD52 [Homo sapiens] Rattus norvegicus YTH34.5HL Berlex Inc. (Wayne NJ USA) (US) / Genzyme Corp. (Cambridge MA USA) (EU) / Millennium Pharmaceuticals Inc. (Cambridge MA USA) (EU/US) Therapeutic Kidney transplant rejection Phase I/II CHO (Chinese Hamster Ovary) cells Immunology FDA: (BLA) 103948

ATC: L01XC04

NCI: C1681

Drugnum: 702

NCT

 [a] [b] [c] [19] [75] [76] [77] [78] [79] [80] [81] [82] [83]
Therapeutic Chronic lymphocytic leukemia (CLL) Phase M FDA approval May 07, 2001 CHO (Chinese Hamster Ovary) cells Hematology, Oncology
Therapeutic Multiple sclerosis (MS) Phase I/II CHO (Chinese Hamster Ovary) cells Immunology
148 basiliximab 7578 76
(1996)		 38
(1997)		 CHI621 SIMULECT® IG Chimeric IgG1 kappa

3iu3
1mim		 IL2RA (interleukin-2 receptor, alpha subunit, IL-2RA, TAC, CD25) [Homo sapiens] Mus musculus CHI621 Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Kidney transplant rejection, acute
(Prevention)
Phase M FDA approval January 02, 2003 Immunology FDA: (BLA) 103764

ATC: L04AC02

Drugnum: 440

NCT

 [a] [b] [d] [f] [j] (53) [56]
Therapeutic Organ transplant rejection, acute
(Prevention)
Phase M FDA approval May 12, 1998 Immunology
266 belimumab 8381 89
(2003)		 51
(2004)		 BENLYSTA® IG Homo sapiens IgG1 nd

TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, B cell activating factor, BAFF, TALL1, BLyS, B lymphocyte activator, CD257) [Homo sapiens] HGSI (Human Genome Sciences Inc.) (Rockville MD USA) Therapeutic Systemic lupus erythematosus (SLE) Phase M FDA approval March 10, 2011 Immunology FDA: (BLA) 125370

ATC: L04AA26

NCT
258 besilesomab 8451 92
(2004)		 54
(2005)		 BW250/183 SCINTIMUN® (EU) IG Mus musculus IgG1 kappa

radiolabelled with Technetium-99m, Tc-99m		 CEACAM8 (carcinoembryonic antigen-related cell adhesion molecule 8 , NCA-95, nonspecific cross-reacting antigen 95 kDa, granulocyte cell antigen, CGM6, CD66b) [Homo sapiens] Iba Molecular Imaging (Louvain-la-Neuve Belgium) Diagnostic Bone marrow scintigraphy Phase M EMA approval January 11, 2010 Osteology EMA: H-C-001045
Diagnostic Peripheral bone infections Phase M EMA approval January 11, 2010 Osteology
Diagnostic Diagnosis of ostomyelitis Phase M EMA approval January 11, 2010 Osteology
24 bevacizumab 8017 83
(2000)		 45
(2001)		 12-IgG1,
F(ab)-12 IgG1,
Fab-12 IgG1,
rhuMAb-VEGF		 AVASTIN® IG Humanized IgG1 nd

8017 1bj1 VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Mus musculus muMAb-VEGF, muMAb VEGF A.4.6.1, muMAb VEGF A4.6.1 Genentech Inc. (S. San Francisco CA USA) (EU) Therapeutic Renal cell carcinoma (RCC) Phase M FDA approval July 31, 2009 Oncology FDA: (BLA) 125085

ATC: L01XC07

Drugnum: 851

NCT

 [a] [b] (20)
Therapeutic Breast cancers (metastatic ERB2 negative) Phase M FDA approval February 22, 2008 CHO (Chinese Hamster Ovary) cells Oncology
Therapeutic Colorectal cancers, metastatic Phase M FDA approval February 26, 2004 CHO (Chinese Hamster Ovary) cells Oncology
Therapeutic Glioblastoma Phase M FDA approval February 08, 2011 Oncology
Therapeutic Non-small cell lung cancers, metastatic Phase M FDA approval October 11, 2006 CHO (Chinese Hamster Ovary) cells Oncology
324 brentuximab vedotin 9144 103
(2010)		 65
(2011)		 cAC10-Val-Cit-MMAE,
SGN-35		 ADCETRIS™ IG Chimeric IgG1 kappa conjugated with monomethyl auristatin E (MMAE)

 9144 TNFRSF8 (tumor necrosis factor receptor (TNFR) superfamily member 8, CD30) [Homo sapiens] Seattle genetics, Inc. (Bothell WA USA) Therapeutic Anaplastic large cell lymphoma (ALCL) Phase M FDA approval August 19, 2011 Oncology FDA: (BLA) 125388


FDA: (BLA) 125399
Therapeutic Hodgkin lymphoma Phase M FDA approval August 19, 2011 Oncology
244 canakinumab 8836 97
(2007)		 59
(2008)		 ACZ885 ILARIS® IG Homo sapiens IgG1 kappa

8836 IL1B (interleukin 1 beta, IL-1B) [Homo sapiens] Homo sapiens Novartis (Basel Switzerland) Therapeutic Rheumatoid arthritis (RA) Immunology FDA: (BLA) 125319

ATC: L04AC08

NCT
Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Cryopyrin-Associated Periodic Syndromes (CAPS) (including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 4 and older) Phase M FDA approval June 17, 2009 Hereditary inflammatory diseases, Immunology
115 capromab 7201 70
(1993)		 34
(1994)		 7E11-C5.3 radiolabelled,
capromab pendetide,
Indium In1111 ProstaScint®		 PROSTASCINT® IG Mus musculus IgG1 kappa conjugated with chelator pendetide (GYK-DPTA)

radiolabelled with Indium-111, In-111		 FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA) [Homo sapiens] Mus musculus 7E11-C5.3 EUSA Pharma (Doylestown PA USA) Diagnostic Prostate cancers Phase M FDA approval October 28, 1996 Oncology FDA: (BLA) 103608

NCT

 [b] [d] [n] (31)
218 catumaxomab 8406 93
(2005)		 55
(2006)		 Mus mus. anti-EPCAM (Ho-3/TP-A-01/TPBs01) G2a kappa / Rat sp. anti-CD3E (26/II/6-1.2/TPBs01) G2b lambda,
TPBs01		 REMOVAB® IG Mus musculus
Rattus sp.
Hybrid		 IgG2a kappa / G2b lambda

CD3E (CD3 epsilon) [Homo sapiens] ;
EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, epithelial cell adhesion molecule, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] ;
bispecific 		Fresenius Biotech GmbH (Bad Homburg Germany) / TRION Pharma (Munich Germany) Therapeutic Ovarian cancers Phase II/III Oncology ATC: L01XC09

 [o] (28) (36)
Therapeutic Gastric cancers Phase II/III EC Orphan drug November 03, 2006 Oncology
Therapeutic Malignant ascites Phase M EMA approval April 20, 2009 Oncology
242 certolizumab pegol 8448 90
(2004)		 52
(2004)		 CDP870,
PHA-738144		 CIMZIA® IG Humanized Fab' conjugated with pegol

 TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Therapeutic Crohn's disease (CD) Phase M FDA approval April 22, 2008 Immunology FDA: (BLA) 125160

REMS

ATC: L04AB05

NCT
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval May 13, 2009 Immunology
151 cetuximab 7906 82
(1999)		 44
(2000)		 Fab C225,
IMC-225		 ERBITUX® IG Chimeric IgG1 kappa

7906 1yy8
1yy9		 EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) (epitope on external domain) [Homo sapiens] Mus musculus C225 ImClone Systems Inc. (Somerville NJ USA) (US) / Merck & Co., Inc. (Whitehouse Station NJ USA) (EU) Therapeutic Colorectal cancers, metastatic (EGFR positive) Phase M FDA approval February 12, 2004 Sp2/0 mouse myeloma cells Oncology FDA: (BLA) 125084

ATC: L01XC06

NCI: C1723

Drugnum: 850

NCT

 [a] [b] [e] [j]
37 eculizumab 8231 87
(2002)		 49
(2003)		 5G1.1 SOLIRIS™ IG Humanized IgG nd

C5 (complement 5) [Homo sapiens] Mus musculus Alexion Pharmaceuticals Inc. (New Haven CT USA) Therapeutic Psoriasis Phase I/II Immunology FDA: (BLA) 125166

REMS

ATC: L04AA25

NCI: C48386

Drugnum: 945

NCT

 [a] [b]
Therapeutic Dermatomyositis Phase I/II Immunology
Therapeutic Paroxysmal nocturnal hemoglobinuria (PNH) Phase M FDA approval March 16, 2007 Hematology
Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
Therapeutic Nephritis Phase II Urology
119 edrecolomab 7471 74
(1995)		 36
(1996)		 17-1A PANOREX® IG Mus musculus IgG2a nd

EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, epithelial cell adhesion molecule, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) Therapeutic Colon cancers Phase M approval (Germany) January 01, 1995 Sp2/0 mouse myeloma cells Oncology ATC: L01XC01

NCI: C1554

 [a] [e]
216 etanercept 7783 81
(1999)		 43
(2000)		 TNFR-immunoadhesin,
TNFRSF1B-Fc		 ENBREL® FPIA Homo sapiens TNFRSF1B (tumor necrosis factor receptor (TNFR) superfamily member 1B, TNFBR, p75, CD120b) - IGHG1 Fc

7783 TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Homo sapiens Immunex Corporation Amgen (Thousand Oaks CA USA) Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval November 02, 1998 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Immunology FDA: (BLA) 103795

REMS

ATC: L04AB01

Drugnum: 737

NCT

 [f] [j] [n] (15) (30)
Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval February 15, 2002 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Immunology
175 golimumab 8497 91
(2004)		 53
(2005)		 CNTO 148 SIMPONI™ IG Homo sapiens IgG1 kappa

TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Homo sapiens Centocor Ortho Biotech Inc. (Horsham PA USA) Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval April 24, 2009 Immunology FDA: (BLA) 125289

REMS

ATC: L04AB06

NCT
Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval April 24, 2009 Immunology
Therapeutic Ankylosing spondylitis (AS) Phase M FDA approval April 24, 2009 Immunology
122 ibritumomab tiuxetan 7873 81
(1999)		 43
(2000)		 In-111 Zevalin,
Y-90 Zevalin		 ZEVALIN® IG Mus musculus IgG1 kappa conjugated with chelator tiuxetan

radiolabelled with Yttrium-90, Y-90 (Therapeutic) and Indium-111, In-111 (Diagnostic)		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus IDEC-Y2B8 Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Schering AG (Berlin Germany) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase M FDA approval February 19, 2002 CHO (Chinese Hamster Ovary) cells Oncology FDA: (BLA) 125019

NCT

 [j] [n] (31)
156 infliximab 7602 77
(1997)		 39
(1998)		 cA2 REMICADE® IG Chimeric IgG1 nd

7602 TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Mus musculus A2 Centocor Inc. (Horsham PA USA) Therapeutic Ankylosing spondylitis (AS) Phase M FDA approval December 17, 2004 Sp2/0 mouse myeloma cells Immunology FDA: (BLA) 103772

REMS

ATC: L04AB02

NCI: C1789

Drugnum: 703

Drugnum: 759

NCT

 [a] [b] [d] [f] [j] [53] [54]
Therapeutic Psoriasis, severe chronic plaque Phase M FDA approval September 26, 2006 Immunology
Therapeutic Crohn's disease (CD)
(Treatment)
Phase M FDA approval August 24, 1998 Sp2/0 mouse myeloma cells Immunology
Therapeutic Ulcerative colitis (UC) Phase M FDA approval September 15, 2005 Sp2/0 mouse myeloma cells Immunology
Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval May 18, 2005 Sp2/0 mouse myeloma cells Immunology
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval November 10, 1999 Sp2/0 mouse myeloma cells Immunology
132 muromonab-CD3 6281 59
(1988)		 29
(1989)		 OKT3 ORTHOCLONE OKT3® IG Mus musculus IgG2a kappa

1sy6 CD3E (CD3 epsilon) [Homo sapiens] Mus musculus Centocor Ortho Biotech Products LP (Raritan NJ USA) Therapeutic Acute kidney transplant rejection (reversal) Phase M FDA approval September 14, 1992 Murine ascites, hybridoma Immunology FDA: (BLA) 103463

ATC: L04AA02

NCI: C1321

NCT

 [a] [b] [d] [j] [n]
Therapeutic Heart transplant rejection (reversal) Phase M FDA approval September 14, 1992 Murine ascites, hybridoma Immunology
Therapeutic Liver transplantation (reversal) Phase M FDA approval September 14, 1992 Murine ascites, hybridoma Immunology
75 natalizumab 7716 79
(1998)		 41
(1999)		 AN100226 TYSABRI®
ANTEGREN® (formerly) 		IG Humanized IgG4 nd

ITGA4 (integrin apha 4 subunit, CD49d) [Homo sapiens] Mus musculus AN100226m Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Elan Pharmaceuticals International Ltd. (Dublin Ireland) Therapeutic Inflammatory conditions, acute and chronic COS cells transient expression Immunology FDA: (BLA) 125104

ATC: L04AA23

Drugnum: 869

NCT

 [a] [b] [c] [e] [j] [k] (3) (4) [7]
Therapeutic Colitis Phase II Immunology
Therapeutic Crohn's disease (CD) Phase M FDA approval January 14, 2008 NSO mouse myeloma cells Immunology
Therapeutic Multiple sclerosis (MS) Phase M FDA SBLA reintroduced June 05, 2006, Market suspension (three patients developed progressive multifocal leukoencephalopathy (PML)) February 28, 2005, FDA approval November 23, 2004 NSO mouse myeloma cells Immunology
76 nimotuzumab 8545 94
(2005)		 56
(2006)		 hR3,
Theraloc		 THERACIM® (India, China, Cuba, Argentina, Columbia) IG Humanized IgG1 kappa

3gkw EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) (epitope on external domain) [Homo sapiens] Mus musculus YM BioSciences Inc. (Mississauga Canada) Therapeutic Pancreatic cancers Phase M EMA Orphan drug June 03, 2008 NSO mouse myeloma cells Oncology NCI: C2733

 [n]
Therapeutic Lung cancers Phase II Oncology
Therapeutic Head cancers Phase M NSO mouse myeloma cells Oncology
Therapeutic Gastric cancers Phase II Oncology
Therapeutic Glioma cancers Phase M EMA withdrawal December 04, 2008, EMA Orphan drug September 02, 2004 NSO mouse myeloma cells Oncology
Therapeutic Pancreatic cancers, metastatic Phase II Oncology
Therapeutic Neck cancers Phase M NSO mouse myeloma cells Oncology
194 ofatumumab 8606 93
(2005)		 55
(2006)		 HuMax-CD20® ARZERRA™ IG Homo sapiens IgG1 kappa

MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) / GlaxoSmithKline (Brentford UK) Therapeutic Chronic lymphocytic leukemia (CLL) (Refractory) Phase M FDA approval October 26, 2009, sBLA April 01, 2009 Hematology, Oncology FDA: (BLA) 125326

ATC: L01XC10

NCI: C66952

NCT
Therapeutic Non-Hodgkin's lymphoma (NHL) (combination study) Phase III Oncology
Therapeutic Rheumatoid arthritis (RA) Phase III Immunology
77 omalizumab 8039 84
(2000)		 46
(2001)		 IGE25,
olizumab,
pSVIE26,
rhuMab-E25		 XOLAIR® IG Humanized IgG1 kappa

8039 IgE Fc [Homo sapiens] Mus musculus MaE11 Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Tanox Inc. (Houston TX USA) Therapeutic Asthma, severe persistent (allergic asthma) Phase M FDA approval (for subcutaneous use) June 20, 2003 CHO (Chinese Hamster Ovary) cells Immunology FDA: (BLA) 103976

REMS

NCI: C29299

NCT

 [a] [b] [l]
79 palivizumab 7753 79
(1998)		 41
(1999)		 MEDI-493 SYNAGIS® IG Humanized IgG1 kappa

RSV (human respiratory syncytial virus, glycoprotein F) [Respiratory syncytial virus] Mus musculus Abbott Laboratories (Abbott Park IL USA) (EU) / MedImmune Inc. (Gaithersburg MD USA) (US) Therapeutic Respiratory Syncytial Virus (RSV) disease (prophylaxis of lower respiratory tract disease in pediatric patients) Phase M AMM Market authorization (Abbott) August 01, 1999, FDA approval June 19, 1998 NSO mouse myeloma cells Infectiology, Pulmonary, Respiratory diseases FDA: (BLA) 103770

NCI: C2625

Drugnum: 447

NCT

 [a] [b] [d] [j] [49]
196 panitumumab 8499 91
(2004)		 53
(2005)		 ABX-EGF,
E7.6.3		 VECTIBIX™ IG Homo sapiens IgG2 kappa

EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) (epitope on external domain) [Homo sapiens] Homo sapiens Amgen (Thousand Oaks CA USA) Therapeutic Colorectal cancers, metastatic Phase M FDA approval September 27, 2006 CHO (Chinese Hamster Ovary) cells Oncology FDA: (BLA) 125147

ATC: L01XC08

NCI: C1857

Drugnum: 933

NCT

 [b] [n] (11) (13) (41)
Therapeutic Colorectal cancers Phase III CHO (Chinese Hamster Ovary) cells Oncology
Therapeutic Neck cancers Phase III CHO (Chinese Hamster Ovary) cells Oncology
Therapeutic Head cancers Phase III CHO (Chinese Hamster Ovary) cells Oncology
84 ranibizumab 8313 90
(2004)		 52
(2004)		 Fab-12 variant Y0317,
RhuFab		 LUCENTIS® IG Humanized Fab

8313 1cz8 VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Mus musculus muMAb-VEGF, muMAb VEGF A.4.6.1, muMAb VEGF A4.6.1 Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Age related macular degeneration (AMD), neovascular (wet) Phase M FDA approval June 30, 2006 E.coli (Escherichia coli) Ophthalmology FDA: (BLA) 125156

Drugnum: 904

NCT
217 rilonacept 8750 95
(2006)		 57
(2007)		 ARCALYST™ FPIA Homo sapiens Interleukin-1 receptor accessory protein (IL1RAP)-type 1 interleukin-1 receptor-IGHG1 Fc

8750 IL1A (interleukin 1 alpha, IL-1A) [Homo sapiens] Homo sapiens Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) Therapeutic Osteoarthritis Immunology FDA: (BLA) 125249

ATC: L04AC04

NCT

 [p] (30)
Therapeutic Rheumatoid arthritis (RA) Immunology
Therapeutic Autoinflammatory diseases Immunology
Therapeutic Cryopyrin-Associated Periodic Syndromes (CAPS)
(Treatment)
(including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS))		 Phase M FDA approval February 27, 2008 Hereditary inflammatory diseases, Immunology
161 rituximab 7609 77
(1997)		 39
(1998)		 IDEC-C2B8 MABTHERA®
RITUXAN® (US, Canada and Japan) 		IG Chimeric IgG1 kappa

7609 1l6x
2osl		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus IDEC-C2B8 CureTech (Yavne Israel) / IDEC Pharmaceuticals, Inc. (San Diego USA CA) Therapeutic Chronic lymphocytic leukemia (CLL) (CD20-positive, in combination with fludaraline and cyclophosphamide (FC) ) Phase M FDA approval (orphan drug) February 18, 2010 Hematology, Oncology FDA: (BLA) 103705


FDA: (BLA) 103737

ATC: L01XC02

NCI: C1702

Drugnum: 349

NCT

 [a] [b] [d] [f] [j] [q] (18) (49) [55]
Genentech Inc. (S. San Francisco CA USA) / IDEC Pharmaceuticals, Inc. (San Diego USA CA) Therapeutic Non-Hodgkin's lymphoma (NHL)
(Treatment)
(follicular, CD20 positive, relapsed or refractory low grade)		 Phase M FDA approval November 01, 1997 Oncology
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval February 28, 2006 Immunology
Therapeutic Wegener's Granulomatosis (WG) and Microscopic Polygamiitis (MPA), in combination with glucocorticoides Phase M FDA approval April 19, 2011 Hematology
96 tocilizumab 8394 90
(2004)		 52
(2004)		 atlizumab,
MRA,
rhPM-1		 ACTEMRA™
RoACTEMRA® (EU) 		IG Humanized IgG1 kappa

8394 IL6R (interleukin 6 receptor, IL-6R, CD126) [Homo sapiens] Mus musculus Chugai pharmaceuticals Co. Ltd. (Tokyo Japan) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) Therapeutic Lymphoproliferative disorder giant lymph node hyperplasia (Castleman's disease) Phase III Approval (by Japan) June 01, 2005, NDA approval April 01, 2005 CHO (Chinese Hamster Ovary) DHFR cells Oncology FDA: (BLA) 125276

REMS

EMA: H-C-955

ATC: L04AC07

NCT

 [c] (5) [38] [84] [85]
Therapeutic Multiple myeloma CHO (Chinese Hamster Ovary) DHFR cells Hematology, Immunology, Oncology
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval January 08, 2010, EMA approval January 16, 2009, Approval (by Japan) April 17, 2008 CHO (Chinese Hamster Ovary) DHFR cells Immunology
Diagnostic, Therapeutic Systemic juvenile idiopathic athritis (SJIA) Phase M FDA approval (sBLA) April 15, 2011 Immunology
142 tositumomab 7827 80
(1998)		 42
(1999)		 BEXXAR® IG Mus musculus IgG2a nd

radiolabelled with Iodine-131, I-131		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus Corixa Corp. (Seattle WA USA) / GlaxoSmithKline (Brentford UK) Therapeutic Non-Hodgkin's lymphoma (NHL) (follicular, CD20 positive, following chemotherapy relapse) Phase M FDA approval June 27, 2003 Hybridoma Oncology FDA: (BLA) 125011

NCI: C2543

Drugnum: 834

NCT

 [j] [n] (31)
97 trastuzumab 7637 78
(1997)		 40
(1998)		 4D5V8,
Herceptin		 HERCEPTIN® IG Humanized IgG1 kappa

7637 1n8z ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340 [Homo sapiens] Mus musculus 4D5 F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) / Genentech Inc. (S. San Francisco CA USA) (US) Therapeutic Breast cancers overexpressing ERBB2, metastatic Phase M AMM Market authorization (Roche) August 01, 2000, FDA approval September 01, 1998 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Oncology FDA: (BLA) 103792

ATC: L01XC03

NCI: C1647

Drugnum: 485

NCT

 [a] [b] [d] [e] [j] [48]
Genentech Inc. (S. San Francisco CA USA) Therapeutic Gastric cancers Phase M FDA approval October 20, 2010 Oncology
172 ustekinumab 8954 99
(2008)		 61
(2009)		 CNTO 1275,
TT-20		 STELARA™ IG Homo sapiens IgG1 nd

8954 IL12B (interleukin 12 beta, IL-12B, IL12 p40, CMLF2, NKSF2) [Homo sapiens] Homo sapiens Centocor Ortho Biotech Inc. (Horsham PA USA) / Medarex (Princeton NJ USA) Therapeutic Inflammation Phase III Immunology FDA: (BLA) 125261

REMS

EMA: H-C-958

ATC: L04AC05

NCT
Therapeutic Psoriasis Phase M FDA approval September 25, 2009, EMA approval January 16, 2009 Immunology
Therapeutic Multiple sclerosis (MS) Phase II Immunology
Therapeutic Crohn's disease (CD) Phase III Immunology

up

IMGT citations:
[a] Mike's Immunoglobulin Structure/Function: Antibodies for Therapeutic Applications.
[b] PhRMA: New Medicines in Development: Biotechnology: A 2000Survey.
[c] Jos
[d] Biopharmaceutical Benchmarks, Nature Biotechnology,18, 831-833 (2000).
[e] The antibodies, vol 6, ed. Zanetti M. and Capra J.D., Harwood academic publishers, Amsterdam, The Netherlands, pp 4-8 (2000).
[f] Information provided by Mitchell Reff, IDEC Pharmaceuticals.
[g] Schopf, R.E., Curr. Opin. Investig. Drugs, 2, 635-638 (2001).
[h] CLL Topics .
[i] Rosenwasser, L.J. et al., J. Allergy Clin. Immunol., 112, 563-570 (2003).
[j] Marie-Paule Lefranc, IMGT (26/12/2005).
[k] Information provided by Tarran Jones (08/02/2002) and from the AERES Biomedical web site (08/01/2004).
[l] Information from the Tanox Inc. web site (08/01/2004).
[m] Krietman RJ et al. PNAS 87, 8291-8295 (1990).
[n] Yan Wu and Marie-Paule Lefranc, IMGT (20/12/2006).
[o] Yan Wu and Marie-Paule Lefranc, IMGT, following information from Christian Behrens. (20/04/2007).
[p] Yan Wu and Marie-Paule Lefranc, IMGT (29/06/2007).
[q] Flavio Forrer, Highlights 2003 Medecine nucleaire:177Lu-DOTA-rituximab
[r] Correlation of TweakR Expression with Her2+ Ductal Breast Cancer and the Preclinical Therapeutic Effect of PDL192, a Humanized anti-TweakR antibody
[s] mAb BT-061
[t] Results from a Phase I Study of MLTA3698A, a Novel Anti-Lymphotoxin-a Monoclonal Antibody: Safety, Tolerability and Biologic Activity in Patients with Active Rheumatoid Arthritis.
[u] The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
IMGT glossary:
AMM: Autorisation de Mise sur le Marché (Market authorization)
ATC: Anatomical Therapeutic Chemical code
Drugnum: Database contains a listing of drugs approved by the Food and Drug Administration (FDA)
EC: European Commission
EMA: European Medicines Agency for the Evaluation of Medical Products
FDA: Food and Drug Administration
NCI: National Cancer Institute
NCT: ClinicalTrials.gov
NDA: New Drug Application
NDC code: National Drug Code
REMS: Risk Evaluation and Mitigation Strategy
sBLA: Supplemental Biologics License Application
IMGT notes:
(1) Since the monoclonal antibody is type-specific it will be limited to certain patients.
(2) A different epitope is recognized by YFC51.1 and 60.3.
(3) Later Celltech produced IgG4.
(4) Stable expressing cell line made at Celltech (UK).
(5) A different epitope is recognized by PM-1.
(6) IgG4 has an amino acid change S241>P to allow complete disulfide bridge formation at the hinge.
(7) HMFG (Human Milk Fat Globule).
(8) Original mouse mAb from Tanox, Inc. (TX).
(9) BEC2 is an anti-idiotypic mAb. By mimicking the GD3 tumour associated antigen, BEC2 appears to stimulate a stronger immune response than natural GD3.
(10) Surface granulocyte nonspecific cross-reacting antigen.
(11) Human Ig from transgenic XenoMouse (Abgenix).
(12) Human antibodies derived from phage display human antibody libraries.
(13) Biopharmaceuticals in the U.S. and European Markets New entries in the 4th edition.
(14) No more information on 23/02/02. Development seems halted.
(15) Fusion protein of the soluble ligand-binding domain of the tumor necrosis factor receptor p75 (TNFrp75) and of the Fc of a human IgG1.
(16) Cytotoxin T lymphocyte-associated antigen 4-Immunoglobulin G1 fragment fusion protein.
(17) Calicheamicin is a cytotoxin antitumor antibiotic, isolated from fermentation of a bacterium, Micromonospora echino spora, ssp. calichensis .
(18) Rituximab proprietary name is RITUXAN® in the USA, Canada and Japan, and MABTHERA® in the other countries.
(19) Previously Techniclone Corp.
(20) The VH domain of ranibizumab (1cz8) differs from the VH domain of bevacizumab (1bj1) by four amino acid changes: VH [CDR1-IMGT: T29>D, N36>H, CDR3-IMGT: H109>Y, S112.2>T] and the V-KAPPA domain by one amino acid change M4>L.
(21) Clenoliximab derives from keliximab. The two antibodies share the same variable domains. In June 1997, IDEC and SmithKline Beecham suspended a clinical trial of a different anti-CD4 antibody (PRIMATIZED? IDEC-CE9.1). In that trial, CD4 cell depletion was noted in a subset of patients, though no serious side effects were reported. The constant human IGHG1 from keliximab has been changed to human IGHG4. Moreover the IGHG4 contains two amino acid changed S10>P (hinge) and L1.2>E (CH2), according to the IMGT unique numbering [57].
(22) Generated from HuCAL? (Human Combinatorial Antibody Library).
(23) J591 is a deimmunized antibody (Biovation, Ltd., Lonza Biologics, Plc.), chelated with DOTA (1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid) (BZL biologics, Inc., Framingham, MA, USA) for allowing labelling with 177Lu, 90Y and 111In (Vallabhajosula S. et al., J Nucl Med., 46, 634-641 (2005))
(24) US patent 5863745.
(25) mAb covalently linked to 2-3 molecules of calicheamicin.
(26) motavizumab derived from palivizumab.
(27) used with foravirumab/rafivirumab in cocktail.
(28) Hybrid: A hybrid antibody is one in which one-half of the antibody (one heavy chain and one light chain) is from one species origin whereas the other half is from another species origin.
An hybrid antibody is identified by a pre-stem made of each species pre-stem separated by the letter 'x' in the INN. For example, a rat-murine hybrid antibody is identified by the pre-stem -axo-.
(29) Immunotoxin: An immunotoxin is an antibody linked to a toxin.
(30) Immunoadhesin: An immunoadhesin is a protein constituted of binding domain(s) (usually from a receptor, ligand, or cell-adhesion molecule) linked to immunoglobulin constant domains (Fc regions).
An immunoadhesin is identified by the suffix -cept in its INN.
(31) mAbs radiolabelled uses Radio Immuno Scintigraphy
(32) Jonhson & Jonhson took over development of bapineuzimab when it bought Elan Corp's Alzheimer program in 2009.
(33) Pfizer (New York NY USA) acquiered Wyeth Pharmaceuticals (Madison NJ USA) in 2010
(35) radiollabelled with Yttrium-90 via an interaction streptavidin (linked to mAb) - biotin (linked to Y-90)
(36) bispecific identifies an antibody with two different variable domain binding sites (Fv), each binding to a different antigen.
(37) NCT00538668
(38) The chimeric mAb has been crystallized ( IMGT/3Dstructure-DB 1bbj )
(39) CTAA16.88 is a complex of cytokeratin polypeptides (35-43kDa) expressed in colorectal tumors
(40) INN obinutuzumab (L101, 2009, pp.176) has replaced afutuzumab (L99, 2008, pp.123-124). Sequences and definition from L99 are still valid.
(41) Origine clone from XenoMouse (Abgenix/ Fremont CA USA)
(42) Origine clone from Cambridge Antibody Technology (CAT) library (Cambridge UK)
(43) HUMANEERED™ obtained by Humaneering™ Technology
(44) Inflazymme pharmaceuticals was purchased in August 2008
(45) As of August 2009, Medarex, Inc. operates as a subsidisary of Brystol-Myers Squibb company.
(46) Feb 2010, Medarex retains full for MDX-H210
(47) MDX-H210 (F(ab')2 Murine 520C9 / Humanized H22) was obtained by cross-linking F(ab') of humanized mAb H22 (anti-Fc gamma RI (CD64)), and F(ab') of murine mAb 520C9 (anti-ERBB2(HER2/neu)).
(48) F(ab') of murine H22 binds FcγRI (CD64) (but outside the normal ligand binding site for IgG) and F(ab') murine 520C9 binds ERBB2 (HER2/neu) directs FcγRI-positive effector cells (monocytes, macrophages, immature dendritic cells, G-CSF primed neutrophilis (polymorphonuclear cells (PMN))) to phagocyte or kill tumor cells that overexpress ERBB2.
(49) 177Lu-DOTA-rituximab (rituximab radiolabelled by 177-Lutunium and conjugated by chelator DOTA) is used in phaseI/II in the treatment of malignant lymphoma by Institute of nuclear medicine in Basel (Swiss)
(50) Fab' format needs to be confirmed
(51) Utilizing the POTELLIGENT® technology
(52) Osteoporosis at high risk for fracture in postmenopausal women
(53) prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.
(54) The murine ImmuRAIT-LL2 was halted in favor of the humanized epratuzumab to obviate immunogenicity
(55) The commercial development of 131I-ONCOLYM® by Peregrine Pharmaceuticals, Inc. was suspended in 2002.
(56) Trademark Corsevin owned by Corvas, Inc. abandonned - no statement use filed (28/05/1993)
(57) E5 and HA-1A bind to distinct epitopes on lipid A (Fujihara Y. et Al., J. Infect. deseases, 1993, vol 168, 1429-1435)
(58) The commercial development of ZAMYL was discontinued the 4th November 2009 in phase III by PDL and SGN-33 was discontinued the 13th Septemer 2010 in Phase IIb by Seatle Genetics.
(59) Agensys, Inc. is an affiliate of Astellas Pharma Inc.
IMGT references:
[1] Maeda, H. et al., Hum. Antibodies Hybridomas, 2, 124-134 (1991). PMID: 1873503
[2] Singer, I.I. et al., J. Immunol, 150, 2844-2857 (1993). PMID: 8095956
[3] Tempest, P.R. et al., Protein Eng., 7, 1501-1507 (1994). PMID: 7716162
[4] Kettleborough, C.A. et al., Protein Eng., 4, 773-783 (1991). PMID: 1798701
[5] Hsiao, K.-C. et al., Protein Eng., 7, 815-822 (1994). PMID: 7937713
[6] Baca, M. et al., J. Biol. Chem., 272, 10678-10684 (1997). PMID: 9099717
[7] Leger, O.J. et al., Hum. Antibodies, 8, 3-16 (1997). PMID: 9265500
[8] Ellis, J.H. et al., J. Immunol., 155, 925-937 (1995). PMID: 7608568
[9] Sato, K. et al., Mol. Immunol., 31, 371-381 (1994). PMID: 8152440
[10] Jones, P.T. et al., Nature, 321, 522-525 (1986). PMID: 3713831
[11] Benhar, I. et al., Proc. Natl. Acad .Sci. USA, 91, 12051-12055 (1994). PMID: 7991583
[12] Sha, Y. and Xiang, J., Cancer Biother., 9, 341-349 (1994). PMID: 7719381
[13] Shearman, C.W. et al., J. Immunol., 147, 4366-4373 (1991). PMID: 1836485
[14] Rosok, M.J. et al., J. Biol. Chem., 271, 22611-22618 (1996). PMID: 8798431
[15] Gussow, D. and Seemann, G., Methods Enzymol., 203, 99-121 (1991). PMID: 1762576
[16] Couto, J.R. et al., Ed. Ceriani, R.L., Plenum Press, New York pp55-59 (1994). PMID: 7985542
[17] Kashmiri, S.V.S. et al., Hybridoma, 14, 461-473 (1995). PMID: 8575795
[18] Baker, T.S. et al., Ed. Ceriani, R.L., Plenum Press, New York pp61-82 (1994). PMID: 7985543
[19] Riechmann, L. et al., Nature, 332, 323-327 (1988). PMID: 3127726
[20] Gorman, S.D. et al., Proc. Natl. Acad. Sci. USA, 88, 4181-4185 (1991). PMID: 1903536
[21] Verhoeyen, M. et al., Science, 239, 1534-1536 (1988). PMID: 2451287
[22] Foote, J. and Winter, G., J. Mol. Biol., 224, 487-499 (1992). PMID: 1560463
[23] Lewis, A.P. and Crowe, J.S., Gene, 101, 297-302 (1991). PMID: 1905261
[24] Co, M.S. et al., Proc. Natl. Acad. Sci. USA, 88, 2869-2873 (1991). PMID: 1849279
[25] Verhoeyen, M. et al., Ed. Epenetos A.A., Chapman and Hall Medical, London pp37-43 (1991). PMID: 1813210
[26] Eigenbrot, C. et al., Proteins, 18, 49-62 (1994). PMID: 7908437
[27] Hamilton, A.A. et al., J. Infect. Diseases, 176, 59-68 (1997). PMID: 9207350
[29] Verhoeyen, M. et al., Immunology, 78, 364-370 (1993). PMID: 7682986
[30] Cook, W.J. et al., Protein Eng., 9, 623-628 (1996). PMID: 8844835
[31] Poul, M.A et al., Mol. Immunol., 32, 101-116 (1995). PMID: 7532786
[32] Co, M.S. et al., J. Immunol., 148, 1149-1154 (1992). PMID: 1737932
[33] Graziano, R. et al., J. Immunol., 155, 4996-5002 (1995). PMID: 7594506
[34] Presta, L.G. et al., J. Immunol., 151, 2623-2632 (1993). PMID: 8360482
[35] Hakimi, J. et al., J. Immunol., 151, 1075-1085 (1993). PMID: 8335891
[36] Roguska, M.A. et al., Proc. Natl. Acad. Sci, 91, 969-973 (1994). PMID: 8302875
[37] Adair, J.R. et al., Hum. Antibodies Hybridoma, 5, 41-47 (1994). PMID: 7858182
[38] BioDrugs., 17(5):369-72 (2003). PMID: 14498766
[39] Tempest, P.R. et al., Biotechnology, 9, 266-271 (1991). PMID: 1367535
[40] Sato, K. et al., Hum. Antibodies Hybridomas, 7,175-183 (1996). PMID: 9140729
[41] Kolbinger, F. et al., Protein Eng., 6, 971-980 (1993). PMID: 8309946
[42] Zhu, Z. et al., J. Immunol., 155, 1903-1910 (1995). PMID: 7636241
[43] Sims, M.J. et al., J. Immunol., 151, 2296-2308 (1993). PMID: 7688398
[44] Routledge, E.G. et al., Eur. J. Immunol., 21, 2717-2725 (1991). PMID: 1834468
[45] Rogusta, M.A. et al., Protein Eng., 9, 895-904 (1994). PMID: 8931129
[46] Queen, C. et al., Proc. Natl. Acad. Sci. USA, 86, 10029-10033 (1989). PMID: 2513570
[47] Carter, P. et al., Proc. Natl. Acad. Sci. USA, 89, 4285-4289 (1992). PMID: 1350088
[48] Weiner, L.M., Semin. Oncol., 26, 43-51 (1999). PMID: 10561017
[49] Saez-Llorens, X. et al., Pediatr. Infect. Dis. J., 17, 787-791 (1998). PMID: 9779762
[50] Ekberg, H. et al., Transplant. Proc., 31, 267-268 (1999). PMID: 10083102
[51] Fukuda, T. et al., Cancer Res., 62, 5603-5610 (2002). PMID: 12359774
[52] Deeg, H.J. et al., Blood, 98, 2052-2058 (2001). PMID: 11567989
[53] Present, D.H., Aliment. Pharmacol. Ther., 13, 23-28 (1999). PMID: 10597336
[54] Maini, R. et al., Lancet, 354, 1932-1939 (1999). PMID: 10622295
[55] Grillo-Lopez, A.J. et al., Semin. Oncol., 26, 66-73 (1999). PMID: 10561020
[56] Mulloy, L.L. et al., Transplant. Proc., 31, 1210-1213 (1999). PMID: 10083541
[57] Reddy M.P. et al., J. Immunol., 164, 1925-1933 (2000). PMID: 10657642
[58] Yazaki P.J. et al., Protein Eng Des Sel., 17, 481-489 (2004). PMID: 15316127
[59] Wong J.Y. et al., Clin Cancer Res. 9, 5842-5852 (2003). PMID: 14676105
[60] Vallabhajosula S. et al., J Nucl Med., 46, 634-641 (2005). PMID: 15809486
[61] Economides AN et al., Nat. Med. 9, 47-52 (2003). PMID: 12483208
[62] Przepiorka D et al., Blood 92(11), 4066-4071 (1998). PMID: 9834211
[63] Eda Y et al. J Virol. 2006 June; 80(11): 5563–5570.. PMID: 16699037
[64] Qian X et al. Mol Oncol. 2008 Jun;2(1):81-93.. PMID: 19383330
[65] van der Woude CJ, et al., Inflamm Bowel Dis. 2010 Oct;16(10):1708-16.. PMID: 20848453
[66] Vaupel, DB, et al., Eur J Pharmacol. 1978 Apr 15;48(4):431-7.. PMID: 648586
[67] Urbain R, Teillaud JL, Prost JF., Med Sci (Paris). 2009 Dec;25(12):1141-4.. PMID: 20035694
[68] Kretz-Rommel A, Bowdish KS., Expert Opin Biol Ther. 2008 Jan;8(1):5-15.. PMID: 18081533
[69] Abraham. E., et. Al., Crit Care Med. 2001 Mar;29(3):503-10.. PMID: 11373411
[70] Haug CE, et al., Transplantation. 1993 Apr;55(4):766-72; discussion 772-3., A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients.. PMID: 8097341
[71] Geiler J, McDermott MF., Curr Opin Mol Ther. 2010 Dec;12(6):755-69.. PMID: 21154167
[72] Antoniu SA., Curr Opin Mol Ther. 2010 Apr;12(2),233-9. PMID: 20373267
[73] Antoniu SA., Curr Opin Mol Ther. 2010 Dec;12(6),770-9. PMID: 21154168
[74] Krinner EM, et Al., Mol Immunol. 2007 Feb;44(5),916-25. Epub 2006 May 11. PMID: 16697465
[75] Montagna, M. et al (2011), Relationship between pharmacokinetic profile of subcoutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia, Haematologica. [Epub ahead of print]. PMID: 21330330
[76] Spyridonidis, A. et al (2010) Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia, Bone Marrow Transplant. [Epub ahead of print]. PMID: 21170091
[77] Levitsky, J. et al (2011) Alemtuzumab induction in non-hepatitis C positive liver transplant recipients. Liver Transpl., 17 (1):32-7. doi: 10.1002/lt.22180.. PMID: 21254342
[78] Fox, EJ. (2010) Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother., 10 (12):1789-97.. PMID: 21091310
[79] Weissenbacher, A. et al (2010) Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation, Immunotherapy; 2(6):783-90.. PMID: 21091110
[80] Rai K, Hallek M. (2002) Future prospects for alemtuzumab (MabCampath), Med Oncol , 19 Suppl:S57-63.. PMID: 12180493
[81] Kennedy, B., Hillmen, P. (2002) Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL, Med Oncol.,19 Suppl:S49-55.. PMID: 12180492
[82] Osterborg, A. Et al (2002) Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia., Med Oncol., 19 Suppl:S21-6.. PMID: 12180488
[83] Keating M, Hallek M. (2002) Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52., Med Oncol., 19 Suppl:S1-2.. PMID: 12180486
[84] Sato K, et al., Cancer Res, 15, 53:851-6 (1993). PMID: 8428365
[85] Sato K, et al., Mol Immunol, 31:371-81 (1994). PMID: 8152440
[86] Tempest, et al., Int J Biol Macromol., 37-42 (1995). PMID: 7772562